Harvard Medical School
Curriculum Vitae

Date Prepared: March 3, 2024

Name: Wendy Beth London

Office Address: 450 Brookline Ave, Dana 3, Boston, MA 02215

Work Phone: 617-632-4895

Work E-mail: wendy.london@childrens.harvard.edu

Place of Birth: Detroit, Michigan, USA

Education

Year	Degree (Honors)	Fields of Study (Thesis advisor for doctoral research degrees)	Institution
05/1982	BS	Atmospheric Science/Mathematics	Purdue University
12/1997	PhD	Biostatistics (Chris Gennings, PhD)	Medical College of Virginia, Virginia Commonwealth University

Faculty Academic Appointments

Year(s)	Academic Title	Department	Academic Institution
1/1998-4/2005	Research Assistant Professor/Biostatistician	Department of Statistics	University of Florida College of Liberal Arts and Science
5/2005-8/2006	Research Assistant Professor/Biostatistician	Dept of Epidemiology and Health Policy Research	University of Florida College of Medicine
8/2006-10/2009	Research Associate Professor/Biostatistician	Dept of Epidemiology and Health Policy Research	University of Florida College of Medicine
12/2010-1/2024	Associate Professor of Pediatrics	Division of Hematology/Oncology	Boston Children's Hospital (BCH), Harvard Medical School, Harvard University
1/2024-present	Professor of Pediatrics	Division of Hematology/Oncology	Boston Children's Hospital (BCH), Harvard Medical School, Harvard University

Faculty Academic Affiliate Appointments

Year(s)	Academic Title	Department	Academic Institution
5/2008-6/2014; and, 12/2019-12/2023	Affiliate Research Associate Professor	Dept of Biostatistics	University of Florida Colleges of Medicine and of Public Health &Health Professions (non-voting)
7/2012-present	Affiliate faculty member	Dept of Data Science	Dana-Farber Cancer Institute (DFCI), HMS, Harvard University (non-voting)
7/2012-12/2023	Affiliate Associate Professor	Dept of Biostatistics	Medical College of Virginia, Virginia Commonwealth University (non-voting)
1/2024-present	Affiliate Research Professor	Dept of Biostatistics	University of Florida Colleges of Medicine and of Public Health &Health Professions (non-voting)
1/2024-present	Affiliate Professor	Dept of Biostatistics	Medical College of Virginia, Virginia Commonwealth University (non-voting)

Other Professional Positions

Year(s)	Position Title	Institution
1982-1983	Meteorologist	Climatological Consulting Corp., Asheville, NC
1983	Meteorologist/Programmer	National Climatic Data Center, Asheville, NC
1983-1987	Programmer/Meteorologist	Simpson Weather Associates, Inc., Charlottesville, VA
1987-1988	Senior Programmer/Analyst	Pharmaceutical Research Associates, Inc. (PRA), Charlottesville
1988-1992	Supervisor of Analysis Programming	Pharmaceutical Research Associates, Inc. (PRA), Charlottesville, VA
1992-1997	Graduate Assistant	Dept. of Biostatistics, Medical College of Virginia, Virginia Commonwealth University
1992-1997	Biostatistician	United Network for Organ Sharing (UNOS), Richmond, VA
2014-2021	Consultant	United Therapeutics Corporation, Silver Spring, MD
2018-present	Consultant	Jubilant Draximage Inc, Kirkland, Quebec
2018-2020	Consultant	ArQule, Inc. Burlington, MA
2020-2023	Consultant	Merck Sharp & Dohme Corp, Kenilworth, NJ
2022	Consultant	Healthcasts, New York, NY
2022-2023	Scientific Advisory Board Member	Y-mAbs Therapeutics, Inc, New York, NY

Major Administrative Leadership Positions

Local

Year(s)	Position Title	Institution (note if specific department)
1995-1996	Biostatistical Consulting Lab Co-Director	Dept. of Biostatistics, Medical College of Virginia, Virginia Commonwealth University
2002-2009	Associate Program Director / Co-Director	National Institutes of Health (NIH)/National Cancer Institute (NCI) Children's Oncology Group[1] (COG) Statistics and Data Center, Univ of Florida
2009-present	Director of Biostatistics	Division of Hematology/Oncology, Boston Children's Hospital, Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Harvard Medical School
2009-2019	Director, Clinical and Translational Investigation Program (CTIP)	Division of Hematology/Oncology, Boston Children's Hospital, Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Harvard Medical School
2012-present	Faculty Director, Survey and Qualitative Methods Core	Dana-Farber / Harvard Cancer Center
2012-present	Co-Director, Research and Data Analysis Core	Partnership of the University of Massachusetts/Boston and Dana-Farber Cancer Institute
2022-present	Director, Biostatistics Core	Dana-Farber/Harvard Cancer Center Glioma SPORE

National and International

(Each COG[1] disease committee is a distinct, scientific working group with its own long term strategic plan. Dr. London was funded full-time by COG[1] grants for 12 years, and 30% effort for five years after moving to Boston Children's Hospital, thus her leadership on multiple COG[1] scientific and administrative committees.)

Year(s)	Position Title	Institution (note if specific department)
1998-present	Scientific Steering Committee Member	Children's Oncology Group (COG[1]) Neuroblastoma Committee
1998-2014	Executive Committee Member	COG[1] Neuroblastoma Committee
1998-2014	Lead Statistician	COG[1] Neuroblastoma Committee

[1] The Children's Oncology Group is not a professional society, it is the only pediatric cancer cooperative group in the country, funded by the NIH / NCI via U10 grants (since ~1975). >220 treating institutions in North America, Australia, New Zealand, and Switzerland comprise the COG, with >5,000 members (oncologists, surgeons, pathologists, nurses, CRAs, statisticians). Half of all children with cancer in North America will enroll on at least one COG study. At any given time, COG is conducting over 100 clinical or biological trials, trials that set the standard of care. The COG Statistics and Data Center provides the infrastructure, including study design, data collection, interim monitoring, statistical analysis, and manuscripts. COG is organized by permanent scientific working 'committees' (led by an Executive committee) to conduct national clinical and basic science research; each competes separately for funding on the NIH U10 grant. COG leadership, including the statisticians, are nationally and internationally prominent members of the pediatric cancer research community.

Year(s)	Position Title	Institution (note if specific department)
1998-2003	Scientific Steering Committee Member	COG[1] Germ Cell Tumor Committee
1998-2003	Scientific Steering Committee Member	COG[1] Liver Tumor Committee
1999-2004	Scientific Steering Committee Member	COG[1] Hodgkin Disease Committee
2002-2003	Executive Committee Member	Children's Oncology Group[1]
2004-2009	Coordinating Statistician	COG[1] Statistics and Data Center, University of Florida site
2004-present	Chair	Statistics Committee of the International Neuroblastoma Risk Groups (INRG) Project
2024-2026	Co-Chair	American Society of Clinical Oncology /American Association for Cancer Research Methods in Clinical Cancer Research Workshop; La Jolla, CA

Committee Service

Local

Year(s) of Membership	Name of Committee Dates of Role(s)	Institution/Organization Title of Role(s)
1999, 2001, 2002	Dept. of Statistics Search Committee 1999, 2001, 2002	University of Florida Member
1999	Graduate Student Forum paper competition of the Graduate Student Council 1999	University of Florida Judge
2000	University of Florida Graduation Ceremony 2000	University of Florida Commencement Marshall
2000-2003	Environmental Health and Safety Committee 2000-2003	University of Florida Member
2002-2009	Pediatric Oncology Working Group 2002-2009	University of Florida Shands Cancer Center Member
2003	Challis Lecture Committee, Dept of Statistics 2003	University of Florida Dept of Statistics Chair
2005	Division of Biostatistics Search Committee 2005	University of Florida Member of 3 committees
2005	Search Committee for Human Resources Staff 2005	University of Florida, Dept of Epi & Health Policy Research, Div of Biostatistics Member
2005-2007	CTSI Community Outreach: Subject Recruitment and Retention Core Committee 2005	University of Florida Member

Year(s) of Membership	Name of Committee Dates of Role(s)	Institution/Organization Title of Role(s)
2005-2006	Search Committee for five tenure track faculty members 2005-2006	University of Florida, Dept of Epi & Health Policy Research, Division of Biostatistics Member
2005-2006	Search Committee for Division Director of Biostatistics 2005-2006	University of Florida, Dept of Epi & Health Policy Research, Division of Biostatistics Member
2005-2007	Epidemiology PhD Planning Committee 2005-2007	University of Florida, Department of Epidemiology and Health Policy Research Member
2007-2008	Search Committee for Division Chief of Pediatric Hematology/Oncology 2007-2008	University of Florida, Department of Pediatrics Member
2009-2019	Search Committees for CTIP positions: MS statistician, PhD statistician, Associate Director, trial monitor, database administrator: 2009-2010 Assoc Director: 2010 Research Nurse: 2012, 2015 Assoc Director: 2019	Division of Hematology/Oncology, Boston Children's Hospital, Dana-Farber/Children's Hospital Cancer Care Chair Member Member Chair
2010- present	Dana-Farber / Harvard Cancer Center Biostatistics Core 2010-present	Division of Hematology/Oncology, Dana-Farber/Boston Children's Cancer and Blood Disorders Center Member
2011	Ad-hoc Promotion Committee for a candidate for Associate Professor 2011	Harvard Medical School Member
2012	Strategic Planning: Clinical Studies Committee 2012	Dana-Farber Cancer Institute Member
2012	OnCore Rollout: Biostatistics Committee 2012	Dana-Farber Cancer Institute Member
2012	OnCore Rollout: Metrics and Reporting Committee 2012	Dana-Farber Cancer Institute Member
2012- present	Executive Committee of the Population Sciences Program 2012-present	Dana-Farber Harvard Cancer Center Member
2014-2015	Search Committee for PhD faculty statistician 2014-2015	Division of Hematology/Oncology, Boston Children's Hospital Chair

Year(s) of Membership	Name of Committee Dates of Role(s)	Institution/Organization Title of Role(s)
2015-2019	Data and Safety Monitoring Board 2015-2019	Boston Children's Hospital protocol: A Phase I/II, double blinded, placebo controlled, single-center Study of Fecal Microbiota Transplant (FMT) for the Treatment of Active Pediatric Ulcerative Colitis Member
2016 & 2024	Search Committee for PhD Survey Methodologist 2016 2024	Dana-Farber/Harvard Cancer Center's Survey and Qualitative Methods Core Chair Chair
2016-2019	Data and Safety Monitoring Board 2016-2019	Boston Children's Hospital protocol: A Phase I/II, double blinded, placebo controlled, single-center Study of Fecal Microbiota Transplant for the Treatment of Active Pediatric Crohn's Colitis Member
2016- present	Pediatric Hematology-Oncology Informatics Steering Committee (Big Data Initiative) 2016- present	Dana-Farber / Boston Children's Cancer and Blood Disorders Center Member
2016-2019	Clinical Research Initiative 2016-2019	Dana-Farber / Boston Children's Cancer and Blood Disorders Center Member
2018-2019	Ad-hoc Promotion Committee for a candidate for Associate Professor 2018-2019	Boston Children's Hospital & Harvard Medical School Member
2021- present	Diversity, Equity, and Inclusion Committee 2021-	Dana-Farber / Boston Children's Cancer and Blood Disorders Center Member
2021-present	Wellesley College Internship Selection Committee 2021-	Dana-Farber / Boston Children's Cancer and Blood Disorders Center Member

National and International

Year(s) of Membership	Name of Committee Dates of Role(s)	Institution/Organization Title of Role(s)
1998- present	NIH/NCI Children's Oncology Group 1998 – present 1999-2004 1999-2012 2000-2006 2001-2014 1998-2014 2002-2003 2004 2006-2012 2011-2013	Member Neuroblastoma Committee Member Informatics Advisory Committee Member Biological and Translational Research Committee Member Biological and Translational Research Committee Member Scientific Review Panel of the Neuroblastoma Biology Committee Member Statistics Discipline Committee Chair Neuroblastoma Common Data Elements Committee Member Search Committee for Group Statistician Executive Committee Member Phase II/III Data Safety Monitoring Committee Member Nominating Committee
2008-2009	Data Safety Monitoring Board 2008-2009	Neurofibromatosis Consortium Member
2009-2015	Data Safety Monitoring Board 2009-2015	Division of Microbiology and Infectious Diseases (DMID) Protocol 07-0012: Randomized Trial of Azithromycin versus Doxycycline for genital Chlamydial infection in females in youth correctional facilities Member
2011-2018	International Neuroblastoma Response Criteria Working Group 2011-2018	National Cancer Institute Executive Committee Member
2019-2022	Data Safety Monitoring Board 2019-2022	"RQ 092 (Miransertib) in Subjects with PIK3CA-related Overgrowth Spectrum and Proteus Syndrome". Sponsor: Merck (originally ArQule, Inc.) Member

Year(s) of Membership	Name of Committee Dates of Role(s)	Institution/Organization Title of Role(s)
2019- present	Data Safety Monitoring Board 2019- present	Jubilant Draximage trial of metaiodobenzylguanidine (MIGB) in neuroblastoma Member
2020-present	The INRG Version 2 Task Force 2020- present	The International Neuroblastoma Risk Groups Project Co-Chair
2022-present	Data Safety Monitoring Board 2022-present	An international multicenter phase II randomised trial comparing two intensification treatment strategies for metastatic neuroblastoma patients with a poor response to induction chemotherapy: A SIOPEN Study ("Veritas") Member
2022-present	Data Safety Monitoring Board 2022-present	Memorial Sloan-Kettering pediatric cancer trials Member
2023-present	FDA Advisory Committee 2023-2027	Cellular, Tissue, and Gene Therapies Advisory Committee of the Food and Drug Administration Member

Professional Societies

Year(s) of Membership	Society Name Dates of Role(s)	Title of Role(s)
1987-1992	SAS Users' Groups International 1987-1992 1990, 1991, 1992 1991, 1992	Member Session Coordinator Section Chair, Northeast SAS Users' Group Pharmaceutical Section
1990- present	American Statistical Association 1990- 1996 1999	Member Member, Local Arrangements Committee for Eastern North American Region (ENAR) of American Statistical Association (ASA) Session Chair, Joint Statistical Meetings
2005- present	American Society of Clinical Oncology (ASCO) 2013-2016	Member, Scientific Program Committee
1999, 2004, 2009-2019, 2022-present	Societe Internationale d'Oncologie Pediatrique (SIOP)	Member

Year(s) of Membership	Society Name Dates of Role(s)	Title of Role(s)
2008- present	Advances in Neuroblastoma Research (ANR) Association 2006, 2010, 2014, 2016, 2018, 2020, 2022, 2023 2008-2023	Abstract Selection Reviewer Elected Member, Advisory Board
2010- present	American Association for Cancer Research (AACR) 2010- present 2020-2022 2021 2023 2024 2024	Member Annual Meeting Clinical Trials Committee Plenary Session Chair of "Early Clinical Trials with New Anticancer Agents" Invited Co-Chair, Clinical Trials Design Workshop at the AACR annual meeting Member, Selection Committee for the Daniel Van Hoff award Plenary Session Chair of "Biostatistics in Clinical Trials Workshop: Out of the Rut and Beyond the Traditional – Parts 1 & 2" at the AACR annual meeting
2011-2014, 2020-present	Society for Clinical Trials (SCT) 2020-2021 2022-	Member Chair, Communications Committee Member, Outreach Committee
2011- present	Society for Pediatric Research (SPR)	Elected Member
2014-2018	American Society of Hematology (ASH)	Member
2017- present	American Pediatric Society (APS)	Elected Member

Grant Review Activities

Year(s) of Membership	Name of Committee Dates of Role(s)	Institution/Organization Title of Role(s)
2005-2010	Clinical Oncology (CONC) Study Section for R01 & R21 grant review 2005 2006-2010	National Institutes of Health (NIH) Ad hoc Member Permanent Member
2005-2009	Grant Productivity Committee 2005-2009	STOP! Children's Cancer Inc., Gainesville, Florida Chair
2010	Subcommittee H Study Section for review of the NIH/NCI cancer cooperative groups 2010	National Institutes of Health (NIH) Ad-hoc Member
2011-2012	Neuroblastoma Innovation Panel 2011-2012	Department of Defense (DoD) Congressionally Directed Medical Research Programs, American Institute of Biological Sciences Member
2012	Cancer Biomarkers Study Section (CBSS) for R01 and R21 grant review 2012	National Institutes of Health (NIH) Ad hoc Member

Year(s) of Membership	Name of Committee Dates of Role(s)	Institution/Organization Title of Role(s)
2016 2021	Neuroblastoma (NB) peer review panel of the Peer Reviewed Cancer Research Program (PRCRP) 2016, 2021	Department of Defense (DoD) Congressionally Directed Medical Research Programs (CDMRP) Member
2018-2019	Clinical Trial Support Award Committee 2018, 2019	Dana-Farber Cancer Institute Member
2018	Scientific peer review panel of grant applications 2018	Neuroblastoma UK Member
2019	Scientific peer review panel of grant applications 2019	Children's Cancer and Leukaemia Group UK Member
2020	International Neuroblastoma Research Initiative - Scientific peer review of grant applications for $1.4M pilot trial 2020	Solving Kids' Cancer UK Member
2021	Emerging Scientist Award ($100,000) Review Committee 2021	Children's Cancer Research Fund Member
2022	Cancer Immunopathology and Immunotherapy (CII) Study Section for R01 and R21 grant review 2022	National Institutes of Health (NIH) Ad-hoc member
2022-present	Therapeutic Immune Regulation (TIR) Study Section for R01 and R21 grant review 2022-present	National Institutes of Health (NIH) Permanent Member
2024	Consortia Project - neuroblastoma grant review (€2,200,000) 2024	KWF Dutch Cancer Society External reviewer

Editorial Activities

Ad Hoc Reviewer

- *New England Journal of Medicine*
- *Journal of Clinical Oncology*
- *Journal of the American Medical Association - Oncology*
- *Annals of Oncology*
- *Pediatric Blood and Cancer*
- *Statistics in Medicine*
- *Journal of Pediatric Hematology/Oncology*
- *Pediatrics*
- *Clinical Cancer Research*
- *Oncology*
- *Future Oncology*

- *Journal of the National Cancer Institute*
- *Journal of the National Cancer Institute – Cancer Spectrum*
- *International Journal of Environmental Research and Public Health*
- *Expert Opinion on Drug Safety*
- *Targeted Oncology*
- *British Journal of Cancer*
- *Controlled Clinical Trials*
- *Cancer*
- *Cancers*
- *Cancer Medicine*
- *Translational Pediatrics*
- *eBioMedicine (A Lancet family journal)*
- *Nature Medicine*
- *Nature Communications*

Other Editorial Roles

Year(s)	Role	Journal Name
2000-2003	Assistant Editor	*Medical and Pediatric Oncology*
2013-2020	Editorial Board Member	*Journal of Clinical Oncology*
2020-present	Editorial Board Member	*Journal of the National Cancer Institute*

Honors and Prizes

Year	Name of Honor/Prize	Awarding Organization	Achievement for which awarded (if unclear from award title)
1989	Honorable Mention Paper	SAS User's Group International Section on Education, Consulting, and Technical Support	
1990	Best Contributed Paper	SAS User's Group International, Section on Education, Consulting, and Technical Support	
2005	International Educator of the Year	University of Florida College of Medicine	Junior Faculty Nominee
2006	Audrey Evans Prize	Advances in Neuroblastoma Research Association, Los Angeles, CA	Outstanding Paper in Clinical Research
2006	International Society of Pediatric Oncology (SIOP) Award	38th Congress of the International Society of Paediatric Oncology, Geneva, Switzerland	Best Clinical Trials Abstract (as a co-author and lead statistician)
2006	Best Clinical Science Poster	University of Florida College of Medicine Research Day	
2007	Best of SIOP Award lecture	American Society of Pediatric Hem/Oncology, Toronto, Ontario	
2008	Audrey Evans Prize	Advances in Neuroblastoma Research Association, Chiba, Japan	Outstanding Paper in Clinical Research (as a co-author and lead statistician)
2010	Faculty 1000 selection	*New England Journal of Medicine*. 2010 Sep 30:363(14): 1324-34	Selected as being within the top 2% of published articles in biology and medicine (as co-author and lead statistician)
2015	Distinguished Clinical Research Achievement Award	The Clinical Research Forum – Top 10 Clinical Research Achievement Award winner	*New England Journal of Medicine*. 2014 *371*(15): 1407-1417 (as co-author and lead statistician)
2016	Audrey Evans Prize	Advances in Neuroblastoma Research Association, Cairns, Australia	Outstanding Paper in Clinical Research (as a co-author and statistician)
2018	Top 10 papers of 2018	Selected by the journal *Blood*	*Blood.* 2018 131:2183-2192 (as co-author and lead statistician)
2021	Reviewer of the Month	Selected by the journal *Translational Pediatrics*	Reviewer of the Month for March 2021

Report of Funded and Unfunded Projects

Funding Information

Past

Date	Grant Title Grant Type and Number Role on Project (if PI or site PI, total indirect costs) Description of the major goals
1998-2001	Pediatric Oncology Group (POG) Statistical Office and Data Center (SDC) Grant NIH/NCI: U10 CA29139 (5th & 6th competitive renewal) Co-Investigator (PI: Jonathan Shuster) Scientific oversight for design and conduct of national and international clinical and biological trials in pediatric cancers at ~220 treating institutions. Determine new standard of care for pediatric cancer patients in North America, Australia, and New Zealand. Faculty (6) and staff (15) collaborate with POG investigators and perform study design, data collection, safety monitoring, statistical analyses, and manuscript generation.
1999	Pediatric Oncology Group (POG) Statistical Office and Data Center Grant Donor gifts from Dr. Sharon Murphy, Children's Memorial Hospital, Chicago, IL Co-Investigator (PI: Jonathan Shuster) Improve computer infrastructure of the POG Statistical Office
1999-2002	Pediatric Oncology Group (POG) Statistical Office and Data Center grant – Phase I Consortium NIH/NCI: U10 CA57745 (5th competitive renewal) Co-Investigator (PI: Jonathan Shuster) Design and conduct Phase I pediatric cancer clinical trials to determine safety and maximum tolerated dose. Perform study design, data collection, safety monitoring, statistical analyses, and manuscript generation.
2001-2002	Supplemental Funding for The Pediatric Oncology Group Statistical Office and Data Center Grant NIH/NCI: U10 CA37379 Co-Investigator (PI: Jonathan Shuster) Scientific oversight for design and conduct of national/international clinical and biological trials in pediatric cancers at ~220 treating institutions. Determine new standard of care for pediatric cancer. Trial/study design, monitoring, statistical analyses, manuscripts.
2002	Pediatric Oncology Group Statistical Office and Data Center Grant NIH/NCI: U10 CA29139 (7th competitive renewal) Co-Investigator and Site PI (PI: James Anderson); $2,202,258 direct costs to site Scientific oversight for design and conduct of national/international clinical and biological trials in pediatric cancers at ~220 treating institutions. Determine new standard of care for pediatric cancer. Trial/study design, monitoring, statistical analyses, manuscripts.
2002	Supplemental Funding for the Children's Oncology Group Research Data Center NIH/NCI: U10 CA37379 (1st renewal) Co-Investigator and Site PI (PI: James Anderson); $329,925 total direct costs to site Scientific oversight for design and conduct of national/international clinical and biological trials in pediatric cancers at ~220 treating institutions. Determine new standard of care for pediatric cancer. Trial/study design, monitoring, statistical analyses, manuscripts.

Date	Grant Title Grant Type and Number Role on Project (if PI or site PI, total indirect costs) Description of the major goals
2002-2006	Community Clinical Oncology Program of the Children's Oncology Group NIH/NCI: U10 CA95861 (3rd competitive renewal) Co-Investigator and Site PI (PI: Bradley Pollock); $115,052 total direct costs to site Scientific oversight for design and conduct of national/international epidemiologic trials in pediatric cancers. Study design, monitoring, statistical analyses, and manuscripts.
2003-2014	Children's Oncology Group Statistics and Data Center NIH/NCI: U10 CA98413 (3 competitive renewals) Co-Investigator Site PI (PI: James Anderson); $9,016,769 total direct costs to site With the merger of the four pediatric cancer cooperative groups, the COG[1] became the only NIH/NCI funded cooperative group for pediatric cancer. Scientific oversight for design/conduct of national/international clinical/biological trials in pediatric cancer at ~230 treating institutions. Determine improved standard of care. Supervise faculty (3) and staff (18) for study design, data collection, safety monitoring, statistical analyses, and manuscripts. My scientific focus: neuroblastoma clinical research trials.
2003	Supplemental Funding for the Children's Oncology Group (COG[1]) Statistics and Data Center (SDC) NIH/NCI: U10 CA30969 Site PI (PI: James Anderson); $323,320 total direct costs to site See "COG[1] SDC goals" 2003-2004. My roles: Administrator for 18 staff and 4 faculty. Led statistical/data teams for trials of neuroblastoma clinical, biologic, and translational research.
2003-2008	Significance of Genetic Alterations in Neuroblastoma Site PI (PI: John Maris); $98,816 total direct costs to site NIH/NCI: R01 CA87847 Create/maintain Neuroblastoma Virtual Tumor Bank (NVTB). Define inclusion criteria, identify tumor specimens, link genetic data to clinical/outcomes data, perform statistical analyses of prognostic factors, and write manuscripts.
2007-2010	Neuroblastoma Virtual Tumor Bank Neuroblastoma Children's Cancer Society PI ($100,000 total direct costs) Maintain and expand the Neuroblastoma Virtual Tumor Bank (specimen type, amount, banking location, and all associated clinical, genetic, biological, and outcomes data). Review scientific proposals, select and distribute specimens to investigators worldwide.
2008-2012	Trk Expression and Inhibition in Human Neuroblastomas NIH/NCI: R01 CA094194-06 Site PI (PI: Garrett Brodeur); $38,100 total direct costs to site Design experiment, define inclusion criteria, select specimens, link to clinical/outcomes data, and perform statistical analysis of prognostic significance of Trk expression.

Date	Grant Title Grant Type and Number Role on Project (if PI or site PI, total indirect costs) Description of the major goals
2009-2011	Targeting Oncogenic ALK Signaling in Neuroblastoma NIH/NCI: R01 CA140198-01 Site PI (PI: Yael Mosse); $41,196 total direct costs to site Design the experiment and perform statistical analyses to determine the clinical and etiologic relevance of ALK aberrations (mutation, amplification, &/or regional allelic gain) in patients with neuroblastoma.
2008-2013	Genetic Susceptibility Factors in the Etiology of Neuroblastoma NIH/NCI: R01 CA132887-01 Site PI (PI: Andrew Olshan); $41,196 total direct costs to site Design epidemiologic retrospective study of COG[1] neuroblastoma patients. Perform statistical analysis of association of genetic and epidemiologic factors.
2008-2014	Neuroblastomas Therapeutically Applicable Research to Generate Effective Treatments (TARGET) initiative NIH/NCI: 3U10 CA098543 Site PI (PI: John Maris); $155,820 total direct costs to site Using specimens and data from the Neuroblastoma Virtual Tumor Bank, identify specimens for genomic analyses. Link genomic results to clinical and outcomes data and upload data into public repository.
2011-2013	Racial and Ethnic Disparities in Survival in Children with Neuroblastoma Alex's Lemonade Stand Foundation Site PI (PI: Susan L. Cohn); $13,092 total direct costs to site Expand the INRG database to include race and ethnicity and perform statistical analyses of the association of race, ethnicity, and genomic markers of race/ethnicity, with outcome.
2011-2016	The Interactive International Neuroblastoma Risk Group (INRG) database St. Baldrick's Site PI (PI: Susan L. Cohn); $65,140 total direct costs to site Lead a team of international statisticians in data collection for neuroblastoma. Perform database design and test website functionality. Collaborate with investigators worldwide to analyze and interpret data.
2012-2013	The Influence of KIR and FcR Genotype in the Efficacy of mAb and IL2 Immunotherapy NIH: 5R01 CA166105-03 Site PI (PI: Paul Sondel); $9,138 total direct costs to site Responsible for provision of HIPAA de-identified clinical and laboratory data. Link these data to study patients for whom DNA is received. Collaborate to write manuscripts.
2014-2015	Molecular Diagnostics for Risk Stratification and Monitoring in Neuroblastoma NIH: R01 CA182633-01 Site PI (PI: Robert Seeger); $14,932 total direct costs to site The major goals of this project are to perform study design and statistical analysis to identify factor prognostic and/or predictive of outcome in patients with neuroblastoma.

Date	Grant Title Grant Type and Number Role on Project (if PI or site PI, total indirect costs) Description of the major goals
2015-2016	Histologic-related genes for improved treatment assignment in neuroblastoma Rally Foundation for Childhood Cancer PI ($25,000 total direct costs) The major goals of this project are to perform statistical analyses to determine the associations of histologic prognostic factors with genetic aberrations, to identify potential new therapeutic targets.
2011-2016	Dana-Farber/Harvard Cancer Center Support Grant – Biostatistics Core NIH/NCI: 2P30 CA006516-49 Site PI (PI: Edward Benz); $238,974 total direct costs to site The major goals of this project are collaborative study design and statistical analyses for therapeutic and non-therapeutic oncology trials at the Dana-Farber Cancer Institute. Lead the Biostatistics Program of the Dana-Farber/Boston Children's Cancer and Blood Disorders Center.
2012-2016	Dana-Farber/Harvard Cancer Center Support Grant - Survey and Data Management Core NIH/NCI: 2P30 CA006516-49 Site PI and Core Faculty Director (PI: Edward Benz); $1,598,512 total direct costs to site The major goals of this project are to provide vision and leadership for the Survey and Data Management Core's work on survey design, data collection, data management, data analyses, and report generation for DF/HCC investigators.
2013-2016	The University of Massachusetts Boston-Dana-Farber/Harvard Cancer Center Comprehensive Partnership for Cancer Disparities Research NIH/NCI: 5U54 CA156732-04 Site PI and Core Director (PI: Kasisomayajula Viswanath); $53,639 total direct costs to site The major goals of this project are to provide vision and leadership for the Research and Data Analysis Core's collaboration with the Univ of Massachusetts Boston on research into racial disparities in cancer treatment and outcomes.
2010-2017	Gene Transfer for SCID-X1 using a self-inactivating gamma retroviral vector NIH/DIS/NIAID- NIAD: 5U01 AI087628-05 Co-Investigator (PI: David A. Williams) Provide statistical oversight in the study design, electronic data capture, data quality and management, safety monitoring, and statistical analysis of the trial to determine the safety, feasibility and efficacy of the vector. NCT01129544
2014-2016	Exploratory Analysis of Ovarian Cancer Data Repository Clearity Foundation Co-Investigator and Site PI (PI: Laura Shawver) Import data from the Clearity Foundation; perform statistical analyses to confirm prognostic factors; determine the benefit of genomic profile-matched therapy.

Date	Grant Title Grant Type and Number Role on Project (if PI or site PI, total indirect costs) Description of the major goals
2014-2017	Pilot and Feasibility Study of Hematopoietic Stem Cell Gene Therapy for the Wiskott-Aldrich Syndrome NIH/Social & Scientific Systems/NHLBI HHSN 268201200021 Co-Investigator (PI: David A. Williams) The major goals of this project are to provide statistical support for a Phase 1 human gene therapy trial in Wiskott-Aldrich syndrome (WAS); to monitor the safety of the transplant and describe preliminary efficacy results. NCT01410825
2011-2018	Phase 1 Dose Escalation Study of Sorafenib and Irinotecan Combination Therapy in Pediatric Patients with Relapsed or Refractory Solid Tumors Bayer and Onyx Pharmaceuticals, Inc Co-Investigator (PI: Holly Meany) – Investigator initiated Perform study design, data collection, analysis to identify the maximum tolerated dose combination, and recommend a phase 2 dose for further study. NCT01518413
2015-2018	Serum Hepcidin Immunoassay: Laboratory to Marketplace NIH/NIDDK: 5 R44 DK083843-05 Co-Investigator (PI: Mark Westerman) The major goals of this project are to perform a prospective clinical trial to validate a definitive differential diagnostic test, in the form of statistical model, for a rare genetic iron disorder, Iron Refractory Iron Deficiency Anemia (IRIDA). NCT03310736
2016	Phase 2 trial of therapy for atypical teratoid rhabdoid tumor (ATRT) Dana-Farber Cancer Institute Co-Investigator (PI: Susan Chi); $27,400 total direct costs to site The major goals are to perform study design and collaborate on writing the protocol.
2016-2017	Extraorally delivered level light therapy for prevention of oropharyngeal mucositis in pediatric patients undergoing hematopoietic stem cell transplantation NIH: 1R34 DE025908-01 Co-Investigator and Site PI (PI: Nathanial Treister); $11,640 total direct costs to site Planning grant to design a phase 2 trial and write the protocol: to test feasibility of delivery of light therapy and estimate its efficacy in preventing mucositis.
2016-2019	Radiation and alkylator-free bone marrow transplant for patients with Dyskeratosis Congenita Mooney Family Initiative in Clinical and Translational Research in Rare Diseases, Boston Children's Hospital Co-Investigator (PI: Suneet Agarwal) The major goals are to write the protocol, perform study design and statistical analysis to monitor safety and estimate the survival rate for patients with Dyskeratosis Congenita who receive a bone marrow transplant. Publish a manuscript of the trial results. NCT01659606
2016-2019	Trial of CUDC-907 in in Children and Young Adults with Relapsed or Refractory Solid Tumors, CNS Tumors, or Lymphoma Dana-Farber Cancer Institute Friends for Life Grant Site PI and Co-Investigator (PI: Steven Dubois) $40,000 total direct costs to site The major goals of this project are statistical design of the phase 1 trial, and statistical analysis to identify a recommended phase 2 dose for CUDC-907, a dual PI3K/HDAC inhibitor. NCT02909777

Date	Grant Title Grant Type and Number Role on Project (if PI or site PI, total indirect costs) Description of the major goals
2017-2019	Melanoma and non-melanoma skin cancer in children and young adults Pediatric Dermatology Research Alliance Co-Investigator (PI: Jennifer Huang) The major goals of this retrospective study are to perform study design and statistical analysis, to describe the incidence and outcomes of children with melanoma and other skin cancers.
2018-2019	Dana-Farber Cancer Institute's Pediatric Global Health Program Co-Investigator (PI: Leslie Lehmann) The major goal is to provide teaching and training sessions on clinical research for physicians and observers from hospitals in low- and middle-income countries.
2013-2020	Registry of patients with pyruvate kinase deficiency (PKD) Agios Pharmaceuticals Director of Biostatistics (PI: Rachael Grace) – Investigator initiated The major goals of this project are to provide leadership for creating a data registry for PKD patients, to perform statistical analyses to mine the registry, and to collaborate on writing manuscripts.
2016-2020	Pilot and Feasibility Trial of Plerixafor for Hematopoietic Stem Cell (HSC) Mobilization in Patients with Sickle Cell Disease Bluebird Bio, Inc. Co-Investigator (PI: David A. Williams) – Investigator initiated The major goals are to lead the statistical efforts on the project: study design, data management, statistical analysis and interpretation; to describe the feasibility and safety of plerixafor adminstration. Collaborate to write the protocol and manuscripts. NCT02989701
2017-2020	Research on the Pyruvate Kinase Disease (PKD) Registry Rocket Pharmaceuticals Co-Investigator (PI: Rachael Grace) – Investigator initiated The major goal is to lead the statistical support for database design, descriptive statistical analyses of treatment and outcomes of PKD, and data export to Rocket Pharma.
2018-2020	Prognostic significance of STAG2 loss and TP53 mutations in Ewing sarcoma Dana-Farber Cancer Institute Co-Investigator, Site PI (PI: Brian Crompton); $7,571 total direct costs to site The major goals are to perform study design, statistical analysis, and manuscript generation; to estimate the incidence of STAG2 and TP53 mutations and describe the outcome for patient with vs without these mutations.
2014-2021	Multicenter Cohort Study to Evaluate Outcomes after Receipt of Targeted Therapy Matched to an Individualized Cancer Therapy (iCat) Recommendations in Children and Young Adults with Solid Tumors: The iCat2, Genomic Assessment Informs Novel Therapy (GAIN) Consortium Study Medel Fund and C&S Grocers Co-Investigator and Site PI (PI: Katherine Janeway); $143,009 total direct costs to site The main goals for this precision oncology project are to perform study design, provide oversight for data collection, perform statistical analysis to estimate the outcome of children who received matched targeted therapy, and collaborate to write manuscripts.

Date	Grant Title Grant Type and Number Role on Project (if PI or site PI, total indirect costs) Description of the major goals
2021	Integrating Longitudinal Clinical, Sociodemographic and Genomic Data into the National Childhood Cancer Registry (NCCR) NIH 3P30CA006516-55S7 Site PI (PI: Katherine Janeway); $16,149 total direct costs to site The goal of this informatics project is data integration from multiple sources, quality checking, and creating new derived variables, for data export/sharing to NCI's NCCR.
2021	Fragility index in pediatric phase 3 trials Dana-Farber Cancer Institute Co-Investigator (PI: Dubois); $15,123 total direct costs to site The goal of this project is to determine the degree to which the results of phase 3 trials are unstable: We will perform a meta-analysis to quantify how small of a change in patient outcomes would be required before a different answer would have been reached by the trial.
2020-2021	DEsign and conDUCt of dose Escalation trials (DEDUCE) Northwestern Mutual Foundation PI; In-Kind contributions of $96,750 of donated workforce – Investigator initiated The major goal of this project is to create an online, open-source application, DEDUCE, for clinical investigators and statisticians to design and conduct novel phase 1 adaptive design clinical trials. To conduct workshops to train clinicians and statisticians in the use of DEDUCE.
2019-2022	The Lymphatic Anomalies Registry The Lymphatic Malformation Institute Co-Investigator (PI: Denise Adams) The major goal is to provide study design, data management, and statistical analysis of a retrospective/prospective registry of patients with vascular anomalies. To mine the registry and perform descriptive statistical analyses of disease subgroups.
2020-2022	ctDNA as a biomarker in Ewing sarcoma and osteosarcoma 1 million 4 Anna Foundation Co-Investigator and Site PI (PI: David Shulman); $35,419 total direct costs to site The major goal of this project is to design the biologic study, coordinate data transfer from the Children's Oncology Group and linkage with data from Dr. Crompton's lab, perform statistical analyses of the level of ctDNA and outcome according to ctDNA level, and write a manuscript summarizing the results.
2019-2022	Phase 2 trial of palbociclib and ganitumab in patients with relapsed or refractory Ewing sarcoma Dana-Farber Cancer Institute Co-Investigator and Site PI (PI: David Shulman); $36,030 total direct costs to site The major goal of this project is to design and conduct the trial, oversee the data collection, perform statistical analyses to estimate the response rate to palbociclib and ganitumab, and write manuscripts. NCT04129151

Date	Grant Title Grant Type and Number Role on Project (if PI or site PI, total indirect costs) Description of the major goals
2021-2022	A Randomized Phase 2 Study to Examine the Impact of Gut Decontamination on Intestinal Microbiome Composition in Pediatric Allogeneic Hematopoietic Stem Cell Transplant Patients Boston Children's Hospital Co-Investigator (PI: Whangbo) The goals are to design and conduct a randomized trial to determine if gut decontamination prior to transplant is beneficial. Statistical analysis for safety monitoring and manuscript generation will be performed. NCT02641236
2018-2022	Phase 1 Study of the Dual MDM2/MDMX Inhibitor ALRN-6924 in Pediatric Cancer Dana-Farber Cancer Institute Co-Investigator and Site PI (PI: David Shulman); $32,222 total direct costs to site The major goals are to design a novel adaptive phase 2 trial, provide oversight for dose escalation, perform statistical analysis to identify a maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of ALRN-6924, and collaborate for manuscript generation. NCT03654716
2020-2022	Phase II Study of Clofarabine in Patients with Recurrent or Refractory Langerhans Cell Histiocytosis and LCH related Disorders Dana-Farber Cancer Institute Co-Investigator and Site PI (PI: Degar); $15,355 total direct costs to site The goals are to design and conduct a phase 2 trial to detect an efficacy signal of clofarabine for treatment of Langerhans cell histiocytosis (LCH) and LCH-related disorders. Statistical analyses for safety monitoring and manuscript generation will be performed. NCT02425904
2020	Phase 1 Trial of Marizomib Alone and in Combination with Panobinostat for Children with Diffuse Intrinsic Pontine Glioma Dana-Farber Cancer Institute Co-Investigator and Site PI (PI: Warren); $33,900 total direct costs to site The goals are to design and conduct a phase 1 study of the safety and feasibility of administering marizomib in combination with Panobinostat using an adaptive design. Statistical analyses for dose recommendation, safety monitoring and manuscript generation will be performed. (Terminated early due to lack of drug.) NCT04341311
2020-2022	Therapeutic BCL11A enhancer gene editing to induce fetal hemoglobin in Beta-hemoglobinopathy NIH 1OT2HL154984-01 Co-Investigator (PI: Bauer) The goals are to perform study design and statistical analyses, and publish findings.
2021	Fragility
2021-2022	Genetic mutations prognostic of overall survival in Diffuse Intrinsic Pontine Glioma Boston Children's Hospital Co-Investigator (PI: Poussaint) The goals are to design and conduct a retrospective study that identifies genetic risk factors associated with worse survival in patients with Diffuse Intrinsic Pontine Glioma

Date	Grant Title Grant Type and Number Role on Project (if PI or site PI, total indirect costs) Description of the major goals
2022	Study of Autoimmune Hemolytic Anemia (AIHA) at Pediatric ITP Consortium of North America (ICON) Agios Pharmaceuticals, Inc. Co-Investigator (PI: Rachael Grace) The major goals of this project are to create a registry of patients with AIHA, perform descriptive analyses, and publish manuscripts.

Current

Date	Grant Title Grant Type and Number Role on Project (if PI or site PI, total indirect costs) Description of the major goals
2006-2025	Statistical Support for International Landmark Research in Neuroblastoma Little Heroes Pediatric Cancer Research Foundation PI; $179,566 (2006) + $15,000 (2023) Assemble largest ever international database of clinical, biological, and outcomes data for neuroblastoma. Perform data mining on hypotheses not possible in smaller databases. Perform statistical analyses to identify unique pre-treatment groups and reach international consensus on the factors defining these groups. Identify new prognostic factors and create novel risk stratification for assignment of treatment intensity.
2013-2026	Dana-Farber/Children's Hospital Cancer Center Developmental Therapeutics Center of Excellence (COE) Alex's Lemonade Stand Foundation (3rd competitive renewal) Multi-PI (additional PI: Steven Dubois); $1,750,000 total direct costs for current funding cycle beginning in 2024 The major goals of this project are to lead the clinical research infrastructure development and biostatistical science for the Experimental Therapeutics Unit. Develop software tool to connect patients with clinical trials. Create informal consortium of the four institutions who are COEs.
2015-2024	Late Effects After High-Risk Neuroblastoma (LEAHRN) Study St. Baldrick's Foundation Co-Investigator and Site PI (PI: Tara Henderson); $271,554 total direct costs to site The major goals of this project are to lead efforts to create the case report forms, and collect and maintain data, interacting with the COG[1] Statistics and Data Center; and to write the protocol and statistical analysis plan, perform the statistical analysis, interpret the results and collaborate in manuscript preparation. NCT03057626

Date	Grant Title Grant Type and Number Role on Project (if PI or site PI, total indirect costs) Description of the major goals
2016-2027	Dana-Farber/Harvard Cancer Center Cancer Center Support Grant – Biostatistics Core NIH/NCI: 5P30 CA006516-56 (12th competitive renewal) Site PI (PI: Laurie Glimcher); $187,510 total direct costs to site for current funding cycle beginning in 2021 The major goals of this project are collaborative study design and statistical analyses for therapeutic and non-therapeutic oncology trials at the Dana-Farber Cancer Institute. Lead the Biostatistics Program of the Dana-Farber/Boston Children's Cancer and Blood Disorders Center.
2016-2027	Dana-Farber/Harvard Cancer Center Support Grant - Survey and Qualitative Methods Core NIH/NCI: 5P30 CA006516-56 (12th competitive renewal) Site PI and Core Faculty Director (PI: Laurie Glimcher); $2,658,608 total direct costs to site for current funding cycle beginning in 2021 The major goals of this project are to provide vision and leadership for the core's work on survey design, data collection, data management, data analyses, and report generation for DF/HCC investigators.
2016-2023	Phase I/II trial of lentiviral gene transfer for SCID-X1 with low dose targeted busulfan conditioning NIH/NIAID 5U01AI125051-05 Co-Investigator (PI: David A. Williams) This project seeks to test the efficacy and safety of a new self-inactivating lentiviral (LV) vector to treat SCID-X1. The major goals are to design the study and perform statistical analysis of safety and efficacy, and write a manuscript. NCT03311503
2016-2026	The University of Massachusetts Boston-Dana-Farber/Harvard Cancer Center Comprehensive Partnership for Cancer Disparities Research NIH/NCI: 5U54 CA156732-10 (2nd competitive renewal) Site PI and Core Director (PI: Kasisomayajula Viswanath); $600,155 total direct costs to site for current funding cycle beginning in 2021 The major goals of this project are to provide vision and leadership for the Research and Data Analysis Core's collaboration with the Univ of Massachusetts Boston on research into racial disparities in cancer treatment and outcomes.
2017-2023	Gene therapy targeting BCL11A to induce fetal hemoglobin and reduce sickle hemoglobin in patients with Sickle Cell Disease NIH / NHLBI 5R01HL137848-05 Co-Investigator (PI: David A. Williams) Decreasing the expression of BCL11A in sickle cell patients could increase the amount of fetal hemoglobin, while simultaneously reducing the amount of sickle hemoglobin, in their blood and therefore potentially cure the condition. Statistical analysis will test the ability of a virus vector to reduce the expression of BCL11A in red blood cells. NCT03282656

Date	Grant Title Grant Type and Number Role on Project (if PI or site PI, total indirect costs) Description of the major goals
2018-2024	ICON3 Pines - A Phase 3 study of Eltrombopag vs. Standard First-Line Management for newly diagnosed immune thrombocytopenia (ITP) in children Novartis Pharmaceuticals Corporation Co-Investigator and Director of Biostatistics for the Data Coordinating Center (PI: Kristin Shimano); $113,841 total direct costs to site – Investigator initiated The major goals of this project are to design and conduct the trial, lead the Data Coordinating and Statistical Center, perform statistical analyses to determine if eltrombopag is superior to standard first-line management in controlling ITP, and write a manuscript summarizing the results of the trial. NCT03939637
2018-2025	Liquid biopsy approaches to inform osteosarcoma prognosis and tumor evolution NIH/NCI 5R37 CA244355-03 Co-Investigator and Site PI (PI: Brian Crompton); $52,601 total direct costs to site The major goals are to perform study design, data integration, statistical analysis to describe the level of circulating tumor DNA (ctDNA) and outcome according to ctDNA level, and manuscript generation.
2019-2020	Natural History and Biology of Long-Term Late Effects Following Hematopoietic Cell Transplant for Childhood Hematologic Malignancies St. Baldrick's Co-Investigator and Site PI (PI: Christine Duncan); $32,216 total direct costs to site The goals of this study are to describe chronic kidney disease (CKD), metabolic syndrome and osteopenia after transplant, including study design, statistical analysis of the incidence and prognostic factors of late effects, and manuscript generation. NCT02338479
2019-2023	A Phase I Study of TAK-580 (MLN2480) for Children with Low-Grade Gliomas and Other RAS/RAF/MEK/ERK Pathway Activated Tumors Dana-Farber Cancer Institute Co-Investigator and Site PI (PI: Karen Wright); $114,400 total direct costs to site The goals are to design and conduct a novel phase 1 adaptive design to identify the recommended phase 2 dose level within each of two weight subgroups. Statistical analyses for real-time dose recommendation, safety monitoring and manuscript generation will be performed. NCT03429803
2019-2023	A phase 1 study of combination nivolumab and ipilimumab with irradiated GM-CSF secreting autologous neuroblastoma cell vaccine (GVAX) for relapsed or refractory neuroblastoma Dana-Farber Cancer Institute Co-Investigator and Site PI (PI: Natalie Collins); $60,390 total direct costs to site The goals are to design and conduct a phase 1 study of the safety and feasibility of administering GVAX in combination with nivolumab and ipilimumab. Statistical analyses for safety monitoring and manuscript generation will be performed. NCT04239040

Date	Grant Title Grant Type and Number Role on Project (if PI or site PI, total indirect costs) Description of the major goals
2020-2025	International integrated analysis to identify markers of poor survival in high-risk neuroblastoma Solving Kids' Cancer United Kingdom Co-PI (PI: Lucas Moreno); $262,051 total direct costs to site The major goals of this project are to identify biomarkers in a systematic review, integrate biomarker data from disparate sources, and perform statistical analysis using an optimal biomarker combination for risk stratification to identify an "ultra-high-risk" cohort.
2020-2023	Phase 1 Study of Cabozantinib in Combination with Topotecan-Cyclophosphamide for Patients with Relapsed Ewing Sarcoma or Osteosarcoma Dana-Farber Cancer Institute Co-Investigator and Site PI (PI: Dubois); $27,480 total direct costs to site The goals are to design and conduct a phase 2 trial to detect an efficacy signal of cabozantinib for treatment of Ewing sarcoma. Statistical analyses for safety monitoring and manuscript generation will be performed. NCT04661852
2020-2023	Phase II trial of olaparib in combination with AZD6738 in patients with recurrent osteosarcoma Dana-Farber Cancer Institute Co-Investigator and Site PI (PI: Janeway); $35,667 total direct costs to site The goals are to design and conduct a phase 2 trial to detect an efficacy signal of the combination of Olaparib and AZD6738 for treatment of recurrent osteosarcoma. Statistical analyses for safety monitoring and manuscript generation will be performed. NCT03682289
2021-2023	Targeting epigenetic dysregulation in central nervous system tumors Stand Up 2 Cancer (SU2C) Co-Investigator and Site PI (PI: Dubois) $45,206 total direct costs to site The goals are to design and conduct a phase 2 trial of targeted therapy for central nervous system tumors, and publish the results. NCT03936465
2021-2024	Phase 2 Study of Hematopoietic Stem Cell Gene Transfer Inducing Fetal Hemoglobin in Sickle Cell Disease California Institute of Regenerative Medicine (CIRM) CLIN2SCD-12031 Co-Investigator (PI: David A. Williams) The goal of this project is to conduct a clinical trial of therapeutic gene editing of the BCL11A erythroid enhancer in patients with sickle cell disease and beta-thalassemia to durably induce fetal hemoglobin. Perform study design and statistical analysis to test the safety and feasibility of gene editing. NCT05353647
2021-2024	Therapeutic BCL11A enhancer gene editing to induce fetal hemoglobin in Beta-hemoglobinopathy patients NIH / NHLBI 1OT2HL154984-01 Co-Investigator (PI: David A. Williams) The goal of this project is to conduct a clinical trial of therapeutic gene editing of the BCL11A erythroid enhancer in patients with sickle cell disease and beta-thalassemia to durably induce fetal hemoglobin. Perform study design and statistical analysis to test the safety and feasibility of gene editing. NCT# pending

Date	Grant Title Grant Type and Number Role on Project (if PI or site PI, total indirect costs) Description of the major goals
2021-2024	DEsign and conDUCt of dose Escalation trials (DEDUCE) Northwestern Mutual Foundation PI; $86,000 – Investigator initiated The major goal of this project is to create an online, open-source application, DEDUCE, for clinical investigators and statisticians to design and conduct novel phase 1 adaptive design clinical trials. To conduct workshops to train clinicians and statisticians in the use of DEDUCE.
2021-2026	The Genetic Basis of Treatment Outcomes and Late Effects After High-Risk Neuroblastoma NIH X01-CA268005 (Gabriella Miller Kids First Pediatric Research Program) Co-Investigator and Site PI (PI: Sharon Diskin); $0 total direct costs to site (Sequencing only) The major goals of this project are to identify genetic factors contributing to high-risk neuroblastoma treatment failure and adverse late effects through sequencing the germline of 1,100 high-risk neuroblastoma subjects and matched tumor DNA and RNA. Mechanism includes sequencing costs only.
2021-2023	A Phase 1/2 Trial of Uproleselan Combined with High Dose Busulfan Pre-Transplant Conditioning in Hematopoietic Stem Cell Transplantation for Patients with Chemotherapy Resistant Acute Myeloid Leukemia Co-Investigator and Site PI (PI: Horan) $34,274 total direct costs to site The major goals of this project are to design and conduct a phase 1/2 trial to identify the dosage of uproleselan and test for an efficacy signal; to perform statistical analysis and write a manuscript.
2021-2028	A Phase I/II Combination Trial of Tazemetostat with Nivolumab and Ipilimumab for Children with INI1-Negative or SMARCA4-Deficient Tumor Co-Investigator and Site PI (PI: Chi) $134,447 total direct costs to site The goals are to design and conduct a phase 1 study to identify the maximum tolerated dose of tazemetostat, followed by a phase 2 study to detect an efficacy signal of the combination. Statistical analyses for safety monitoring and manuscript generation will be performed
2022-2024	The Dana-Farber/Harvard Cancer Center Glioma SPORE - Biostatistics Core NIH / NCI P50-CA165962-09 Co-Investigator, Director of Biostatistics Core, and Site PI (PI: Batchelor) $53,166 total direct costs to site The major goals of this project are to provide statistical support to the investigators on the SPORE, including the design and conduct clinical trials for patients with glioma.
2022-2024	Association of enoxaparin with risk of thrombosis and hemorrhage Co-Investigator (PI: Kumar) $14,995 total direct costs to site The major goal is to perform a statistical analysis of a cohort of patients with thrombosis from the PHIS database, and to identify risk factors and describe the use of enoxaparin. Technical reports and a manuscript will be written.

Date	Grant Title Grant Type and Number Role on Project (if PI or site PI, total indirect costs) Description of the major goals
2022-2023	Venous thromboembolism and acute ischemic stroke in children with COVID-19 Co-Investigator (PI: Kumar) $25,019 direct costs to site The major goal is to perform a statistical analysis of a cohort of patients with COVID-19 from the PHIS database, and to describe and estimate the incidence of venous thromboembolism and acute ischemic stroke. Technical reports and a manuscript will be written.
2022-2024	A Single Center Pilot Study of Intraoral Photobiomodulation Therapy for the Prevention of Oral Mucositis in Patients Undergoing Myeloablative Allogeneic Hematopoietic Cell Transplantation Co-Investigator (PI: Treister) $34,578 direct costs to site The major goal is to design and conduct a clinical trial to test the safety and feasibility of intraoral photobiomodulation therapy. Statistical analysis will be performed, and technical reports and a manuscript will be written.
2023	Venous thromboembolism and acute ischemic stroke in transgender children Co-Investigator (PI: Kumar) $10,603 direct costs to site The major goal is to perform a statistical analysis of a cohort of transgender patients from the PHIS database, and to describe and estimate the incidence of venous thromboembolism and acute ischemic stroke. Technical reports and a manuscript will be written.
2023-2024	Immature platelet fraction (IPF) in children with immune thrombocytopenic purpura Co-Investigator (PI: Grace) $11,562 direct costs to site The major goal is to perform a retrospective statistical analysis to identify an association between the level of pre-treatment IPF and treatment response. Technical reports and a manuscript will be written.
2023-2025	A Phase 2 randomized trial of intraoral, extraoral, and combined intraoral/extraoral photobiomodulation for the prevention of oral mucositis in patients undergoing myeloablative allogeneic hematopoietic cell transplantation. Co-Investigator (PI: Treister) $55,477 direct costs to site The major goal is to design and conduct a three-arm selection design clinical trial to test the efficacy and safety of intraoral and extraoral photobiomodulation therapy. Statistical analysis will be performed, and technical reports and a manuscript will be written.
2024	Outcomes associated with upfront exposure to MIBG therapy for High-Risk Neuroblastoma NIH/NCI/Children's Oncology Group - Star Act Co-Investigator (PI: Diller) $9,658 direct costs to site The major goal is to perform a case-control study using data from COG study ALTE15N2 to identify late effects associated with MIBG treatment. Statistical analysis will be performed, and technical reports and a manuscript will be written.

Training Grants and Mentored Trainee Grants

Date	Grant Title Grant Type and Number Role on Project (if PI or site PI, total indirect costs) Description of the major goals
2009-2010	Using item response theory to improve children's quality of life assessment NIH 1K23HD057146-01A2 Mentor of I-Chan Huang The major goal is to train Dr. Huang to become an independent researcher in the area of children's health-related quality of life (HRQOL) assessment, which measures physical and psychosocial functioning, and its clinical application.
2014-2019	Research Training in Pediatric Oncology NIH 2T32CA136432-06A1 Faculty The major goal is to train physicians who will be the future academic leaders in basic and/or clinical pediatric oncology research and who will work to reduce the burden of cancer in the pediatric population.

Current Unfunded Projects

Year(s) funded	Role on Project/ Title of Project Purpose of the Project
2010-present	U.S. News and World Report – Best Children's Hospitals survey Role: Statistician The major goal of this project was to accurately and reproducibly answer questions on the survey on an annual basis, including the 5-year pediatric cancer survival rates and number of oncology patients on clinical trials.
2012-present	Datamart: The Pediatric Patient Informatics Platform (*PPIP*) Role: PI The major goal of this project is to create and maintain a datamart to serve as a local and national resource. The *PPIP* datamart integrates patient data (clinical, outcome, genomics, specimens) and protocol data (PI, accrual goal, activation date) from disparate sources at BCH and DFCI, to facilitate research, operations and safety reporting, and strategic planning.

<u>Report of Local Teaching and Training</u>

Teaching of Students in Courses

Year(s)	Course Title Type of student/audience	Location Level of Effort
2006-2008	Science of Clinical and Translational Research Course Medical students, residents, fellows, and faculty members	University of Florida College of Medicine Annual 1 hr lecture
2007	Writing the statistical section of a grant Epidemiology graduate students	University of Florida, Division of Epidemiology and Health Policy Research 1 hr lecture

Formal Teaching of Residents, Clinical Fellows and Research Fellows (post-docs)

Year(s)	Course Title Type of student/audience	Location Level of Effort
2005-2009	Evaluating experimental design and statistics of research publications 2nd and 3rd year surgery residents	University of Florida, Dept of Surgery Annual 1-hour lecture
2009-2017	Data Blitz Fellows and faculty	Dana-Farber Cancer Institute/ Boston Children's Hospital, Division of Hematology/Oncology Annual 5-min lecture, 5 min Q&A
2010-present	Consolidation course Fellows and faculty	Dana-Farber Cancer Institute/Boston Children's Hospital, Division of Pediatric Hematology/Oncology Annually: two 1-hour lectures
2017	Innovative Phase 1 Study Designs Fellows, faculty, and staff of the Experimental Therapeutics Program	Dana-Farber Cancer Institute/Boston Children's Hospital, Division of Pediatric Hematology/Oncology 1-hour lecture

Research Supervisory and Training Responsibilities

Year(s)	Type of responsibility	Level of Effort
2001-2008	Advised/instructed a statistics department graduate assistant in the design and statistical analysis of the Children's Oncology Group clinical trials	Mentorship 3 days a week for 1 year
2009-present	Train and educate statisticians of the Biostatistics Program: authorship on scholarly works for peer-reviewed publication	Mentorship 4-5 hours per week
2009-present	Train and educate residents, fellows, and junior faculty regarding the design and conduct of clinical research	Mentorship 2-4 hours per week

Formally Mentored Harvard Medical, Dental, and Graduate Students

Year(s)	Student Type of supervision/ Specific accomplishment
2016-2022	Derek Shyr, MS / Department of Biostatistics, Harvard School of Public Health Class of 2022 Conducting clinical research in neuroblastoma prognostic factors in my laboratory. Poster presentation at the Dana-Farber/Harvard Cancer Center (DF/HCC) Celebration of Early Career Investigators in Cancer Research. Submitted a neuroblastoma risk stratification manuscript.

Year(s)	Student Type of supervision/ Specific accomplishment
2020-2021	Alana McGovern, MS / Department of Biostatistics, Harvard School of Public Health Class of 2021 Conducted an adaptive designed phase 1 trial for pediatric low-grade glioma. Poster presentation at the DF/HCC Celebration of Early Career Investigators in Cancer Research.
2021-present	Hannah Bender / Medical Student, Harvard Medical School Career stage: HMS student, Resident at BCH. Mentoring role: Clinical research mentor. Accomplishments: Poster presentation at the 2021 American Society of Clinical Oncology annual meeting and 2023 manuscript published in the *Journal of Clinical Oncology* on reduction of therapy in neuroblastoma due to age stratification change.

Other Mentored Trainees and Faculty

Year(s)	Student Type of supervision/ Specific accomplishment
2000-2013	Patrick McGrady, MS / retired Career stage: Statistician, University of Florida. Mentoring role: Research supervisor. Accomplishments: Authorship on 17 scholarly publications on pediatric cancer as a result of my supervision, including two in *Nature* and one in *New England Journal of Medicine.*
2002-2005	Pavlina Rumcheva, PhD / Senior Risk Analyst, GE Capital, Sydney, Australia Career stage: Statistics graduate student, University of Florida. Mentoring role: Research advisor & graduate committee member. Accomplishments: Published two neuroblastoma manuscripts, including one in *Journal of Clinical Oncology.* PhD at University of Florida.
2002-2014	Allen Buxton, MS / Statistician, COG[1], Monrovia, CA Career stage: Statistician, Children's Oncology Group. Mentoring role: Research supervisor. Accomplishments: Authorship on six scholarly publications on neuroblastoma as a result of my supervision, including two in *New England Journal of Medicine.*
2002-2009	Rani George, MD, PhD / Associate Professor of Pediatrics, Dana-Farber Cancer Institute, Harvard Medical School Career stage: Fellow. Mentoring role: Clinical research mentor. Accomplishments: Published three manuscripts, including one in *Nature.* Achieved a faculty appointment in HMS and then promoted to Associate Professor.
2003-2009	Robert Gerbing, MA / Statistician, COG[1], Monrovia, CA Career stage: Statistician, Children's Oncology Group. Mentoring role: Research supervisor. Accomplishments: Authorship on five scholarly publications on neuroblastoma as a result of my supervision, including two in the *Journal of Clinical Oncology.*
2004-2012	Suzanne Shusterman, MD / Assistant Professor of Pediatrics, Dana-Farber Cancer Institute, Harvard Medical School Career stage: Instructor. Mentoring role: Clinical research mentor, COG[1] mentor. Accomplishments: Wrote two clinical trial protocols, conducted trials, presentations at the American Society of Clinical Oncology, and published two manuscripts, including one in the *Journal of Clinical Oncology.*

Year(s)	Student Type of supervision/ Specific accomplishment
2003-2009	Rochelle Bagatell, MD / Professor of Pediatrics, Children's Hospital of Philadelphia; Chair, Neuroblastoma Committee, Children's Oncology Group (COG[1]) Career stage: Assistant Professor. Mentoring role: Clinical research mentor, COG[1] mentor. Accomplishments: Design, protocol writing, and conduct of two practice-changing clinical trials for neuroblastoma in COG[1]. Published two manuscripts in *Journal of Clinical Oncology*.
2006-2008	John Yap, PhD / Mathematical Statistician, Food and Drug Administration (FDA) Career stage: Graduate student. Mentoring role: Clinical research and statistical methods mentor. Accomplishments: Published one manuscript and collaborated on SIOP award-winning abstract.
2006-2009	Yang Zhang, MS / Statistician, COG[1], University of Florida Career stage: First year biostatistician. Mentoring role: Clinical research and statistical methods mentor. Accomplishments: Authorship on three scholarly publications, including one in *Journal of Clinical Oncology*.
2007-2010	I-Chan Huang, PhD / Faculty member, St. Jude Children's Research Hospital Career stage: Post-doctoral fellow. Mentoring role: Outcomes research mentor. Accomplishments: K23 award from the NIH, "Using item response theory to improve children's quality of life assessment".
2007-present	Arlene Naranjo, PhD / Research Associate Professor of Biostatistics, University of Florida Career stage: Graduate student. Mentoring role: Clinical research, statistical methods, and COG[1] mentor. Accomplishments: Published 38 manuscripts, including one in *Lancet Oncology*. Lead Statistician for the COG[1] Neuroblastoma Committee.
2007-2008	Steven Dubois, MD, MPH / Associate Professor of Pediatrics and Director of Experimental Therapeutics, Boston Children's Hospital and Dana-Farber Cancer Institute, Harvard Medical School Career stage: Fellow. Mentoring role: Clinical research mentor, INRG mentor. Accomplishments: First paper in *Pediatric Blood and Cancer* (2008), plus >5 publications. Design and conduct of clinical trials, including adaptive designs.
2008-2010	Tamekia Jones, PhD / Associate Professor of Pediatrics & Preventive Medicine, University of Tennessee Health Science Center; Director, Children's Foundation Research Institute Biostatistics Core, Le Bonheur Children's Hospital, Memphis, TN Career stage: First PhD faculty position. Mentoring role: Clinical research, statistical methods, and COG[1] mentor. Accomplishments: Design, conduct, and analysis of COG[1] trials.
2008-2010	Xiaomin Lu, PhD / Assistant Professor of Biostatistics, University of Florida Career stage: Research Assistant Professor. Mentoring role: Clinical research, statistical methods, and COG[1] mentor. Accomplishments: Design, conduct, and analysis of COG[1] trials.
2008-2009	Joanne Lagmay, MD / Associate Professor of Pediatrics, University of Florida Career stage: Resident. Mentoring role: Clinical research mentor. Accomplishments: Publication in *Clinical Cancer Research*. Now leads the Pediatric Solid Tumor program at Shands Hospital, University of Florida.

Year(s)	Student Type of supervision/ Specific accomplishment
2009-2010	Ning Li, PhD / Associate Professor, Division of General Internal Medicine and Health Services Research, University of California-Los Angeles Career stage: first-year Assistant Professor. Mentoring role: Clinical research, statistical methods, and COG[1] mentor. Accomplishments: Design, conduct, and analysis of COG[1] trials.
2010-2020	Veronica Moroz, MS / Biostatistician, Cancer Research UK Clinical Trials Unit, University of Birmingham, Birmingham, UK Career stage: junior biostatistician. Mentoring role: Clinical research, statistical methods, and INRG mentor. Accomplishments: Design, conduct, and publication of two INRG projects.
2010-present	Paola Angelini, MD / Consultant in Pediatric Oncology, The Royal Marsden NHS Foundation Trust Career stage: Fellow. Mentoring role: Clinical research mentor. Accomplishments: One neuroblastoma publication, and another neuroblastoma manuscript in preparation.
2010-2011	Kelly Strait, MS / Biostatistician, Center for Outcomes Research and Evaluation, Yale School of Medicine Career stage: first-year statistician. Mentoring role: Clinical research and statistical methods mentor. Accomplishments: Authorship on four scholarly publications on pediatric cancer or hematology as a result of my supervision.
2010-present	Madhumitha Sridharan, BS / Database Administrator III, Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Harvard Medical School Career stage: Database Administrator I. Mentoring role: Clinical research, informatics, and data management. Accomplishments: Authorship on six scholarly publications on pediatric cancer or hematology as a result of my supervision. Major achievements on the *PPIP* datamart. Two promotions: from Database Administrator (DBA) I, to DBA II, to DBA III.
2010-2011	Daniel Bauer, MD, PhD / Associate Professor of Pediatrics, Director of the Gene Therapy Program, Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Harvard Medical School Career stage: Fellow. Mentoring role: Clinical research mentor. Accomplishments: Wrote a protocol for a nut midline carcinoma registry; published a manuscript in the *Journal of Clinical Oncology*.
2010-2012	Paola Friedrich-Medina, MD, MPH / Assistant Member, St. Jude Faculty, St. Jude Children's Research Hospital Career stage: Fellow. Mentoring role: Clinical research mentor. Accomplishments: Study design, conduct, and manuscript publication.
2010-2012	Nathan Robison, MD / Assistant Professor of Pediatrics at the University of Southern California Keck School of Medicine Career stage: Clinical Instructor. Mentoring role: Clinical research mentor. Accomplishments: At DFCI, design, analysis, and publication of a retrospective study

Year(s)	Student Type of supervision/ Specific accomplishment
2010-2020	Inga Hofmann, MD, PhD / Assistant Professor, Director - Pediatric Bone Marrow Transplant Program, Medical Director – University of Wisconsin Program for Advanced Cellular Therapy, Division of Pediatric Hematology, Oncology and Bone Marrow Transplant, University of Wisconsin School of Medicine and Public Health Career stage: Instructor. Mentoring role: Clinical research mentor. Accomplishments: At BCH, protocol writing, design and creation of two rare disease registries, resulting in two abstracts and two publications.
2010-2018	Allison O'Neill, MD / Assistant Professor of Pediatrics, Clinical Director – Solid Tumor Center, Boston Children's Hospital and Dana-Farber Cancer Institute, Harvard Medical School Career stage: Fellow. Mentoring role: Clinical research mentor. Accomplishments: design and conduct of three clinical research protocols, two retrospective studies, and one publication.
2010-2015	Cameron Trenor, MD / Senior TME 1, Novartis Institutes for BioMedical Research Career stage: Fellow. Mentoring role: Clinical research mentor. Accomplishments: Designed four clinical trials and created a rare disease registry.
2011-2017	Christine Duncan, MD / Assistant Professor of Pediatrics, Medical Director of Clinical Research and Clinical Development, Gene Therapy Program, Boston Children's Hospital and Dana-Farber Cancer Institute, Harvard Medical School Career stage: Clinical Instructor. Mentoring role: Clinical research mentor. Accomplishments: Obtained a 5-year grant from St. Baldrick's to study late effects after transplant.
2012-2105	Phillip Poorvu, MD / Instructor in Medicine, Dana-Farber Cancer Institute, Harvard Medical School Career stage: Medical student. Mentoring role: Clinical research mentor. Accomplishments: publication of a retrospective analysis on the effectiveness of GnRH agonists.
2012-2021	Dongjing Guo, MPH / Senior Biostatistician, Intuitive Surgical Inc, Los Altos, CA Career stage: Biostatistician I (new graduate). Mentoring role: Clinical research and statistical methods mentor. Accomplishments: Authorship on 16 scholarly publications on pediatric cancer or hematology as a result of my supervision. Two promotion at HMS: from Biostatistician I to II, and II to III.
2012-2016	Venee Tubman, MD, MMSc / Assistant Professor of Pediatrics-Hematology, Co-Director, Hemoglobinopathies Program, Texas Children's Hospital, Baylor College of Medicine Career stage: Fellow. Mentoring role: Clinical research mentor. Accomplishments: Design, conduct, and publication of a sickle cell disease infant screening study in Liberia.
2012-2015	Natasha Archer, MD / Assistant Professor of Pediatrics, Boston Children's Hospital and Dana-Farber Cancer Institute, Harvard Medical School Career stage: Fellow. Mentoring role: Clinical research mentor. Accomplishments: Design and conduct a screening/education study of sickle cell disease in Haiti.
2012-2021	Natalie Bezler, MD/ Assistant Professor of Pediatrics, Connecticut Children's Medical Center, University of Connecticut Career stage: Fellow. Mentoring role: Clinical research mentor. Accomplishments: Study design and conduct, and a publication on health literacy (project funding obtained).

Year(s)	Student Type of supervision/ Specific accomplishment
2012-2018	Kira Bona, MD/ Assistant Professor of Pediatrics, Boston Children's Hospital and Dana-Farber Cancer Institute, Harvard Medical School Career stage: Fellow. Mentoring role: Clinical research mentor. Accomplishments: Wrote a protocol, obtained grant funding, and published three manuscripts on financial hardship/disparity in families of children with cancer.
2012-present	Daniel Morgenstern, MD / Assistant Professor of Paediatrics, Hospital for Sick Kids, University of Toronto Career stage: Fellow, Royal Marsden Hospital. Mentoring role: Clinical research mentor, INRG mentor. Accomplishments: Conducted and published four manuscripts on neuroblastoma prognostic factors. Wrote and submitted a 5-year grant to Canadian Institutes of Health Research for an international randomized cancer prevention trial for patients with Li-Fraumeni syndrome.
2012-2017	Pratiti Bandopadhayay, MBBS, PhD / Assistant Professor of Pediatrics, Boston Children's Hospital and Dana-Farber Cancer Institute, Harvard Medical School Career stage: Fellow. Mentoring role: Clinical research mentor. Accomplishments: Wrote a protocol and published two retrospective studies on low-grade glioma and ependymoma.
2013-2017	Richard Li, MD / Internist, Brookline, MA Career stage: Resident. Mentoring role: Clinical research mentor. Accomplishments: Designed, conducted, and published a retrospective study on patterns of relapse in high-risk neuroblastoma in *International Journal of Radiation Oncology Biology Physics*.
2013-present	Erica Esrick, MD/ Instructor, Boston Children's Hospital and Dana-Farber Cancer Institute, Harvard Medical School Career stage: Fellow. Mentoring role: Clinical research mentor. Accomplishments: Wrote three clinical trial protocols; one activated so far. Two publications, including one in *New England Journal of Medicine*.
2013-2017	Suneet Agarwal, MD, PhD / Associate Professor of Pediatrics, Boston Children's Hospital and Dana-Farber Cancer Institute, Harvard Medical School Career stage: Instructor. Mentoring role: Clinical research mentor. Accomplishments: Design and conduct of clinical trial for dyskeratosis congenita; presentation at the American Society of Hematology. Manuscript underway.
2013-present	David Shulman, MD / Instructor, Boston Children's Hospital and Dana-Farber Cancer Institute, Harvard Medical School Career stage: Resident. Mentoring role: Clinical research mentor. Accomplishments: Design, conduct, and publication of two retrospective studies. Design, protocol writing, and conduct of two ongoing adaptive clinical trials. Mentor on his K08 grant application.
2013-2023	Junne Kamihara, MD / Instructor, Boston Children's Hospital and Dana-Farber Cancer Institute, Harvard Medical School. Career stage: Fellow. Mentoring role: Clinical research mentor. Accomplishments: Design and conduct of two ongoing genetic predisposition protocols.
2013-2018	Robert Grant Rowe, MD / Assistant Professor of Pediatrics, Boston Children's Hospital and Dana-Farber Cancer Institute, Harvard Medical School Career stage: Resident. Mentoring role: Clinical research mentor. Accomplishments: Design, conduct, and publication of a retrospective study on risk factors for infection in stem cell transplant.

Year(s)	Student Type of supervision/ Specific accomplishment
2013-2023	Jennifer Huang, MD / Associate Professor, Boston Children's Hospital, Harvard Medical School Career stage: Instructor. Mentoring role: Clinical research mentor. Accomplishments: Design, conduct, and publication of six retrospective research studies on risk factors for skin cancer in children. Designed and wrote protocol for therapeutic trial for skin cancer prevention (ongoing).
2013-2018	Johanna Sheu Song, MD / Internist, Dermatology Clinic at Mount Zion, University of California-San Francisco Career stage: HMS student. Mentoring role: Clinical research mentor. Accomplishments: Design, conduct, and publication of three retrospective research studies on risk factors for skin cancer in children.
2013-2016	Collin Van Ryn, MS / Researcher, Biostatistics, University of Minnesota Career stage: first-year statistician. Mentoring role: Clinical research and statistical methods mentor, COG[1] mentor. Accomplishments: Authorship on seven scholarly publications on pediatric cancer as a result of my supervision.
2014-2015	Craig Forester, MD / Assistant Professor, Pediatrics-Heme/Oncology and Bone Marrow Transplantation, University of Colorado Career stage: Resident. Mentoring role: Clinical research mentor. Accomplishments: Design, conduct, and publication of a retrospective research study on outcome and predictors of pediatric aplastic anemia.
2014-2018	Christina Ullrich, MD / Assistant Professor of Pediatrics, Boston Children's Hospital and Dana-Farber Cancer Institute, Harvard Medical School Career stage: Clinical Instructor. Mentoring role: Clinical research mentor. Accomplishments: Design of two prospective quality of life studies. Publication of two retrospective studies, including one evaluating end-of-life care patterns.
2014-2017	Michelle Lee, MD, PhD / Assistant Professor of Pediatrics, Director of the Transplantation and Cellular Therapy Program, The Children's Hospital at Montefiore. Albert Einstein College of Medicine Career stage: Clinical Instructor. Mentoring role: Clinical research mentor. Accomplishments: Designed and wrote a clinical research transplant protocol.
2014-2018	Brian Crompton, MD / Assistant Professor of Pediatrics, Boston Children's Hospital and Dana-Farber Cancer Institute, Harvard Medical School Career stage: Clinical Instructor. Mentoring role: Clinical research mentor. Accomplishments: Design, conduct, and publication of research on the association of circulating tumour DNA with inferior outcomes in sarcoma. Obtained R37 grant funding.
2014-2018	Prasanna Ananth, MD / Assistant Professor of Pediatrics (Hematology/Oncology), Yale School of Medicine Career stage: Fellow. Mentoring role: Clinical research mentor. Accomplishments: Design, conduct, and publication of a retrospective research study of medical marijuana in children with cancer.
2014-2018	Jonathan Marron, MD / Instructor in Pediatrics, Boston Children's Hospital and Dana-Farber Cancer Institute, Harvard Medical School Career stage: Fellow. Mentoring role: Clinical research mentor. Accomplishments: Wrote GAIN consortium protocol aims about reporting of genomic results. Two grant proposals written and funded. Won an American Society of Clinical Oncology young investigator award.

Year(s)	Student Type of supervision/ Specific accomplishment
2014-2016	Sonia Rubens, PhD / Assistant Professor, Department of Counseling Psychology, Santa Clara University, Santa Clara, CA Career stage: post-doctoral fellow. Mentoring role: Clinical research mentor. Accomplishments: Design, conduct, and publication of a prospective study of a pediatric cancer school consultation program.
2014-2017	Lisa Northman, PhD / Instructor in Psychology, Clinical Director of Psychosocial Services for Pediatric Stem Cell Transplant, Boston Children's Hospital and Dana-Farber Cancer Institute, Harvard Medical School Career stage: Instructor. Mentoring role: Clinical research mentor. Accomplishments: Design, conduct, and publication of a two prospective studies of a hospital-based school liaison program for children with cancer.
2014-present	Joanna Yi, MD / Assistant Professor, Dept of Pediatrics, Section of Hematology/Oncology, Baylor College of Medicine Career stage: Fellow. Mentoring role: Clinical research mentor. Accomplishments: Design and write two phase 1/2 clinical trial protocols (ongoing).
2014-present	Rachael Grace, MD / Associate Professor of Pediatrics, Boston Children's Hospital, Harvard Medical School Career stage: Instructor. Mentoring role: Clinical research mentor. Accomplishments: Built prospective registry of rare patients with pyruvate kinase deficiency (PKD). Award for Top 10 papers of 2018 from *Blood*. Four abstracts and five manuscripts published. Design, protocol writing, and conduct of phase 3 clinical trial for immune thrombocytopenia (ITP) (ICON3 - ongoing).
2014-2018	Susanne Baumeister, MD / Assistant Professor of Pediatrics, Boston Children's Hospital and Dana-Farber Cancer Institute, Harvard Medical School Career stage: Fellow. Mentoring role: Clinical research mentor. Accomplishments: Wrote a phase 2 protocol for a neuroblastoma vaccine trial. Funded by my Alex's Lemonade Stand Foundation grant.
2014-present	Lucas Moreno, MD, PhD / Clinical Director, Paediatric Oncology and Haematology, Vall d'Hebron Hospital, Barcelona, Spain Career stage: Post-doctoral Investigator. Mentoring role: Clinical research mentor, INRG mentor. Accomplishments: Design and publication of a retrospective international neuroblastoma study. Three neuroblastoma manuscripts in preparation. Obtained 3-year $420,000 grant from Solving Kids Cancer, on prognostic factors in high-risk neuroblastoma.
2015-2023	Daniel Gundersen, PhD / Lead Scientist, Dana-Farber Cancer Institute Career stage: Senior Scientist. Mentoring role: Clinical research mentor, INRG mentor. Accomplishments: Promoted to Lead Scientist. Synergistic for substantial growth in the DF/HCC Survey and Qualitative Methods Core in terms of quantity and quality of grants and funding.
2015-present	Anna Revette, PhD / Senior Scientist, Dana-Farber Cancer Institute Career stage: Scientist II. Mentoring role: Clinical research mentor. Accomplishments: Promoted to Senior Scientist. Submitted a NIH R50 grant. Synergistic for substantial growth in the DF/HCC Survey and Qualitative Methods Core.

Year(s)	Student Type of supervision/ Specific accomplishment
2015-2018	Amanda Marinoff, MD / Fellow, Pediatric Hematology/Oncology, University of California San Francisco Medical Center Career stage: HMS student. Mentoring role: Clinical research mentor. Accomplishments: Published a manuscript in on a retrospective study.
2015-2019	Mark Applebaum, MD / Assistant Professor of Pediatrics, University of Chicago Career stage: Fellow. Mentoring role: Clinical research mentor, INRG mentor. Accomplishments: Published 4 manuscripts in high-impact factor journals. Audrey Evans Prize in Clinical Research at the 2016 Advances in Neuroblastoma Research meeting. Brigid Leventhal Special Merit Award from the Conquer Cancer Foundation.
2015-2019	Lillian Guenther, MD / Instructor of Pediatrics, Boston Children's Hospital and Dana-Farber Cancer Institute, Harvard Medical School Career stage: Fellow. Mentoring role: Clinical research mentor. Accomplishments: Published a retrospective analysis of sarcoma patients in *Pediatric Blood and Cancer*.
2015-present	Clement Ma, PhD/ Assistant Professor of Biostatistics, Centre for Addition and Mental Health, Dalla Lana School of Public Health, University of Toronto Career stage: Instructor (first-year faculty). Mentoring role: Clinical research and statistical methods mentor. Accomplishments: Published four manuscripts to date; two additional papers underway. Lead biostatistician on >50 projects while at HMS. Informatics achievements on the *PPIP* datamart. Statistical methods development on the DEDUCE adaptive phase 1 trial design website. Promoted to Assistant Professor of Pediatrics while at HMS.
2015-2020	Hasan Al-Sayegh, MS/ Senior Researcher, Axios International, Dubai, United Arab Emirates Career stage: Biostatistician I. Mentoring role: Clinical research and statistical methods mentor. Accomplishments: Authorship on 12 scholarly publications on pediatric cancer or hematology as a result of my supervision. Promoted to Biostatistician II while at HMS.
2015-2020	Ami Desai, MD / Assistant Professor of Pediatrics, Division of Pediatric Oncology/Hematology/Transplant, University of Chicago Career stage: Fellow. Mentoring role: Clinical research mentor, INRG mentor. Accomplishments: Wrote a clinical trial protocol at the AACR/ASCO Methods in Clinical Cancer Research Workshop; trial is underway. Presentation at the 2018 Advances in Neuroblastoma Research meeting. Two publications in the *Journal of Clinical Oncology*.
2016-2023	Kevin Campbell, MD / Fellow, Boston Children's Hospital and Dana-Farber Cancer Institute, Harvard Medical School Career stage: HMS student. Mentoring role: Clinical research mentor. Accomplishments: Four publications on retrospective analyses. Design and conduct of a clinical trial. Accepted to the fellowship program in our division.
2017-present	Pei-Chi (Paige) Kao, MPH / Biostatistician II, Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Harvard Medical School Career stage: Biostatistician I (new graduate). Mentoring role: Clinical research and statistical methods mentor. Accomplishments: Authorship on six scholarly publications on pediatric cancer or hematology as a result of my supervision. Promotion to Biostatistician II.

Year(s)	Student Type of supervision/ Specific accomplishment
2017-2020	Anran (Annie) Li, BS / Medical student, University of Michigan Career stage: undergraduate; Wellesley intern. Mentoring role: Clinical research and statistical methods mentor. Accomplishments: Learned SAS programming, database design, statistical methods, and diagnostic coding systems. Authorship on two scholarly publications on pediatric cancer or hematology as a result of my supervision. Major achievements on the *PPIP* datamart. Acceptance to medical school.
2017-2020	Elizabeth Sokol, MD / Assistant Professor of Pediatrics, Hematology, Oncology, and Stem Cell Transplantation, Northwestern University Feinberg School of Medicine Career stage: Fellow. Mentoring role: Clinical research mentor, INRG mentor. Accomplishments: Two publications in the *Journal of Clinical Oncology*. Presentation at the 2018 Advances in Neuroblastoma Research meeting.
2018-2020	Connie Zhong, MD / Resident, Brigham and Women's Hospital, Harvard Medical School Career stage: HMS student. Mentoring role: Clinical research mentor. Accomplishments: Publication on non-melanoma skin cancer.
2018-2021	Maya Ilowite, MD / Instructor in Pediatrics, Boston Children's Hospital and Dana-Farber Cancer Institute, Harvard Medical School Career stage: Fellow. Mentoring role: Clinical research mentor. Accomplishments: Submitted manuscript on our prospective study of health literacy in patients and parents of children with cancer.
2018-present	Natalie Collins, MD, PhD / Instructor in Pediatrics, Boston Children's Hospital and Dana-Farber Cancer Institute, Harvard Medical School Career stage: Fellow. Mentoring role: Clinical research mentor. Accomplishments: Design and conduct (underway) of two phase 2 clinical trials of novel targeted therapy for cancer.
2019-2023	Adam Durbin, MD, PhD / Assistant Member, St. Jude Faculty, St. Jude Children's Research Hospital Career stage: Fellow. Mentoring role: Clinical research mentor. Accomplishments: Published a study of pAKT in neuroblastoma/ganglioneuroblastoma vs ganlioneuroma. New translational neuroblastoma research project underway. K08 grant application.
2019-2020	Danielle Bitterman, MD / Instructor of Radiation Oncology, Brigham and Women's Hospital/Dana-Farber Cancer Institute, Harvard Medical School Career stage: Fellow. Mentoring role: Clinical research mentor. Accomplishments: Published a study of racial disparities in proton radiotherapy in *JAMA Oncology*.
2019	Alexandra Nieuwesteeg / Medical Student, Royal College of Surgeons, Dublin, Ireland Career stage: Medical Student. Mentoring role: Clinical research mentor. Accomplishments: Data curation - Categorization and improved coding of toxicity in neuroblastoma patients receiving dinutuximab.
2019	Yaa Obeng / Undergraduate, Amherst College, Amherst, MA Career stage: Undergraduate and DF/HCC CURE program summer intern. Mentoring role: Clinical research and statistical mentor. Accomplishments: - Publication on prognostic factors LDH and ferritin in neuroblastoma.
2019-present	Suzanne Forrest, MD / Instructor in Pediatrics, Boston Children's Hospital and Dana-Farber Cancer Institute, Harvard Medical School Career stage: Fellow. Mentoring role: Clinical research mentor. Accomplishments: Design and conduct (underway) of two phase 2 clinical trials of novel targeted therapy for cancer.

Year(s)	Student Type of supervision/ Specific accomplishment
2021-present	Emma Anghel / Undergraduate, Wellesley College Career stage: Undergraduate, Wellesley summer intern. Mentoring role: Clinical research and biostatistical methods mentor, INRG mentor. Accomplishments: Analysis of sex as a neuroblastoma prognostic factor. Manuscript draft in progress.
2021-2023	Whitney Eng, MD / Instructor in Pediatrics, Boston Children's Hospital, Harvard Medical School Career stage: Instructor. Mentoring role: Clinical research mentor. Accomplishments: Manuscript in progress on vascular anomalies.
2021-2024	Michelle Schoettler, MD / Acting Assistant Professor of Pediatrics, Children's Heathcare of Atlanta, Emory University School of Medicine Career stage: Fellow. Mentoring role: Clinical research mentor. Accomplishments: Several retrospective research projects in progress.
2021-present	Nan Chen, MS / Biostatistician I, Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Harvard Medical School Career stage: Biostatistician I. Mentoring role: Clinical research and statistical methods mentor. Accomplishments: Authorship on scholarly publications on pediatric cancer or hematology as a result of my supervision.
2021-present	Kee Kiat (Aaron) Yeo, MD / Instructor in Pediatrics, Boston Children's Hospital and Dana-Farber Cancer Institute, Harvard Medical School Career stage: Instructor. Mentoring role: Clinical research mentor. Accomplishments: Manuscript in development on a retrospective study of IDH mutant glioma.
2021-present	Mary Jane Lim Fat, MD / Fellow, Boston Children's Hospital and Dana-Farber Cancer Institute, Harvard Medical School Career stage: Fellow. Mentoring role: Clinical research mentor. Accomplishments: Manuscript in development on a retrospective study of IDH mutant glioma.
2022-present	Riten Kumar, MD, MSc / Associate Professor of Pediatrics, Boston Children's Hospital, Harvard Medical School Career stage: Assoc Professor. Mentoring role: Clinical research mentor. Accomplishments: Manuscripts in development on VTE during COVID and VTE in transgender children.
2022-present	Boris Decarolis, MD / University of Cologne, UOC Children's Hospital Career stage: junior faculty. Mentoring role: Clinical research mentor. Accomplishments: Manuscript in development on changes in therapy-associated outcome over time in neuroblastoma
2023-present	Jung Joo Kim / undergraduate student, Wellesley College Career stage: student. Mentoring role: Clinical research mentor. Accomplishments: Manuscript in development on changes in therapy-associated outcome over time in neuroblastoma

Formal Teaching of Peers (e.g., CME and other continuing education courses)

No presentations below were sponsored by 3rd parties/outside entities.

Year(s)	Title(s) or topic(s) or talk(s) Course Name (Sponsor, if you)	Number of talks in a single course Location(s) (city or country)
2012	Clinical trials in small patient cohorts: Designs to detect efficacy or monitor adverse effects Translational Research Program, Boston Children's Hospital	Single presentation Boston, MA
2020	The evolution of prognostic factors in neuroblastoma (NB), and their changing roles in risk stratification to assign intensity of therapy Pediatric Oncology Conference, Dana-Farber / Boston Children's Cancer and Blood Disorders Center, Harvard Medical School CME	Single presentation Boston, MA
2021	De-mystifying adaptive designs: Four examples from phase 1 trials in our division Pediatric Oncology Conference, Dana-Farber / Boston Children's Cancer and Blood Disorders Center, Harvard Medical School CME	Single presentation Boston, MA
2023	Clinical Trials Design Workshop (Invited Organizer and Co-Chair) American Association of Cancer Research Annual Meeting CME	One-day workshop Orlando, FL
2024	Phase 1 Clinical Trial Development Workshop, featuring the DEDUCE app (Organizer)	4-day workshop Tucson, AZ
2024	Biostatistics in Clinical Trials Workshop: Out of the Rut and Beyond the Traditional – Parts 1 & 2 (Invited Organizer and Chair) American Association of Cancer Research Annual Meeting CME	One-day workshop San Diego, CA

Local Invited Presentations

No presentations below were sponsored by 3rd parties/outside entities.

Year(s)	Title of presentation Department and Institution where presented (if any)
1996	A survival analysis of a prospective study comparing a new procedure to the standard procedure for variceal bleeding / Seminar Department of Biostatistics, Medical College of Virginia, Virginia Commonwealth University
1999	Simulation of multivariate gamma data with exponential marginals for independent clusters / Seminar Department of Statistics, University of Florida

Year(s)	Title of presentation Department and Institution where presented (if any)
2001	The role of statistics in clinical trials research: Basic statistical concepts that clinical researchers need to know / Grand Rounds Department of Hematology/Oncology, Shands Hospital, University of Florida
2005	Evidence for an age cutoff higher than 365 days for neuroblastoma risk group stratification in the Children's Oncology Group (COG[1]) / Seminar Topics in Cancer Cell Biology Seminar Series, University of Florida Shands Cancer Center
2006	Study designs for clinical trials in humans / Seminar Department of Epidemiology and Health Policy Research, University of Florida
2008	The use of biologic, genetic and clinical risk factors for treatment determination of patients with neuroblastoma / Seminar Topics in Cancer Cell Biology Seminar Series, University of Florida
2009	The use of biologic, genetic, clinical, and morbidity factors to determine treatment for children with cancer / Seminar Division of Biostatistics, University of Florida
2010	The use of biologic, genetic, clinical, and morbidity factors to determine treatment for children with cancer / Seminar Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Harvard Medical School
2011	Factors predictive of survival in newly diagnosed and relapsed neuroblastoma patients / Seminar Division of Pediatric Hematology/Oncology, Boston Children's Hospital and Dana-Farber Cancer Institute, Harvard Medical School
2012	Success of chimeric anti-GD2 antibody + GM-CSF + IL2 immunotherapy in high-risk neuroblastoma (NB) in first response: A critical appraisal / Seminar Division of Pediatric Hematology/Oncology, Boston Children's Hospital and Dana-Farber Cancer Institute, Harvard Medical School
2013	What makes for a good endpoint? / Seminar Gamma Globin Induction Mini-retreat, Division of Pediatric Hematology/Oncology, Boston Children's Hospital, Harvard Medical School
2014	Snapshots from Pediatric Oncology / Seminar Biostatistics Briefing, Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute
2016	Leadership update: *PPIP*, our Data Resource and *PPIP*360, our Query Tool / Invited Seminar Dana-Farber / Boston Children's Cancer and Blood Disorders Center
2017-present	The *PPIP* and the *PPIP*360 / Invited Training Course (>5 sessions) Dana-Farber / Boston Children's Cancer and Blood Disorders Center
2017-present	*PPIP* Data Governance / Invited Training Course (>5 sessions) Dana-Farber / Boston Children's Cancer and Blood Disorders Center
2017	Infrastructure and Biostatistics for the Conduct of Clinical Research – Session 1 / Invited Seminar for our physician visitors from Beijing Dana-Farber / Boston Children's Cancer and Blood Disorders Center

Year(s)	Title of presentation Department and Institution where presented (if any)
2017	Infrastructure and Biostatistics for the Conduct of Clinical Research – Session 2 / Invited Seminar for our physician visitors from Beijing Dana-Farber / Boston Children's Cancer and Blood Disorders Center
2017	Infrastructure and Biostatistics for the Conduct of Clinical Research / Invited Seminar for our physician visitors from Egypt Dana-Farber / Boston Children's Cancer and Blood Disorders Center
2018	Infrastructure and Biostatistics for the Conduct of Clinical Research / Invited Seminar for our physician visitors from Beijing Dana-Farber / Boston Children's Cancer and Blood Disorders Center
2018	Statistical Aspects of Correlative Studies / Invited Seminar DF/HCC-UMass-Boston U54 Research and Data Analysis Core Seminar Series Dana-Farber/Harvard Cancer Center
2019	Infrastructure and Biostatistics for the Conduct of Clinical Research / Invited Seminar for our physician visitors from China Dana-Farber / Boston Children's Cancer and Blood Disorders Center
2022	The Research Design and Analysis Core / Invited virtual presentation DF/HCC-UMass-Boston U54 Scientific Advisory Committee meeting
2022	Validation of the change in age cut-off, from 12-months to 18-months, for assignment to reduction of therapy in COG neuroblastoma risk stratification / Invited Seminar Endicott Retreat, Dana-Farber/Boston Children's Cancer and Blood Disorders Center
2022	Design of adaptive phase 1 clinical trials for dose escalation using the DEDUCE application / Invited Seminar Seminar series of the Univ. of Mass Boston-DF/HCC Comprehensive Partnership for Cancer Disparities Research
2022	Design and implementation of Bayesian adaptive phase 1 trials in oncology using the DEDUCE application / Invited Seminar Dana-Farber Cancer Institute Frontiers in Biostatistics Seminar series
2023	Biostatisticians: What we do on investigator-initiated trials / Invited Seminar for the Clinical and Translational Investigation Program (CTIP) Staff Development Workshop Dana-Farber / Boston Children's Cancer and Blood Disorders Center
2023	The Biostatistics Program of the Dana-Farber/Boston Children's Cancer and Blood Disorders Center / Invited meeting

Report of Regional, National and International Invited Teaching and Presentations

One presentation below* was sponsored by an outside entity, a health education company, Healthcasts.

Invited Presentations and Courses

National

Year(s)	Title of presentation or name of course/Type of presentation/role(s) (note if presentation the result of a selected abstract) Location (Sponsor, if any)
1989	Standard operating procedure in the creation, maintenance, and quality assurance of SAS programs / Platform presentation (abstract) SAS Users Group International 14th Annual Conference, San Francisco, CA
1990	Teaching the SAS programming language to programmers and non-programmers / Platform presentation (abstract) SAS Users Group International 15th Annual Conference, Nashville, TN
1992	How to gain a working knowledge of the FREQ procedure without freaking out / Platform presentation (abstract) SAS Users Group International 17th Annual Conference, Honolulu, HI
1997	Characteristics of patients placed on the transplant waiting list before requiring dialysis / Platform presentation (abstract) American Society of Nephrology 30th Annual Meeting, Orlando, FL
1997	A survival analysis of dependent waiting times to transplant with censoring using a generalized estimating equations approach / Platform presentation (abstract) Joint Statistical Meetings of the American Statistical Association, Anaheim, CA
1998	A survival analysis of clusters of dependent times to event with censoring using a generalized estimating equations (GEE) approach / Platform presentation (abstract) Joint Statistical Meetings of the American Statistical Association, Dallas, TX
1999	Simulation of multivariate gamma data with exponential marginals for independent clusters / Platform presentation (abstract) Joint Statistical Meetings of the American Statistical Association, Baltimore, MD
1999	The role of statistics in clinical trials research / Invited platform presentation Joint Meeting of the Pediatric Oncology Group/Children's Cancer Group, St. Petersburg, FL
2000	Criteria for validating ordinal surrogates for time-related endpoints in randomized experiments / Platform presentation (abstract) Joint Statistical Meetings of the American Statistical Association, Indianapolis, IN
2001	Designs for stratified phase II clinical trials / Platform presentation (abstract) Joint Statistical Meetings of the American Statistical Association, Atlanta, GA
2003	One- and two-stage designs for stratified phase II clinical trials / Platform presentation (abstract) Joint Statistical Meetings of the American Statistical Association, San Francisco, CA
2004	Evidence for an age cutoff higher than 365 days for neuroblastoma risk group stratification in the Children's Oncology Group (COG[1]) / Platform presentation (invited) Children's Oncology Group meeting, Tuscon, AZ
2005	Evidence for an age cutoff higher than 365 days for neuroblastoma risk group stratification in the Children's Oncology Group (COG[1]) / Platform presentation (abstract) American Society for Clinical Oncology, Orlando, FL

Year(s)	Title of presentation or name of course/Type of presentation/role(s) (note if presentation the result of a selected abstract) Location (Sponsor, if any)
2005	Contrasting roles of the hazard ratio and the p-value in identifying a continuous variable's cut-off for prognostic stratification / Platform presentation (abstract) Joint Statistical Meetings of the American Statistical Association, Minneapolis, MN
2006	Prognostic factors and risk stratification in neuroblastoma: From specimens to treatment groups / Invited Seminar Pediatric Oncology Branch of the National Cancer Institute, Bethesda, MD
2006	Interim monitoring against a fixed standard: A3961 and D9602 / Invited Seminar Statistics Symposium, Children's Oncology Group meeting, Dallas, TX
2006	Proposed risk groups for neuroblastoma / Invited Seminar Statistics Symposium, Children's Oncology Group meeting, Dallas, TX
2007	Preliminary efficacy results of COG[1] study A3973: purged versus unpurged peripheral blood stem cell transplant / Invited platform presentation Children's Oncology Group meeting, Dallas, TX
2007	Utilization of the Neuroblastoma Virtual Tumor Bank (NVTB) for microarray analyses / Invited platform presentation Translational Genomics in Neuroblastoma, Rockville, MD
2008	Prognostic stratification of children with neuroblastoma: Statistical methods and collaborative application for clinical consensus / Invited seminar University of Alabama–Birmingham Comprehensive Cancer Center Seminar
2008	The use of biologic, genetic, and clinical risk factors to determine treatment for patients with neuroblastoma / Invited seminar Division of Pediatric Hematology/Oncology, University of Chicago
2008	The use of biologic, genetic, clinical, and morbidity risk factors to determine treatment for children with cancer / Invited seminar Children's Hospital of Philadelphia, University of Pennsylvania
2008	The use of biologic, genetic, clinical, and morbidity risk factors to determine treatment for children with cancer / Invited seminar Dana-Farber Cancer Institute, Harvard Medical School
2009	One- and two-stage designs for stratified Phase 2 clinical trials / Invited seminar Children's Hospital of Philadelphia, University of Pennsylvania
2010	Factors predictive of survival after relapse in patients with neuroblastoma. / Invited Platform presentation American Society for Clinical Oncology (ASCO) Annual Meeting, Chicago, IL
2010-present	Methods in Clinical Cancer Research Workshop / Invited Course American Society of Clinical Oncology /American Association for Cancer Research Workshop; Vail, Colorado ~60 hours of non-HMS teaching each year
2012	Electronic data capture of central laboratory results to direct (in real time) risk-based therapy for COG[1] neuroblastoma patients / Invited platform presentation (abstract) Society of Clinical Trials meeting, Miami, Florida
2012	Success of chimeric anti-GD2 antibody + GM-CSF + IL2 immunotherapy in high-risk neuroblastoma in first response: A critical appraisal / Invited seminar Dept of Biostatistics, Virginia Commonwealth University, Richmond, VA

Year(s)	Title of presentation or name of course/Type of presentation/role(s) (note if presentation the result of a selected abstract) Location (Sponsor, if any)
2016	Statistical Aspects of Correlative Studies / Invited Plenary Lecture American Society of Clinical Oncology /American Association for Cancer Research Methods in Clinical Cancer Research Workshop; Vail, Colorado
2017	Integration and user-accessibility of diverse, cross-institutional systems of clinical, outcome, and genomic data via a common datamart technology: The Dana-Farber/Boston Children's "Pediatric Patient Informatics Platform" (*PPIP*) / Invited Seminar St. Jude Children's Research Hospital; Memphis, Tennessee
2017	Statistical Aspects of Correlative Studies / Invited Plenary Lecture American Society of Clinical Oncology /American Association for Cancer Research Methods in Clinical Cancer Research Workshop; Vail, Colorado
2018	The evolution of prognostic factors in neuroblastoma, and their changing roles in risk stratification to assign intensity of therapy / Invited Seminar Biostatistics Seminar Series, Memorial Sloan Kettering Cancer Center, New York, New York
2018	The evolution of prognostic factors in neuroblastoma, and their expanding role in study design / Invited Seminar Division of Pediatric Hematology/Oncology, Columbia University, New York, New York
2018	The evolution of prognostic factors in neuroblastoma, and their changing roles in risk stratification to assign intensity of therapy / Invited Seminar Division of Pediatric Hematology/Oncology/Stem Cell Transplant, University of Chicago; Chicago, Illinois
2018	The evolution of prognostic factors in neuroblastoma, and their changing roles in risk stratification to assign intensity of therapy / Invited Seminar Division of Pediatric Hematology/Oncology, Stanford University, Palo Alto, California
2018	Statistical Aspects of Correlative Studies / Invited Plenary Lecture American Society of Clinical Oncology /American Association for Cancer Research Methods in Clinical Cancer Research Workshop; Vail, Colorado
2019	The evolution of prognostic factors in neuroblastoma, and their changing roles in risk stratification to assign intensity of therapy / Invited Pediatric Grand Rounds Pediatric Hematology/Oncology, Oklahoma University Health Science Center, Oklahoma City, Oklahoma
2019	Statistical Aspects of Correlative Studies / Invited Plenary Lecture American Society of Clinical Oncology /American Association for Cancer Research Methods in Clinical Cancer Research Workshop; Vail, Colorado
2021	Statistical Aspects of Correlative Studies / Invited Plenary Lecture American Society of Clinical Oncology /American Association for Cancer Research Methods in Clinical Cancer Research Workshop (virtual)
2021	Adaptive Clinical Trials Initiative: Translating from bench to bedside / Invited Seminar Northwestern Mututal Foundation
2022	Statistical Aspects of Correlative Studies / Invited Plenary Lecture American Society of Clinical Oncology /American Association for Cancer Research Methods in Clinical Cancer Research Workshop; Vail, Colorado

Year(s)	Title of presentation or name of course/Type of presentation/role(s) (note if presentation the result of a selected abstract) Location (Sponsor, if any)
2023	Statistical and Practical Aspects of Correlative Studies / Invited Plenary Lecture American Society of Clinical Oncology /American Association for Cancer Research Methods in Clinical Cancer Research Workshop; La Jolla, CA
2023	Statistical and Practical Guidance for Biomarker Studies / Invited Plenary Lecture American Association for Cancer Research Annual Meeting; Orlando, FL
2024	Introduction to design of phase 1 trials / Invited Platform presentation Phase 1 clinical trial development workshop, featuring the DEDUCE app Tucson, AZ
2024	Practical considerations for the conduct of phase 1 trials / Invited Platform presentation Phase 1 clinical trial development workshop, featuring the DEDUCE app Tucson, AZ
2024	Design and implementation of Bayesian adaptive designs for pediatric Phase 1 clinical trials / Invited Seminar Texas Children's Hospital**,** Department of Pediatrics, Section of Hematology/Oncology, Baylor College of Medicine
2024	Implementation of Phase 1 Trials that Use Adaptive Designs / Invited Plenary Lecture American Association for Cancer Research Annual Meeting; San Diego, CA
2024	Bayesian adaptive design of phase 1 dose-finding trials / Invited Roundtable Discussion Society for Clinical Trials annual meeting; Boston, MA

International

Year(s)	Title of presentation or name of course/Type of presentation/role(s) (note if presentation the result of a selected abstract) Location (Sponsor, if any)
2006	Age, tumor grade, and MKI are independently predictive of outcome in neuroblastoma / Platform presentation (prize-winning abstract) Advances in Neuroblastoma Research (ANR[2]) Meeting, Los Angeles, CA
2006	The International Neuroblastoma Risk Group project: Report of the Statistics Committee / Invited platform presentation International Neuroblastoma Risk Group meeting in Los Angeles, CA
2006	Univariate versus multivariable analyses of histologic features / Invited platform presentation International Meeting of Neuroblastoma Pathologists, Children's Hospital of Los Angeles, Los Angeles, CA
2007	Evidence for an age cut-off >365 days: INRG results / Invited platform presentation International Society for Pediatric Oncology – Neuroblastoma, Tel Aviv, Israel
2007	Surgery and restricted use of chemotherapy as treatment of low-risk neuroblastoma: Preliminary results of Children's Oncology Group protocol P9641 / Invited platform presentation "Best of SIOP" Award Lecture, American Society of Pediatric Hematology/Oncology, Toronto, Ontario

[2] ANR is an international, and the primary, organization of scientists who perform research on neuroblastoma. Meetings are held bi-annually in locations around the world. See www.anrmeeting.org.

Year(s)	Title of presentation or name of course/Type of presentation/role(s) (note if presentation the result of a selected abstract) Location (Sponsor, if any)
2007	An optimality criterion for prognostic risk groups in pediatric cancer: Analysis of data from the Children's Oncology Group / Platform presentation (abstract) 28th Annual Conference of the International Society for Clinical Biostatistics (ISCB), Alexandroupolis, Greece
2007	A proposal for two versions of the International Neuroblastoma Pathologic Classification (INPC): with and without age / Invited platform presentation International Neuroblastoma Pathology Meeting, Los Angeles, CA
2008	Use of intravenous gammaglobulin therapy for patients with neuroblastoma associated opsoclonus-myoclonus-ataxia syndrome treated with chemotherapy and prednisone: COG[1] Protocol ANBL00P3 / Invited platform presentation Fourth Dancing Eye Syndrome Workshop, Oxford, United Kingdom
2009	Success of chimeric anti-GD2 antibody + GM-CSF + IL2 immunotherapy in high-risk neuroblastoma (NB) in first response: A critical appraisal. / Invited platform presentation Societe Internationale D'Oncologie Pediatrique (SIOP), Sao Paulo, Brazil
2009	Success of chimeric anti-GD2 antibody + GM-CSF + IL2 immunotherapy in high-risk neuroblastoma (NB): COG[1] Study ANBL0032 / Invited seminar Royal Marsden, Sutton, United Kingdom
2009	Success of chimeric anti-GD2 antibody + GM-CSF + IL2 immunotherapy in high-risk neuroblastoma (NB): COG[1] Study ANBL0032 / Invited seminar University of Cologne, Cologne, Germany
2010	Changes over three decades in the prognostic influence of age in patients with neuroblastoma: A report from the International Neuroblastoma Risk Group Project / Platform presentation (abstract) Advances in Neuroblastoma Research (ANR[2]) Meeting, Stockholm, Sweden
2010	Clinical and biological features predictive of survival after relapse of neuroblastoma / Invited seminar Neuroblastoma Update Course, Advances in Neuroblastoma Research (ANR[2]) meeting, Stockholm, Sweden
2012	Ultra-high-risk neuroblastoma: Phenotype according to outcome versus definition according to risk factors. / Invited platform presentation NCI Clinical Trials Planning Meeting (CTPM) for Neuroblastoma, Washington, DC
2012	Using a selection design ('Pick the Winner') in a COG[1] Phase II study of relapsed neuroblastoma. / Invited platform presentation Joint Meeting of the Royal Statistical Society Medical Section, the Medical Research Council Hubs for Trials and Methodology Research, the European Network for Cancer Research in Children and Adolescents, and the International Rare Cancers Initiative. London, United Kingdom
2012	Factors that contribute to inferior survival of low-risk stage 2B neuroblastoma patients: A Children's Oncology Group study / Platform presentation (abstract) Advances in Neuroblastoma Research (ANR[2]) Meeting, Toronto, Ontario
2012	Neuroblastoma in Older Children, Adolescents and Young Adults: A Report from the International Neuroblastoma Risk Group Project / Platform presentation (abstract) Advances in Neuroblastoma Research (ANR[2]) Meeting, Toronto, Ontario

Year(s)	Title of presentation or name of course/Type of presentation/role(s) (note if presentation the result of a selected abstract) Location (Sponsor, if any)
2014	A neuroblastoma risk classification model for developing countries: A study from the International Neuroblastoma Risk Group (INRG) database / Platform presentation (abstract) Societe Internationale D'Oncologie Pediatrique (SIOP), Toronto, Ontario
2014	Historical gold standard for time-to-progression (TTP) and progression-free survival (PFS) from relapsed/refractory neuroblastoma modern era (2002-14) patients / Platform presentation (abstract) Societe Internationale D'Oncologie Pediatrique (SIOP), Toronto, Ontario
2021	Data Quality of the International Neuroblastoma Risk Groups (INRG) Data Commons / Virtual platform presentation International Neuroblastoma Risk Groups (INRG) Task Force meeting, Advances in Neuroblastoma Research (ANR^2) Meeting
2021	Development Plans for the INRG Risk Classification Version 2.0 / Virtual platform presentation International Neuroblastoma Risk Groups (INRG) Task Force meeting, Advances in Neuroblastoma Research (ANR^2) Meeting
2021	The London Clinical Neuroblastoma Risk Groups (LCNRG) / Virtual platform presentation International Neuroblastoma Risk Groups (INRG) Task Force meeting, Advances in Neuroblastoma Research (ANR^2) Meeting
2022	The International Neuroblastom Risk Groups Data Commons – Statistical and Data Quality Update / Virtual platform presentation International Neuroblastoma Risk Groups (INRG) Task Force meeting, Advances in Neuroblastoma Research (ANR^2) Meeting
2022	The International Neuroblastom Risk Groups Classification, Version 2 / Virtual platform presentation International Neuroblastoma Risk Groups (INRG) Task Force meeting, Advances in Neuroblastoma Research (ANR^2) Meeting
2022	Survival of patients with neuroblastoma before vs after reduction of therapy due to the change in age cut-off from 12 to 18 months in COG risk stratification Healthcasts website, https://app.healthcasts.com/asset/id/10095/?view_type=primary
2023	Design and implementation of Bayesian adaptive designs for pediatric Phase 1 clinical trials / Invited Plenary Presentation International Society of Pediatric Oncology (SIOP) annual meeting; Ottawa, Ontario, Canada
2023	The BORNEO project: BiOmarkers in high-Risk NEurOblastoma / Platform Presentation Advances in Neuroblastoma Research Meeting; Amsterdam, The Netherlands
2023	The BORNEO project: BiOmarkers in high-Risk NEurOblastoma / Invited Virtual Platform Presentation Neuroblastoma Parent Global Symposium, Sponsored by Solving Kids Cancer UK
2023	Beyond 3+3 Phase 1 clinical trials: Design and implementation of Bayesian adaptive designs – Session 1 / Invited Virtual Platform Presentation First Affiliated Hospital of Sun Yat Sen Medical Center; Guangzhou, China

Year(s)	Title of presentation or name of course/Type of presentation/role(s) (note if presentation the result of a selected abstract) Location (Sponsor, if any)
2023	Beyond 3+3 Phase 1 clinical trials: Design and implementation of Bayesian adaptive designs – Session 2 / Invited Virtual Platform Presentation First Affiliated Hospital of Sun Yat Sen Medical Center; Guangzhou, China

Report of Clinical Activities and Innovations

Report of Technological and Other Scientific Innovations

Innovation (date if applicable)	Patent (if any, pending, or awarded) Describe the influence or potential influence of the innovation on research or clinical care
1998-2014 The COG[1] Neuroblastoma Virtual Tumor Bank (NVTB)	In this cutting-edge informatics project, I designed and built a database, integrating and harmonizing biology, clinical, and outcome data from POG, COG[1], and CCG, and specimen data from a multi-center national laboratory system, to create the Neuroblastoma Virtual Tumor Bank (NVTB) database. I had the vision to recognize the critical added value that linking the clinical/outcome data with specimen data would provide. I initiated efforts to obtain data from POG institutions and labs. This resource includes >10,000 COG[1] neuroblastoma patients enrolled nationally 1990-present, and has been invaluable for identification of neuroblastoma prognostics factors and mapping the genomic landscape of neuroblastoma. Investigators nationally and internationally rely on the NVTB for specimens and data for basic science and clinical research.
2004- present The International Neuroblastoma Risk Group (INRG) Data Commons	The INRG Data Commons is a shared repository of data from neuroblastoma patients at all major pediatric cancer treatment centers in the world. In 2004, I developed the data dictionary of standardized data items, gathered data on 8,800 patients from 12 countries or cooperative groups, and harmonized the data on a central platform. As the largest database of neuroblastoma patients of its kind, it has supported over 30 published analyses of prognostic factors to date, including the landmark analysis to create the INRG risk stratification, which I performed [Cohn et al, *Journal of Clinical Oncology* 2009]. In 2014, the University of Chicago assumed responsibility for the technical oversight of the INRG Data Commons. This database has set the standard; the Pediatric Cancer Data Commons, a national federally-funded organization, is using the INRG Data Commons as a model for other national disease-specific data commons.

Innovation (date if applicable)	**Patent (if any, pending, or awarded)** **Describe the influence or potential influence of the innovation on research or clinical care**
2012- present Datamart: The Pediatric Patient Informatics Platform (*PPIP*)	I provide vision and lead the efforts to develop and implement a database, the *PPIP*, that integrates patient data (clinical, outcome, genomics, specimens) and protocol data (PI, accrual goal, activation date) from disparate sources at BCH and DFCI [Ma et al, *J Clin Oncol Clinical Cancer Informatics* 2021]. The *PPIP* facilitates research, operations and safety reporting, and strategic planning. This innovative resource of data on >30,000 patients may be queried by faculty and staff, and allows biostatisticians to perform analyses using data previously inaccessible. The *PPIP* will contribute data to DFCI's multicenter Pragmatic Implementation of Phenomic Data Standards for Curating Outcomes of Cancer Treatment (PRISSMM) project, to the Massachusetts Cancer Registry and the NCI's National Childhood Cancer Registry, and internationally through the American Association for Cancer Research's Project Genomics Evidence Neoplasia Information Exchange (GENIE).
2015- present MicroStrategy *PPIP360* query tool	I provide vision, leadership, and technical oversight for the development of the *PPIP360* query tool in MicroStrategy. A series of customizable reports are accessible to independent local users, to generate aggregate counts from the *PPIP* database.
2019- present DEDUCE application	The DEDUCE application is a tool to create, simulate, and compare cutting-edge adaptive designs for phase 1 clinical trials. Dr. Clement Ma (mentee) and Dr. London partnered with Northwestern Mutual Foundation (NMF) (who donated their IS/IT workforce) to initiate app development. Drs. Ma and London lead ongoing work to add new designs to DEDUCE. A statistician-clinical investigator team use the DEDUCE's point-and-click interface to design and conduct their adaptive trial according to their specific requirements for safety, accrual rate, and available resources. Funded by NMF, a nationwide DEDUCE program will provide training and access to statisticians and clinicians, thereby increasing the use of phase 1 adaptive designs, for more accurate identification of the optimal dose of an experimental drug. A workshop for adaptive phase 1 trial design using DEDUCE was conducted in February 2024. https://deduce.shinyapps.io/DEDUCE/
2019-present Nomogram of clinical/biologic factors to predict survival in high-risk NB	Building on a foundation of two decades of my experience in identification of NB prognostic factors and NB risk stratification, my mentee Lucas Moreno and I developed a user-friendly online nomogram to calculate the estimated 3-year OS of high-risk NB patients based on optimally-selected particular risk factors: *MYCN* status, bone marrow metastases, and LDH (lactate dehydrogenase). PMID: 33205902. https://neuroblastoma.shinyapps.io/High-Risk-Neuroblastoma-Nomogram/

Report of Education of Patients and Service to the Community

Activities

Year(s)	Organization or institution/Role (Sponsor, if any) Description
2004-2009	"Big Sister", Big Brothers Big Sisters of Mid-Florida, Gainesville, Florida Served as a Big Sister to child whose parents were in prison.
2005-2009	Board of Directors of STOP! Children's Cancer Inc., Gainesville, Florida Performed strategic planning for fundraising.
2005-2009	Chair, Grant Productivity Committee of STOP! Children's Cancer Inc., Gainesville, Florida Reviewed/scored research grants; instituted accountability for use of funding.
2008-2009	Board of Directors, Big Brothers Big Sisters of Mid Florida, Gainesville, Florida Performed strategic planning for programming and fundraising.
2008-2009	Board of Directors, Pace Center for Girls, Gainesville, Florida Strategic planning for fundraising; chaired the golf tournament committee.
2015-2017	Member/Fundraiser/Runner, Dana-Farber Marathon Challenge Team Dana-Farber/Harvard Cancer Center, Boston, MA Ran three marathons; raised over $25,000 for Dana-Farber/Harvard Cancer Center.
2018	Member/Fundraiser/Runner, Boston Marathon "Team Eye and Ear", Massachusetts Eye and Ear Institute, Boston, MA Ran one marathon; raised over $13,000 for Massachusetts Eye and Ear Institute.

Recognition

Year(s)	Name of award/recognition	Organization conferring recognition
2008	STOP! Children's Cancer Board Member of the Quarter, 4th quarter 2008	

Report of Scholarship

ORCiD: 0000-0003-3571-6538; Web of Science Researcher ID: ABA-8948-2021
*co-first or co-senior authorship
**denotes a mentee

Peer-reviewed scholarship in print or other media
Research Investigations

1. Garstang M, Kelbe B, Emmitt GD, **London W**. Generation of convective storms over the escarpment of northeastern South Africa. *Monthly Weather Review* 1987 115:734-751.

2. Wood MA, Simpson PM, **London W**, Stambler BS, Herre JM, Bernstein RC, Ellenbogen KA. Circadian pattern of ventricular tachyarrhythmias in patients with implantable cardioverter-defibrillators. *Journal of the American College of Cardiology* 1995 25:901-907.

3. Stastny, JF, Remmers RE, **London W**, Pedigo MA, Cahill LA, Ryan M, Frable WF. Atypical squamous cells of undetermined significance: A comparative review of original and automated rescreen diagnosis of cervicovaginal smears with long term follow up. *Cancer* 1998 81:348-353.

PMID: 9438460

4. Ellenbogen KA, Wood MA, Gilligan DM, Crofts TA, **London W**, McClish DK. Immediate reproducibility of upper limit of vulnerability measurements in patients undergoing transvenous implantable cardioverter defibrillator implantation. *Journal of Cardiovascular Electrophysiology* 1998 9:588-595. PMID: 9654223

5. Kasiske BL, **London W**, Ellison MD. Race and socioeconomic factors influencing early placement on the kidney transplant waiting list. *Journal of the American Society of Nephrology* 1998 *9:* 2142-7. PMID: 9808103

6. Elser DM, **London W**, Fantl JA, McBride M, Beck RP. A comparison of urethral profilometry using Microtip and Fiberoptic catheters. *International Urogynecology Journal* 1999 10:371-374. PMID: 10614972

7. Tang XX, Evans AE, Zhao H, Cnaan A, **London W**, Cohn SL, Brodeur GM, Ikegaki N. High level expression of *EPHB6*, *EFNB2*, and *EFNB3* is associated with low tumor stage and high *TrkA* expression in human neuroblastomas. *Clinical Cancer Research* 1999 5:1491-1496. PMID: 10389937

8. **London WB**, Gennings C. Simulation of multivariate gamma data with exponential marginals for independent clusters. *Communications in Statistics: Simulation and Computation* 1999 28(2):487-500.

9. Alvarado CS, **London WB**, Look AT, Brodeur GM, Altmiller DH, Thorner DS, Joshi VV, Rowe ST, Nash MB, Smith EI, Castleberry RP, Cohn SL. Natural history and biology of stage A neuroblastoma: A Pediatric Oncology Group study. *Journal of Pediatric Hematology/Oncology* 2000 22(3): 197-205. PMID: 10864050

10. Tang XX, Zhao H, Robinson ME, Cohen B, Cnaan A, **London W**, Cohn SL, Cheung NK, Brodeur GM, Evans AE, Ikegaki N. Implications of EPHB6, EFNB2, and EFNB3 expressions in human neuroblastoma. Proc Natl Acad Sci U S A. 2000 Sep 26; 97(20):10936-41. PMID: 10984508

11. Cohn SL, **London WB**, Huang D, Katzenstein HM, Salwen HR, Reinhart T, Madafiglio J, Marshall GM, Norris MD, Haber M. *MYCN* expression is not prognostic of adverse outcome in advanced-stage neuroblastoma with non-amplified *MYCN*. *Journal of Clinical Oncology* 2000 18(21):3604-3613. PMID: 11054433

12. Tang XX, Zhao H, Robinson ME, Cnaan A, **London W**, Cohn SL, Cheung NK, Brodeur GM, Evans AE, Ikegaki N. Prognostic significance of *EPHB6*, *EFNB2*, and *EFNB3* expressions in neuroblastoma, *Medical and Pediatric Oncology* 2000 35: 656-658. PMID: 11107140

13. Billmire D, Vinocur C, Rescorla F, Columbani P, Cushing B, Hawkins E, **London WB**, Giller R, Lauer S. Malignant mediastinal germ cell tumors: An intergroup study. *Journal of Pediatric Surgery*. 2001. 36(1):18-24. PMID 11150432

14. Katzenstein H, Kent PM, **London WB**, Cohn SL. Treatment and outcome of 83 children with intraspinal neuroblastoma: The Pediatric Oncology Group experience, *Journal of Clinical Oncology* 2001 19(4):1047-55. PMID: 11181668

15. Omura-Minamisawa M, Diccianni MB, Change RC, Batova A, Bridgeman LJ, Schiff J, Cohn SL, **London WB**, Yu AL. p16/p14 (ARF) cell cycle regulatory pathways in primary neuroblastoma: p16 expression is associated with advanced stage disease, *Clinical Cancer Research* 2001 7(11):3481-90. PMID: 11705866

16. Katzenstein HM, **London WB**, Douglass EC, Reynolds M, Plaschkes J, Finegold MJ, Bowman LC. Treatment of unresectable/metastatic hepatoblastoma: A Pediatric Oncology Group phase II study, *Journal of Clinical Oncology*. 2002 20(16):3438-3444. PMID: 12177104

17. Schlatter M, Rescorla F, Giller R, Cushing B, Vinocur C, Columboni P, Cullen J, **London WB**, Davis M, Lauer S, Olson T. Excellent outcome in patients with Stage I germ cell tumors of the testes: A study of the Children's Cancer Group / Pediatric Oncology Group, *Journal of Pediatric Surgery* 2003 38(3):319-324. PMID: 12632342

18. Billmire D, Vinocur C, Rescorla F, Colombani P, Cushing B, Hawkins E, Davis M, **London WB**, Lauer S, Giller R; Children's Oncology Group. Malignant retroperitoneal and abdominal germ cell tumors: An intergroup study. *J Pediatr Surg*. 2003 Mar;38(3):315-8. PMID: 12632341

19. Rescorla F, Billmire D, Vinocur C, Columboni P, **London WB**, Giller R, Cushing B, Davis M, Lauer S, David M, Hawkins E. The effect of neoadjuvant chemotherapy and surgery in children with malignant germ cell tumors of the genital region: A Pediatric Intergroup trial (POG 9049/CCG 8882). *Journal of Pediatric Surgery* 2003 38(6):910-912. PMID: 12778391

20. Billmire D, Vinocur C, Rescorla F, Cushing B, **London W**, Schlatter M, Davis M, Giller R, Lauer S, Olson T, Children's Oncology Group (COG[1]). Outcome and staging evaluation in malignant germ cell tumors of the ovary in children and adolescents: an intergroup study. Journal of Pediatric Surgery 39(3), pp424-429, March 2004. https://doi.org/10.1016/j.jpedsurg.2003.11.027

21. Adkins ES, Sawin R, Gerbing RB**, **London WB**, Matthay KK, Haase GM. Efficacy of complete resection for high-risk neuroblastoma: a Children's Cancer Group study. *Journal of Pediatric Surgery*. 2004 39(6):931-936. PMID: 15185228

22. Cushing B, Giller R, Cullen JW, Marina NM, Lauer SJ, Olson TA, Rogers PC, deGraaf S, Cohen LJ, Weetman RM, Colombani P, Rescorla F, Billmire DF, Vinocur CD, Hawkins EP, Davis MM, Perlman EJ, **London WB**, Castleberry RP. Randomized comparison of combination chemotherapy with etoposide, bleomycin and either high-dose (HDPEB) or standard dose cisplatin (PEB) in children and adolescents with high-risk malignant germ cell tumors (MGCT): A pediatric intergroup study (POG 9049/CCG8882). *Journal of Clinical Oncology* 2004 22(13):2691-700. PMID: 15226336

23. Yu AL, Batova A, Gribi R, Diccianni M, Bridgeman L, Geske D, **London W**, Gilman A, Ozkaynak F. Antibody-dependent cellular cytotoxicity (ADCC) in COG ANBL0032: A phase III randomized trial of chimeric anti-GD2 and GM-CSF/IL2 in high risk neuroblastoma following myeloablative therapy and autologous stem cell transplant (ASCT). J Clin Oncol. 2004 Jul 15; 22(14_suppl):2582. PMID: 28015284.

24. Frantz CN, **London WB**, Diller L, Seeger R, Sawyer K. Recurrent neuroblastoma: Randomized treatment with topotecan + cyclophosphamide (T+C) vs. topotecan alone(T). A POG/CCG Intergroup

Study. J Clin Oncol. 2004 Jul 15; 22(14_suppl):8512. PMID: 28013780.

25. Rogers PC, Olson TA, Cullen JW, Billmire DF, Marina NM, Rescorla F, Davis MM, Weetman RM, **London WB**, Lauer SJ, Giller R, Cushing B. Treatment of children and adolescents with Stage II testicular and Stage I/II ovarian malignant germ cell tumors (MGCT): A Pediatric Intergroup study (POG 9048/CCG 8891). *Journal of Clinical Oncology* 2004 22(17):3563-9. PMID: 15337806

26. Kretschmar CS, Kletzel M, Thorner P, Cohn SL, **London WB**, Castleberry RP. Response to paclitaxel, taxol, topotecan and to topotecan-cyclophosphamide in children with untreated disseminated neuroblastoma treated in an upfront phase II investigational window: A Pediatric Oncology Group study. *Journal of Clinical Oncology* 2004 22(20):4119-26. PMID: 15483021

27. Rodriguez-Galindo C, Wofford M, Castleberry RP, Swanson GP, **London WB**, Fontanesi J, Pappo AS, Douglass EC. Pre-radiation chemotherapy with methotrexate, cisplatin, 5-fluorouracil, and leucovorin for pediatric nasopharyngeal carcinoma. *Cancer*. 2005 Feb 15;103(4):850-7. PMID: 15641027

28. Norris MD, Smith J, Tanabe K, Tobin P, Flemming C, Scheffer GL, Wielinga P, Cohn SL, **London WB**, Marshall GM, Allen J, Haber M. 2005. Expression of multidrug transporter *MRP*4/ABCC4 is a marker of poor prognosis in neuroblastoma and confers resistance to irinotecan *in vitro*. *Mol Cancer Ther*. 2005 Apr;4(4):547-53. PMID: 15827327

29. **London WB**, Castleberry RP, Matthay KK, Look AT, Seeger RC, Shimada H, Thorner P, Garrett B, Maris JM, Reynolds CP, Cohn SL. Evidence for an age cut-off greater than 365 days for neuroblastoma risk group stratification in the Children's Oncology Group (COG[1]). J Clin Oncol. 2005 Jun; 23(16_suppl):8500. PMID: 27944578.

30. Park JR, Villablanca JG, Seeger R, Shimada H, **London W**, Gerbing R**, Reynolds CP, Matthay KK. Outcome of high risk (HR) stage 3 neuroblastoma (NB) with myeloablative therapy and 13-cis-retinoic Acid. J Clin Oncol. 2005 Jun; 23(16_suppl):8503. PMID: 27944565.

31. Attiyeh EF, Mosse YP, Wang Q, Winter C, Khazi D, Hii G, McGrady PW**, Matthay KK, **London WB**, Maris JM. Chromosome arm 11q deletion predicts for neuroblastoma outcome: A Children's Oncology Group study. J Clin Oncol. 2005 Jun; 23(16_suppl):6. PMID: 27946613.

32. Marina N, Chang KW, Malogolowkin M, **London WB**, Frazier L, Rescorla F, Billmire D, Davis M, Perlman E, Giller R, Lauer S, Olson T. Amifostine does not protect against the ototoxicity of high-dose cisplatin combined with etoposide and bleomycin (HD-PEB) in pediatric germ cell tumors (PGCT): a Children's Oncology Group (COG[1]) study. *Cancer* 2005 Aug 15;104(4):841-7. PMID: 15999362

33. George RE**, **London WB**, Cohn SL, Maris JM, Kretschmar C, Diller L, Brodeur GM, Castleberry RP, Look AT. Hyperdiploidy plus nonamplified *MYCN* confers a favorable prognosis in children 12 to 18 months old with disseminated neuroblastoma: A Pediatric Oncology Group study. *Journal of Clinical Oncology* 2005 Sep 20;23(27):6466-73. PMID: 16116152

- Highlighted cover story

34. **London WB**, Castleberry RP, Matthay KK, Look AT, Seeger B, Shimada H, Thorner P, Brodeur G, Maris JM, Reynolds CP, Cohn SL. 2005. Evidence for an age cut-off greater than 365 days for neuroblastoma risk group stratification in the Children's Oncology Group. *Journal of Clinical Oncology* 2005 Sep 20;23(27):6459-65. PMID: 16116153

    - Highlighted cover story

35. **London WB**, Chang MN. One- and two-stage designs for stratified Phase II clinical trials, *Statistics in Medicine* 2005 15;24(17):2597-2611. PMID: 16118809

36. De Bernardi B, Balwierz W, Bejent J, Cohn SL, Garre ML, Iehara T, Plantaz D, Thorsten S Angelini P, Cama A, **London WB**, Katzenstein HM, Tortori-Donati P, Rossi A, D'Angio GJ, Evans AE. Epidural compression in neuroblastoma: Diagnostic and therapeutic aspects. *Cancer Letters* 2005 Oct 18;228(1-2):283-99. PMID: 15975710

37. **London WB**, Boni L, Simon T, Berthold F, Twist C, Schmidt ML, Castleberry RP, Matthay KK, Cohn SL, De Bernardi B. The role of age in neuroblastoma risk stratification: The German, Italian, and Children's Oncology Group perspectives. *Cancer Letters* 2005 Oct 18;228(1-2):257-66. PMID: 16024170

38. Attiyeh EF, **London WB**, Mosse YP, Wang Q, Winter C, Khazi D, McGrady P**, Seeger RC, Look AT, Shimada H, Brodeur GM, Cohn SL, Matthay KK, Maris JM. Chromosome 1p and 11q deletions and outcome in neuroblastoma: a Children's Oncology Group study. *New England Journal of Medicine* 2005 Nov 24;353(21):2243-53. PMID: 16306521

39. Bagatell R**, Rumcheva P**, **London WB**, Cohn SL, Look AT, Brodeur GM, Frantz C, Joshi V, Thorner PS, Rao PV, Castleberry RP, Bowman LC. Outcomes of children with intermediate-risk neuroblastoma after treatment stratified by *MYCN* status and tumor cell ploidy. *Journal of Clinical Oncology* 2005 Dec 1;23(34):8819-27. PMID: 16314642

40. Tebbi CK, Mendenhall N, **London WB,** Williams JL, de Alarcon PA, Chauvenet AR. Treatment of stage I, IIA, $IIIA_1$ pediatric Hodgkin disease with doxorubicin, bleomycin, vincristine, and etoposide (DBVE) and radiation: A Pediatric Oncology Group (POG) study. *Pediatric Blood and Cancer*. 2006 Feb;46(2):198-202. PMID: 16136581

41. Wimmer RS, Chauvenet AR, **London WB,** Villaluna D, de Alarcon PA, Schwartz CL. APE chemotherapy for children with relapsed Hodgkin disease: A Pediatric Oncology Group trial. *Pediatric Blood and Cancer*. 2006 Mar;46(3):320-4. PMID: 16200630

42. Haber M, Smith J, Bordow SB, Flemming C, Cohn SL, **London WB**, Marshall GM, Norris MD. Association of high-level *MRP1* expression with poor clinical outcome in a large prospective study of primary neuroblastoma. *Journal of Clinical Oncology*. 2006 Apr 1;24(10):1546-53. PMID: 16575006

43. Sano H, Bonadio J, Gerbing RB**, **London WB**, Matthay KK, Lukens JN, Shimada H. International Neuroblastoma Pathology Classification (INPC) adds independent prognostic information beyond the

prognostic contribution of age. *European Journal of Cancer* 2006 May;42(8):1113-1119. PMID: 16624549

44. Marina N, **London WB**, Frazier L, Lauer S, Rescorla F, Cushing B, Malogolowkin M, Castleberry R, Womer R, Olson T. Prognostic factors in children with extragonadal germ cell tumors: A Pediatric Intergroup study. *Journal of Clinical Oncology*. 2006 Jun 1;24:2544-8. PMID: 16735707

45. Kung FH, Schwartz CL, Ferree CR, **London WB**, Ternberg JL, Behm FG, Wharam MD, Falletta JM, de Alarcon P, Chauvenet AR. POG 8625: A randomized trial comparing chemotherapy with chemoradiotherapy for children and adolescents with Stages I, IIa, IIIa$_1$ Hodgkin disease. *Journal of Pediatric Hematology and Oncology* 2006 Jun;28:362-368. PMID: 16794504

46. Wang Q, Diskin S, Rappaport E, Attiyeh E, Mosse Y, Shue D, Seiser E, Jagannathan J, Shusterman S, Bansal M, Khazi D, Winter C, Okowa E, Grant G, Cnaan A, Zhao H, Cheung NK, Gerald W, **London WB**, Matthay KK, Brodeur GM, Maris JM. Integrative genomics identifies distinct molecular classes of neuroblastoma and shows that multiple genes are targeted by regional alterations in DNA copy number. *Cancer Research* 2006 Jun 15; 66(12): 6050-62. PMID: 16778177

47. Park JR, Stewart CF, **London WB**, Santana VM, Shaw PJ, Cohn SL, Matthay KK. A topotecan-containing induction regimen for treatment of high risk neuroblastoma. J Clin Oncol. 2006 Jun 20; 24(18_suppl):9013. PMID: 27954204.

48. Malogolowkin MH, **London WB**, Cushing B, Giller R, Davis M, Cullen J, Olson TA. Site of metastases does not influence the clinical outcome of children with metastatic Germ Cell Tumors (GCT). A report from the Children's Oncology Group (COG[1]). J Clin Oncol. 2006 Jun 20; 24(18_suppl):9002. PMID: 27954253.

49. Tebbi CK, **London WB**, Friedman D, Villaluna D, De Alarcon PA, Constine LS, Mendenhall NP, Sposto R, Chauvenet A, Schwartz CL. Dexrazoxane-associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin's disease. J Clin Oncol. 2007 Feb 10;25(5):493-500. Doi: 10.1200/JCO.2005.02.3879. PMID: 17290056.

50. Kreissman SG, Villablanca JG, Seeger RC, Grupp SA, **London WB**, Maris JM, Park JR, Cohn SL, Matthay KK, Reynolds CP. A randomized phase III trial of myeloablative autologous peripheral blood stem cell (PBSC) transplant (ASCT) for high-risk neuroblastoma (HR-NB) employing immunomagnetic purged (P) versus unpurged (UP) PBSC: A Children's Oncology Group study. J Clin Oncol. 2008 May 20; 26(15_suppl):10011. PMID: 27951329.

51. Beierle EA, Massoll NA, Li MK, Donnelly WH, Hartwich J, Clarke T, Campbell-Thompson M, Kurenova EV, Golubovskaya VM, Cance WG, McGrady P**, **London WB**. Focal adhesion kinase expression in human neuroblastoma: Immunohistochemical and real-time PCR and analyses. *Clinical Cancer Research* 2008 Jun 1;14(11):3299-305. PMID: 18519756

52. Fujita T, Igarashi J, Okawa ER, Gotoh T, Manne J, Kolla V, Kim J, Zhao H, Pawel BR, **London WB**, Maris JM, White PS, Brodeur GM. CHD5, a tumor suppressor gene deleted from 1p36.31 in neuroblastomas. *Journal of the National Cancer Institute* 2008 Jul 2;100(13):940-9. PMID: 18577749. PMCID: PMC2483574.

53. George RE, Sanda T, Hanna M, Frohling S, Luther II W Zhang J, Zozulya S, **London WB**, Gregor V, McGrady P**, Gray NS, Webb TR, Xue L, Gilliland DG, Greulich H, Morris SW, Meyerson M, Look AT. Inhibitor-sensitive mutations in the ALK receptor tyrosine kinase provide a therapeutic target in neuroblastoma. *Nature* 2008 Oct 16;455(7215):975-978. PMID: 18923525. PMCID: PMC2587486

54. Frazier AL, Rumcheva P**, Olson T, Giller R, Cushing B, Cullen J, Marina N, **London WB**, & Children's Oncology Group (2008). Application of the adult international germ cell classification system to pediatric malignant non-seminomatous germ cell tumors: a report from the Children's Oncology Group. *Pediatric Blood & Cancer*, 2008 Apr;50(4):746-51. doi: 10.1002/pbc.21304. PMID: 18085675; PMCID: PMC3836436

55. DuBois SG**, **London WB**, Zhang Y**, Matthay KK,Monclair T, Ambros PF, Cohn SL, Pearson A, Diller L. Lung metastases in neuroblastoma at initial diagnosis: A Report from the International Neuroblastoma Risk Group (INRG) project. *Pediatric Blood and Cancer.* 2008 Nov;51(5):589-92. PMID: 18649370. PMCID: PMC2746936.

56. Monclair T, Brodeur GM, Ambros PF, Brisse H, Cecchetto G, Holmes K, Kaneko M, **London WB**, Matthay KK, Nuchtern JG, von Schweinitz D, Cohn SL, Pearson ADJ for the INRG Working Group. The International Neuroblastoma Risk Group (INRG) Staging System. *Journal of Clinical Oncology* 2009 Jan 10;27(2):298-303. Epub 2008 Dec 1. PMID: 19047290 PMCID: PMC2650389.

57. Hogarty MD, Norris MD, Davis K, Liu X, Evageliou NF, Hayes CS, Pawel B, Guo R, Zhao H, Sekyere E, Keating J, Thomas W, Cheng NC, Murray J, Smith J, Sutton R, Venn N, **London WB**, Buxton A**, Gilmour SK, Marshall GM, Haber M. *ODC1* is a critical determinant of *MYCN* oncogenesis and a therapeutic target in neuroblastoma. *Cancer Research.* 2008 Dec 1;68(23):9735-45. PMID: 19047152. PMCID: PMC2596661.

58. Zage PE, Kletzel M, Murray K, Marcus R, Joshi V, Castleberry R, Zhang Y**, **London WB**, Kretschmar C. Outcomes of the POG 9340/9341/9342 trials for children with High-Risk Neuroblastoma: A Report from the Children's Oncology Group. *Pediatric Blood and Cancer* 2008 Dec;51(6):747-53. PMID: 18704922.

59. Bagatell R**, Beck-Popovic M, **London WB**, Zhang Y**, Pearson ADJ, Matthay KK, Monclair T, Ambros PF, Cohn SL. Significance of *MYCN* amplification in INSS stage 1 and 2 neuroblastoma: A Report from the International Neuroblastoma Risk Group (INRG) database. *Journal of Clinical Oncology* 2009 Jan 20;27(3):365-70. Epub 2008 Dec 1. PMID: 19047282 PMCID: PMC2651034

60. Cohn SL*, Pearson ADJ*, **London WB**, Monclair T, Ambros PF, Faldum A, Hero B, Iehara T, Machin D, Mosseri V, Matthay KK, for the INRG Task Force. The International Neuroblastoma Risk Group (INRG) Classification System. *Journal of Clinical Oncology* 2009 Jan 10;27(2):289-97. Epub 2008 Dec 1. [* = share first authorship] PMID: 19047291 PMCID: PMC2650388.

61. Park JR, Villablanca J, **London WB**, Gerbing R**, Haas-Kogan D, Adkins S, Attiyeh EF, Maris JM , Seeger RC, Reynolds CP, Matthay KK. Favorable outcome of high-risk stage 3 neuroblastoma with myeloablative therapy and 13-cis-retinoic acid. *Pediatric Blood and Cancer* 2009 Jan;52(1):44-50. PMID: 18937318 PMCID: PMC:2731719.

62. Matthay KK, Villablanca J, Seeger RC, Gerbing RB**, **London WB**, Reynolds CP. Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: A Children's Oncology Group study. *Journal of Clinical Oncology.* 2009 Mar 1;27(7):1007-13. [Epub 2009 Jan 26] PMID: 19171716 PMCID: PMC2738615

63. Hunsberger S, Albert P, **London WB**. A finite mixture survival model to characterize risk groups of neuroblastoma. *Statistics in Medicine* 2009 Apr 15;28(8):1301-14. PMID: 19184977

64. Capasso M, Hou C, Asgharzadeh S, Attiyeh EF, Mosse YP, Diskin SJ, Cole KA, Bosse K, Diamond M, Laudenslager M, Winter C, Bradfield JP, Scott RH, Jagannathan J, Glessner JT, Kim C, **London WB**, Seeger RC, Li H, Rahman N, Rappaport E, Hakonarson H, Devoto M, Maris JM. Common variations in the *BARD1* influence susceptibility to high-risk neuroblastoma. *Nature Genetics* 2009 Jun;41(6):718-723. PMID: 19412175 PMCID: PMC2753610.

65. Ambros PF, Ambros IM, Brodeur GM, Haber M, Khan J, Nakagawara A, Schleiermacher G, Speleman F, Spitz R, **London WB**, Cohn SL, Pearson ADJ, Maris JM. International consensus for neuroblastoma molecular diagnostics: Report from the International Neuroblastoma Risk Grouping (INRG) biology committee. *British Journal of Cancer* 2009 May 5;100(9):1471-82. PMID: 19401703 PMCID: PMC2694415

66. Taggart DR**, **London WB**, Schmidt ML, Zhang Y**, Dubois SG**, Monclair T, Pearson AD, Cohn SL, Matthay KK. Significance of tumor biology compared to metastatic pattern (INSS 4 versus 4s) and age for prognosis of neuroblastoma less than 18 months of age. J Clin Oncol. 2009 May 20; 27(15_suppl):10010. PMID: 27962519.

67. Bagatell R, Wagner LM, Cohn SL, Maris JM, Reynolds CP, Stewart CF, Voss SD, Gelfand M, Kretschmar CS, **London WB**. Irinotecan plus temozolomide in children with recurrent or refractory neuroblastoma: A phase II Children's Oncology Group study. J Clin Oncol. 2009 May 20; 27(15_suppl):10011. PMID: 27962521.

68. Vermeulen J, De Preter K, Naranjo A**, Vercruysse L, Van Roy N, Hellemans J, Swerts K, Bravo S, Scaruffi P, Tonini GP, Noguera R, Piqueras M, Janoueix-Lerosey I, Delattre O, Combaret V, Fischer M, Oberthuer A, Ambros P, Beiske K, Bénard J, Marques B, Michon J, Schleiermacher G, De Bernardi B, Rubie H, Cañete A, Castel V, Kohler J, Pötschger U, Ladenstein R, Hogarty MD, McGrady P**, **London WB**, Laureys G, Speleman F, Vandesompele J. Improved outcome prediction of children with Neuroblastoma using a multigene expression signature, a SIOPEN Study. *The Lancet Oncology* 2009 Jul;10(7):663-71. PMID: 19515614 PMCID: PMC3045079.

69. Diskin SJ, Hou C, Glessner JT, Attiyeh EF, Laudenslager M, Cole K, Mosse YP, Kim C Wood A, Wang K, Geiger EA, McGrady PW**, Blakemore AIF, **London WB**, Shaikh TH, Bradfield J, Li H, Devoto M, Rappaport ER, Hakonarson H, Maris JM. Copy number variation at 1q21.1 associated with neuroblastoma. *Nature.* 2009 Jun 18;459(7249):987-91. PMID: 19536264 PMCID: PMC2755253.

70. Schwartz CL, Constine LC, Villaluna D, **London WB**, Hutchison R, Sposto R, Lipshultz S, Turner C, deAlarcon P, Chauvenet A. Risk-adapted, response-based approach using ABVE-PC for children and adolescents with intermediate and high risk Hodgkin lymphoma: The results of P9425. *Blood* 2009 Sep 3;114(10):2051-9. PMID: 19584400 PMCID: PMC2744567.

71. Lagmay J**, **London WB**, Gross T, Termuhlen A, Sullivan N, Axel A, Mundy B, Ranalli M, Canner J, McGrady P**, Hall B. Prognostic significance of interleukin-6 single nucleotide polymorphism genotypes in neuroblastoma: *rs1800795* (promoter) and *rs8192284* (receptor). *Clinical Cancer Research* 2009 Aug 15;15(16):5235-9. PMIC: 19671870 PMCID: PMC2740837.

72. Combaret V, Hogarty MD, **London WB**, McGrady P**, Iacono I, Brejon S, Swerts K, Noguera R, Gross N, Rousseau R, Puisieux A. Influence of neuroblastoma stage on serum-based detection of *MYCN* amplification. *Pediatric Blood and Cancer* 2009 Sep;53(3):329-31. PMID: 19301388 PMCID: PMC2857568.

73. Okamatsu C, **London WB**, Naranjo A**, Hogarty MD, Gastier-Foster JM, Look AT, LaQuaglia M, Maris JM, Cohn SL, Matthay KK, Seeger RC, Saji T, and Shimada H. Clinicopathological characteristics of ganglioneuroma and ganglioneuroblastoma: A report from the CCG and COG[1]. *Pediatric Blood and Cancer*. 2009 Oct;53(4):563-9. PMID: 19530234 PMCID: PMC2730988.

74. Bray I, Bryan K, Prenter S, Buckley PG, Foley NH, Murphy DM, Alcock L, Mestdagh P, Vandesompele J, Speleman F, **London WB**, McGrady PW**, Higgins DG, O'Meara A, O'Sullivan M, Stallings RL. Widespread dysregulation of MiRNAs by MYCN amplification and chromosomal imbalances in neuroblastoma: association of miRNA expression with survival. *PloS One*. 2009 Nov 16;4(11):e7850.PMID: 19924232. PMCID: PMC2773120

75. **London WB**, Sondel P, Gilman AL, Ozkaynak F, Kreissman S, Buxton A**, Chen H, Matthay KK, Cohn SL, Maris JM, Yu AL. Success of chimeric anti-GD2 antibody+GM-CSF+IL2 immunotherapy in high-risk neuroblastoma (NB) in first response: a critical appraisal. *Pediatr. Blood Cancer.* 2009 Sept; 53(5):708-708. https://doi.org/10.1002/pbc.22234

76. Katzenstein HM, Chang KW, Krailo M, Chen Z, Bowman LC, Finegold MJ, Rowland J, Greffe B, Reynolds M, Newman K, Womer R, Castleberry RP, Pappo A, **London WB,** Malogolowkin M. Amifostine does not prevent platinum-induced hearing loss associated with the treatment of children with hepatoblastoma. A report of the Intergroup hepatoblastoma study P9645 as part of the Children's Oncology Group. 2009. *Cancer* 2009 Dec 15;115(24):5828-5835. PMID: 19813275 PMCID: PMC2795100

77. Devidas M, **London WB**, Anderson JR. The use of central laboratories and remote electronic data capture to risk–adjust therapy for pediatric acute lymphoblastic leukemia and neuroblastoma. *Seminars in Oncology*. 2010 Feb 37(1):53-59. PMID: 20172365 PMCID: PMC2843557

78. Bensimhon P, Villablanca JG, Sender LS, Matthay KK, Park JR, Seeger R, **London WB**, Yap JS**, Kreissman SG. Peripheral blood stem cell support for multiple cycles of dose intensive induction therapy is feasible with little risk of tumor contamination in advanced stage neuroblastoma: A report from the Children's Oncology Group. *Pediatric Blood and Cancer*. 2010 Apr;54(4):596-602. PMID: 20049927 PMCID: PMC2905158.

79. **London WB**, Frantz FN, Campbell LA, Seeger RC, Brumback BA, Cohn SL, Matthay KK, Castleberry RP, Diller L. Phase II Randomized Comparison of Topotecan plus Cyclophosphamide vs. Topotecan Alone in Children with Recurrent or Refractory Neuroblastoma: A Children's Oncology Group Study. *Journal of Clinical Oncology* 2010 Aug 20:28(24**):**3808-15. PMID: 20660830 PMCID:

PMC2940398

80. Lin RJ, Lin YC, Chen J, Kuo HH, Chen YY, Diccianni MB, **London W**, Chang CH, Yu AL. microRNA signature and expression of Dicer and Drosha can predict prognosis and delineate risk groups in neuroblastoma. *Cancer Research* 2010 Oct 15;70(20):7841-50. Epub 2010 Aug 30. PMID: 20805302 PMCID: PMC4095771.

81. Baker DL, Schmidt ML, Cohn SL, Maris JM, **London WB**, Buxton A**, Stram D, Castleberry RP, Shimada H, Sandler A, Shamberger R, Look AT, C. Reynolds CP, Seeger RC, Matthay KK. Outcome after reduced chemotherapy for intermediate-risk neuroblastoma. *New England Journal of Medicine*. 2010 Sep 30:363(14): 1313-23. PMID: 20879880 PMCID: PMC2993160.

82. Yu AL, Gilman AL, Ozkaynak MF, **London WB**, Kreissman SG, Chen HX, Smith M, Anderson B, Villablanca JG, Matthay KK, Shimada H, Grupp SA, Seeger R, Reynolds CP, Buxton A**, Reisfeld R, Gillies SD, Cohn SL, Maris JM, Sondel PM, for the Children's Oncology Group (COG[1]). Anti-GD2 Antibody with GM-CSF, IL2 and Isotretinoin for Neuroblastoma. *New England Journal of Medicine*. 2010 Sep 30:363(14): 1324-34. PMID: 20879881 PMCID: PMC3086629

    - Selected as a "Must Read" by the Faculty of 1000

83. Shusterman S**, **London WB**, Gillies SD, Hank JA, Voss S, Seeger RC, Reynolds CP, Willis D, Kimball J, Albertini MA, Wagner B, Gan J, Eickhoff J, Cohn SL, Hecht T, Gadbaw B, Reisfeld RA, Maris JM, Sondel PM. Anti-tumor activity of hu14.18-IL2 in relapsed/refractory neuroblastoma patients: a Children's Oncology Group (COG[1]) phase II study. *Journal of Clinical Oncology* 2010 Nov 20;28(33):4969-75. Epub 2010 Oct 4. PMID: 20921469 PMCID: PMC3020698.

84. Delgado DC, Hank JA, Kolesar J, Lorentzen D, Gan J, Seo S, Kim KM, Shusterman S, Gillies SD, Reisfeld RA, Yang R, Gadbaw B, DeSantes KD, **London WB**, Seeger RC, Maris JM, Sondel PM. Genotypes of NK cell KIR Receptors, Their Ligands, and Fcγ Receptors in the Response of Neuroblastoma Patients to Hu14.18-IL2 Immunotherapy. *Cancer Research* 2010 Dec 1;70(23):9554-61. Epub 2010 Oct 8. PMID: 20935224 PMCID: PMC2999644.

85. Henderson TO, Crotty K, Bhatia S, **London WB**, Cohn SL. Racial and Ethnic Disparities in Risk and Survival in Children with Neuroblastoma: A Children's Oncology Group (COG[1]) Study. *Journal of Clinical Oncology* 2011 Jan 1;29(1):76-82. Epub 2010 Nov 22. PMID: 21098321 PMCID: PMC3055862.

86. Moroz V**, Machin D, Faldum A, Hero B, Iehara T, Mosseri V, Ladenstein R, De Bernardi B, Rubie H, Berthold F, Matthay KK, Monclair T, Ambros PF, Pearson ADJ, Cohn SL, **London WB**. Changes over three decades in outcome and the prognostic influence of age-at-diagnosis in young patients with neuroblastoma: A report from the International Neuroblastoma Risk Group Project. *European Journal of Cancer*. 2011 Mar; 47(4):561-71. Epub 2010 Nov 26. PMID: 21112770

87. Bagatell R, **London WB**, Wagner LM, Voss S, Reynolds CP, Stewart C, Gelfand M, Maris JM, Kretschmar C, Cohn SL. Phase II Study of Irinotecan + Temozolomide in Children with Relapsed or Refractory Neuroblastoma: A Children's Oncology Group Study. *Journal of Clinical Oncology*. 2011 Jan 10;29(2):208-13. Epub 2010 Nov 29. PMID: 21115869 PMCI: PMC3058276.

88. Wang K, Diskin SJ, Zhang H, Attiyeh EF, Winter C, Hou C, Schnepp RW, Diamond M, Bosse K, Mayes PA, Glessner J, Kim C, Frackelton E, Garris M, Wang Q, Glaberson W, Chiavacci R, Nguyen R, Jagannathan J, Saeki N, Sasaki H, Grant SFA, Iolascon A, Mosse YP, Cole KA, Li H, Devoto M, McGrady PW**, **London WB**, Capasso M, Rahman N, Hakonarson H, Maris JM. Integrative genomics identifies *LMO1* as a neuroblastoma oncogene. *Nature.* 2011 Jan 13;469(7329):216-20. Epub 2010 Dec 1. PMID: 21124317 PMCID: PMC3320515.

89. Liu Z, Yang X, Li Z, McMahon C, Sizer C, Barenboim-Stapleton L, Bliskovsky V, Mock B, Ried T, **London WB**, Maris J, Khan J, Thiele CJ. CASZ1, a candidate tumor-suppressor gene, suppresses neuroblastoma tumor growth through reprogramming gene expression. *Cell Death Differ*. 2011 Jan 21. [Epub ahead of print] PMID: 21252912 PMCID: PMC3131958.

90. Naranjo A**, Parisi MT, Shulkin BL, **London WB**, Matthay KK, Kreissman SG, Yanik GA. Comparison of I-123 and I-131 MIBG Semi-Quantitative Scores in Predicting Survival in Patients with Stage 4 Neuroblastoma: A Report From the Children's Oncology Group. *Pediatric Blood and Cancer* 2011 Feb 15. Doi: 10.1002/pbc.22991. [Epub ahead of print] PMID: 21328522

91. Brisse HJ, McCarville MB, Granata C, Krug KB, Wootoon-Gorges SL, Kanegawa K, Giammarile M, Shulkin BL, Matthay KK, Lewington VJ, Kaneko M, **London WB**, Pearson AD, Cohn SL, Monclair T. Guidelines for imaging and staging neuroblastic tumors: Consensus report from the International Neuroblastoma Risk Group project. *Radiology.* 2011 Oct;261(1):243-57. Epub 2011 May 17. PMID: 21586679

92. Weiser D**, Laudenslager M, Rappaport E, Carpenter E, Attiyeh EF, Diskin S, **London WB**, Maris JM, Mosse YP. Stratification of patients with neuroblastoma for targeted ALK inhibitor therapy. J Clin Oncol. 2011 May 20; 29(15_suppl):9514. PMID: 28019813.

93. Landier W, Knight KR, Wong FL, Lee JK, Thomas O, Kim H, Kreissman SG, Schmidt ML, Chen L, **London WB**, Bhatia S, Gurney JG. Ototoxicity in children with high-risk neuroblastoma: Prevalence, risk factors, and concordance of grading scales-A report from the Children's Oncology Group (COG[1]). J Clin Oncol. 2011 May 20; 29(15_suppl):9515. PMID: 28019812.

94. **London WB***, Castel V*, Monclair T, Ambros PF, Pearson ADJ, Cohn SL, Berthold F, Nakagawara A, Ladenstein RL, Iehara T, Matthay KK. Clinical and biologic features predictive of survival after relapse of neuroblastoma: A report from the International Neuroblastoma Risk Group (INRG) Project. *Journal of Clinical Oncology.* 2011 Aug 20;29(24):3286-92. Epub 2011 Jul 18. PMID: 21768459 PMCID: PMC3158599.

95. Henderson MJ, Haber M, Porro A, Munoz MA, Iraci N, Xue C, Murray J, Flemming CL, Smith J, Fletcher JI, Gherardi S, Kwek CK, Russell AJ, Valli E, **London WB**, Buxton AB**, Ashton LJ, Sartorelli AC, Cohn SL, Schwab M, Marshall GM, Perini G, Norris MD. ABCC Multidrug Transporters in Childhood Neuroblastoma: Clinical and Biological Effects Independent of Cytotoxic Drug Efflux. *Journal of the National Cancer Institute*. 2011 Aug 17;103(16):1236–1251. Epub 2011 July 28. Doi: 10.1093/jnci/djr256 PMID:21799180 PMCID: PMC3156802

96. Villablanca JG, **London WB**, Naranjo A**, McGrady P**, Ames MM, Reid JM, McGovern RM, Buhrow SA, Jackson H, Stranzinger E, Kitchen BJ, Sondel PM, Parisi MT, Shulkin B,Yanik GA, Cohn SL, Reynolds CP. Phase II study of oral capsular 4-hydroxyphenylretinamide (4-

HPR/fenretinide) in pediatric patients with refractory or recurrent neuroblastoma: A report from the Children's Oncology Group. *Clinical Cancer Research*. 2011 Nov. 1;17(21)6858-66. Epub 2011 Sept. 9. Doi:10.1158/1078-0432.CCR-11-0995 PMID: 21908574 PMCID: PMC3207022.

97. Taggart DR**, **London WB**, Schmidt ML, DuBois SG**, Monclair T, Nakagawara A, De Bernardi B, Ambros P, Pearson AD, Cohn SL, Matthay KK. Prognostic value of the stage 4S metastatic pattern and tumor biology in patients with metastatic neuroblastoma diagnosed between birth and 18 months of age. *Journal of Clinical Oncology.* 2011 Nov. 20;29(33):4358-64. Epub 2011 Oct. 3. Doi:10.1200/JCO.2011.35.9570 PMID: 21969516 PMCID: PMC3221520.

98. Light JE**, Koyama H, Minturn JE, Ho R, Simpson AM, Iyer R, Mangino JL, Kolla V, **London WB**, Brodeur GM. Clinical significance of NTRK family gene expression in neuroblastomas. *Pediatr Blood Cancer.* 2012 Aug;59(2):226-32. Doi: 10.1002/pbc.23343. Epub 2011Oct 11. PMID: 2199026

99. Park JR, Scott JR, Stewart CF, **London WB**, Naranjo A**, Santana VM, Shaw PJ, Cohn SL, Matthay KK. A pilot induction regimen incorporating pharmacokinetically guided topotecan for treatment of newly diagnosed high-risk neuroblastoma: a Children's Oncology Group study. *J Clin Oncol.* 2011 Nov 20;29(33):4351-7. Epub 2011 Oct 17. PMID: 22010014 PMCID: PMC3221519.

100. De Preter K*, Mestdagh P*, Vermeulen J*, Zeka F, Naranjo A**, Bray I, Castel V, Chen C, Drozynska E, Eggert A, Hogarty MD, Iżycka E, **London WB**, Noguera R, Piqueras M, Bryan K, Schowe B, van Sluis P, Molenaar JJ, Schramm A, Schulte JH, Stallings RL, Versteeg R, Laureys G, Van Roy N, Speleman F, Vandesompele J. miRNA expression profiling enables risk stratification in archived and fresh neuroblastoma tumor samples. *Clinical Cancer Research*. 2011 Dec. 15;17(24)7684-92. Epub 2011 Oct. 26. Doi10,1158/1078-0432.CCR-11-0610.: [* = share first authorship] PMID: 22031065 PMCID: PMC4008338

101. Angelini P**, **London WB**, Cohn SL, Pearson AD, Matthay KK, Monclair T, Ambros PF, Shimada H, Leuschner I, Peuchmaur M, Irwin MS, Baruchel S. Characteristics and outcome of patients with ganglioneuroblastoma, nodular subtype: a report from the INRG project. *Eur J Cancer*. 2012 May;48(8):1185-91. Epub 2011 Dec 1. PMID: 22137163

102. George RE, Perez-Atayde AR, Yao X, **London WB**, Shamberger RC, Neuberg D, Diller L. Tumor histology during induction therapy in patients with high-risk neuroblastoma. *Pediatric Blood & Cancer*. 2011 Dec. 11. [Epub ahead of print] doi:10.1002/pbc.24013 PMID: 22162143

103. Fletcher JI, Gherardi S, Murray J, Burkhart CA, Russell A, Valli E, Smith J, Oberthuer A, Ashton LJ, **London WB**, Marshall GM, Norris MD, Perini G, Haber M. *N-Myc* regulates expression of the detoxifying enzyme glutathione transferase GSTP1, a marker of poor outcome in neuroblastoma. *Cancer Research*. 2012 Feb 15;72(4):845-53. Epub 2011 Dec 27. PMID: 22202125

104. Koyama H, Zhuang T, Light JE, Kolla V, Higashi M, McGrady PW**, **London WB**, Brodeur GM. Mechanisms of chd5 inactivation in neuroblastomas. *Clin Cancer Res.* 2012 Mar 15;18(6):1588-97. Epub 2012 Jan 31. PMID: 22294723 PMCID: PMC3306487.

105. Muller LU, Milsom MD, Harris CE, Vyas R, Brumme KM, Parmar K, Moreau LA, Schambach A, Park IH, **London WB**, Strait K**, Schlaeger T, Devine AL, Grassman E, D'Andrea A, Daley GQ, Williams DA. Overcoming reprogramming resistance of Fanconi anemia cells. *Blood* 2012 Jun

7;119(23):5449-57. PMID: 22371882 PMCID: PMC3369681.

106. Manley PE**, McKendrick K, McGillicudy M, Chi SN, Kieran MW, Cohen LE, Kothare S, Michael Scott R, Goumnerova LC, Sun P, **London W**, Marcus KJ, Pomeroy SL, Ullrich NJ. Sleep dysfunction in long term survivors of craniopharyngioma. *J Neurooncol*. 2012 Jul;108(3):543-9. Epub 2012 Apr 19. PubMed PMID: 22528788

107. Strother DR, **London WB**, Schmidt ML, Brodeur GM, Shimada H, Thorner P, Collins MH, Tagge E, Adkins S, Reynolds CP, Murray K, Lavey RS, Matthay KK, Castleberry R, Maris JM, Cohn SL. Outcome Following Surgery Alone or with Restricted Use of Chemotherapy for Patients with Low-Risk Neuroblastoma: Results of Children's Oncology Group Study P9641. *J Clin Oncol*. 2012 May 20;30(15):1842-8. Epub 2012 Apr 23. PMID: 22529259 PMCID: PMC3383182

- International Society of Pediatric Oncology (SIOP) award for Best Clinical Trials Abstract

- American Society of Pediatric Hematology/Oncology – Best of SIOP Lecture

108. Suganuma R, Wang LL, Sano H, Naranjo A**, **London WB**, Seeger RC, Hogarty MD, Gastier-Foster JM, Look AT, Park JR, Maris JM, Cohn SL, Amann G, Beiske K, Cullinane CJ, d'Amore ES, Gambini C, Jarzembowski JA, Joshi VV, Navarro S, Peuchmaur M, Shimada H. Peripheral neuroblastic tumors with genotype discordance: A report from the Children's Oncology Group and the International Neuroblastoma Pathology Committee. *Pediatr Blood Cancer*. 2013 Mar;60(3):363-70. Doi: 10.1002/pbc.24238. Epub 2012 Jun 28. PMID: 22744966 PMCID: PMC3397468

109. Granger M, Grupp SA, Kletzel M, Kretschmar C, Naranjo A**, **London WB**, Diller L. Feasibility of a tandem autologous peripheral blood stem cell transplant regimen for high risk neuroblastoma in a cooperative group setting: a Pediatric Oncology Group study: a report from the Children's Oncology Group. *Pediatr Blood Cancer*. 2012 Nov;59(5):902-7. Doi: 10.1002/pbc.24207. Epub 2012 Jun 28. PMID: 22744917.

110. Bauer DE**, Mitchell CM, Strait KM**, Lathan CS, Stelow EB, Lüer SC, Muhammed S, Evans AG, Sholl LM, Rosai J, Giraldi E, Oakley RP, Rodriguez-Galindo C, **London WB**, Sallan SE, Bradner JE, French CA. Cliniopathologic Features and Long-Term Outcomes of NUT Midline Cacinoma. *Clin Cancer Res.* 2012 Oct 15;18(20):5773-5779. Epub 2012 Aug 15. PMID 22896655 PMCID: PMC3473162.

111. Tebbi CK, Mendenhall NP, **London WB**, Williams JL, Hutchison RE, FitzGerald TJ, de Alarcón PA, Schwartz C, Chauvenet A. Response-dependent and reduced treatment in lower risk Hodgkin lymphoma in children and adolescents, results of P9426: A report from the Children's Oncology Group. *Pediatr Blood Cancer.* 2012 Dec 15;59(7):1259-65. Doi: 10.1038/bjc.2012.375. Epub 2012 Aug 21. PMID: 22911615. PMCID: PMC3468662

112. Asgharzadeh S, Salo JA, Ji L, Oberthuer A, Fischer M, Berthold F, Hadjidaniel M, Liu CW, Metelitsa LS, Pique-Regi R, Wakamatsu P, Villablanca JG, Kreissman SG, Matthay KK, Shimada H, **London WB**, Sposto R, Seeger RC. Clinical significance of tumor-associated inflammatory cells in metastatic neuroblastoma. *J Clin Oncol.* 2012 Oct 1;30(28):3525-32. Epub 2012 Aug 27. PMID:

22927533 PMCID: PMC3675667.

113. Friedrich P**, Ortiz R, Strait K**, Fuentes S, Gamboa Y, Arambu I, Ah-Chu-Sanchez M, **London W**, Rodriguez-Galindo C, Antillon-Klussmann F, Baez F. Pediatric Sarcoma in Central America: Outcomes, Challenges and Plans for Improvement. *Cancer.* 2013 Feb 15;119(4):871-9. Doi: 10.1002/cncr.27816. Epub 2012 Sep 12. PMID: 22972687 PMCID: PMC3535564

114. Schleiermacher G, Mosseri V, **London WB**, Maris JM, Brodeur GM, Attiyeh E, Haber M, Khan J, Nakagawara A, Speleman F, Fischer M, Ambros I, Monclair T, Matthay KK, Ambros P, Cohn SL, Pearson ADJ. Segmental chromosomal alterations have prognostic impact in neuroblastoma: A report from the INRG project. *British Journal of Cancer* 2012, Oct 9;107(8):1418-22 Epub 2012 Sep 13. Doi: 10.1038/bjc.2012.375. PMID 22976801 PMCID: PMC3494425.

115. DuBois SG, Geier E, Batra V, Yee SW, Neuhaus J, Segal M, Martinez D, Pawel B, Yanik G, Naranjo A**, **London WB**, Kreissman S, Baker D, Attiyeh E, Hogarty MD, Maris JM, Giacomini K, Matthay KK. Evaluation of Norepinephrine Transporter Expression and Metaiodobenylguanidine Avidity in Neuroblastoma: A Report from the Children's Oncology Group. *Int J Mol Imaging*. 2012;2012250834. Epub 2012 Sep 25. Doi: 10.1155/2012/250834 PMID 23050139 PMCID: PMC3463166.

116. Nuchtern JG, **London WB**, Barnewolt CE, Naranjo A**, McGrady PW**, Geiger JD, Diller L, Schmidt ML, Maris JM, Cohn SL, Shamberger RC. A prospective study of expectant observation as primary therapy for neuroblastoma in young infants: a Children's Oncology Group study. *Ann Surg.* 2012 Oct;256(4):573-80. PMID:22964741

117. Myers LC, Sun P, Brennan LL, **London WB**, Guinan EC. Effect of Weight on Outcomes of Children Undergoing Hematopoietic Cell Transplantation. *Pediatr Hematol Oncol*. 2013 Mar;30(2):116-30. Doi: 10.3109/08880018.2012.743201. Epub 2012 Nov 28 PMID: 23189973

118. Gamazon ER, Pinto N, Konkashbaev, A, Im HK, Diskin SJ, **London WB**, Maris JM, Dolan ME, Cox J, Cohn SL. Trans-population Analysis of Genetic Mechanisms of Ethnic Disparities in Neuroblastoma Survival. *Journal of the National Cancer Inst*. 2013 Feb 20;105(4):302-9. Doi: 10.1093/jnci/djs503. Epub 2012 Dec 14. PMID: 23243203 PMCID: PMC3691940

119. Park JR, Bagatell R, **London WB**, Cohn SL, Maris JM, Matthay KK, Hogarty M, on behalf of the COG Neuroblastoma Committee. Children's Oncology Group 2013 blueprint for research: Neuroblastoma. *Pediatr Blood Cancer*. 2013 Jun;60(6):985-93. Doi: 10.1002/pbc.24433. Epub 2012 Dec 19. PMID: 23255319.

120. Pugh TJ, Morozova O, Attiyeh EF, Asgharzadeh S, Wei JS, Auclair D, Carter SL, Cibulskis K, Hanna M, Kiezun A, Kim J, Lawrence MS, Lichenstein L, McKenna A, Pedamallu CS, Ramos AH, Shefler E, Sivachenko A, Sougnez C, Stewart C, Ally A, Birol I, Chiu R, Corbett RD, Hirst M, Jackman SD, Kamoh B, Khodabakshi AH, Krzywinski M, Lo A, Moore RA, Mungall KL, Qian J, Tam A, Thiessen N, Zhao Y, Cole KA, Diamond M, Diskin SJ, Mosse YP, Wood AC, Ji L, Sposto R, Badgett T, **London WB**, Moyer Y, Gastier-Foster JM, Smith MA, Auvil JM, Gerhard DS, Hogarty MD, Jones SJ, Lander ES, Gabriel SB, Getz G, Seeger RC, Khan J, Marra MA, Meyerson M, Maris JM. The genetic landscape of high-risk neuroblastoma. *Nature Genetics.* 2013 Mar;45(3):279-84.

Doi: 10.1038/ng.2529. Epub 2013 Jan 20. PMID: 23334666 PMCID: PMC3682833

121. Seif AE, Naranjo A**, Baker DL, Bunin NJ, Kletzel M, Kretschmar CS, Maris JM, McGrady PW**, von Allmen D, Cohn SL, **London WB,** Park, JR, Diller LS, Grupp S. A Pilot Study of Tandem High Dose Chemotherapy with Stem Cell Rescue as Consolidation for High Risk Neuroblastoma: Children's Oncology Group study ANBL00P1. *Bone Marrow Transplantation*. 2013 Jan 21. Doi: 10.1038/bmt.2012.276. [Epub ahead of print] PMID: 23334272. PMCID: PMC3638062

122. Yanik GA, Parisi MT, Shulkin BL, Naranjo A**, Kreissman SG, **London WB**, Villablanca JG, Maris JM, Park JR, Cohn SL, McGrady P**, Matthay KK. Semiquantitative mIBG scoring as a prognostic indicator in patients with stage 4 neuroblastoma: a report from the Children's oncology group. *J Nucl Med.* 2013 Apr;54(4):541-8. Doi: 10.2967/jnumed.112.112334. Epub 2013 Feb 25. PMID: 23440556

123. Kirby C, Ambros PF, Billiter D, **London WB**, Mendonca E, Monclair T, Pearson AD, Cohn SL, Volchenboum SL. Development of an open-source, flexible framework for complex inter-institutional disparate data sharing and collaboration. *AMIA Summits Transl Sci Proc*. 2013 Mar 18;2013:103. eCollection 2013. PMID: 24303312.

124. Robison NJ**, Prabhu SP, Sun P, Chi SN, Kieran MW, Manley PE, Cohen LE, Goumnerova L, Smith ER, Scott RM, **London WB**, Ullrich NJ. Predictors of neoplastic disease in children with isolated pituitary stalk thickening. *Pediatr Blood Cancer*. 2013 Oct;60(10):1630-5. Doi: 10.1002/pbc.24577. Epub 2013 May 14. PMID: 23670879

125. Kreissman SG, Seeger RC, Matthay KK, **London WB**, Sposto R, Grupp SA, Haas-Kogan DA, LaQuaglia M, Yu AL, Diller L, Buxton A**, Park JR, Cohn SL, Maris JM, Reynolds CP, Villablanca JG. Prospective Randomized Trial of Purged versus Non-Purged Peripheral Blood Stem Cell Transplant for High Risk Neuroblastoma. *Lancet Oncology* 2013 Sep;14(10):999-1008. Doi: 10.1016/S1470-2045(13)70309-7. Epub 2013 Jul 25. PMID: 23890779. PMCID: PMC3963485

- Audrey Evans Prize for the Outstanding Paper in Clinical Research, Advances in Neuroblastoma Research (ANR) 2008 meeting

126. Wang LL, Suganuma R, Ikegaki N, Tang X, Naranjo A**, McGrady P**, **London WB**, Hogarty MD, Gastier-Foster JM, Look AT, Park JR, Maris JM, Cohn SL, Seeger RC, Shimada H. Neuroblastoma of undifferentiated subtype, prognostic significance of prominent nucleolar formation, and MYC/MYCN protein expression: A report from the Children's Oncology Group. *Cancer.* 2013 Oct 15;119(20):3718-26. Doi: 10.1002/cncr.28251. Epub 2013 Jul 30. PMID: 23901000

127. Mosse Y**, Deyell R, Berthold F, Nakagawara A, Ambros P, Monclair T, Cohn S, Pearson A, **London WB***, Matthay, KK*. Neuroblastoma in Older Children, Adolescents and Young Adults: A Report from the International Neuroblastoma Risk Group Project. *Pediatric Blood and Cancer*. 2014 Apr;61(4):627-35. Doi: 10.1002/pbc.24777. Epub 2013 Sep 13. PMID: 24038992. [* shared senior authorship]

128. Fox E, Mosse' YP, Meany HM, Gurney JG, Khanna G, Jackson HA, Gordon G, Shusterman S, Park JR, Cohn SL, Adamson PC, **London WB**, Maris JM, Balis FM. Time to disease progression in children with relapsed or refractory neuroblastoma treated with ABT-751: A report from the

Children's Oncology Group (ANBL0621). *Pediatr Blood Cancer*. 2013 Jun;61(6):990-6. Doi: 10.1002/pbc.24900. Epub 2013 Dec 18. PMID: 24347462*

129. Landier W, Knight K, Wong FL, Lee J, Thomas O, Kim H, Kreissman SG, Schmidt ML, Chen L, **London WB**, Gurney JG, Bhatia S. Ototoxicity in Children with High-Risk Neuroblastoma – Prevalence, Risk Factors, and Concordance of Grading Scales: A Report from the Children's Oncology Group. *J Clin Oncol* 2014 Feb 20;32(6):527-34. Doi: 10.1200/JCO.2013.51.2038. Epub Jan 13. PMID: 24419114 PMCID: PMC3918536.

130. Bandopadhayay P**, Bergthold G, **London WB**, Goumnerova LC, Morales La Madrid A, Marcus K, Guo D**, Ullrich NJ, Robison NJ, Chi SN, Beroukhim R, Kieran MW, Manley PE. Long-term outcome of 4,040 children diagnosed with pediatric low-grade gliomas: An analysis of the Surveillance Epidemiology and End Results (SEER) database. *Pediatric Blood and Cancer* 2014 Jul;61(7):1173-9. Doi: 10.1002/pbc.24958. Epub 2014 Jan 30. PMID:24482038.

131. Stricker TP, Morales La Madrid A, Chlenski A, Guerrero L, Salwen HR, Gosiengfiao Y, Perlman EJ, Furman W, Bahrami A, Shohet JM, Zage PE, Hicks MJ, Shimada H, Suganuma R, Park JR, So S, **London WB**, Pytel P, Maclean KH, Cohn SL. Validation of a prognostic multi-gene signature in high-risk neuroblastoma using the high throughput digital NanoString nCounter™ system. *Mol Oncol*. 2014 May;8(3):669-78. Doi: 10.1016/j.molonc.2014.01.010. Epub 2014 Jan 31. PMID: 24560446. PMCID: PMC40046651

132. Pinto N, Gamazon ER, Antao N, Myers J, Stark AL, Konkashbaev A, Im HK, Diskin SJ, **London WB**, Ludeman SM, Maris JM, Cox NJ, Cohn SL, Dolan ME. Integrating Cell-Based and Clinical Genome-Wide Studies to Identify Genetic Variants Contributing to Treatment Failure in Neuroblastoma Patients. *Clinical Pharmacology & Therapeutics*. 2014 2014 Jun;95(6):644-52. Doi: 10.1038/clpt.2014.37. Epub 2014 Feb 18. PMID:24549002 PMCID: PMC4029857.

133. Morgenstern DA**, **London WB**, Stephens D, Volchenbaum S, Hero B, Di Cataldo A, Nakagawara A, Shimada H, Ambros PF, Matthay KK, Cohn SL, Pearson ADJ, Irwin MS. Metastatic neuroblastoma confined to distant lymph nodes (stage 4N) predicts outcome in patients with stage 4 disease: a study from the International Neuroblastoma Risk Group (INRG) database. *J Clin Oncol* 2014 Apr 20;32(12):1228-35. Doi: 10.1200/JCO.2013.53.6342. Epub 2014 Mar 24. PMID:24663047.

134. Kesselheim JC, Sun P, Woolf AD, **London WB**, Boyer D. Balancing education and service in graduate medical education: Data from pediatric trainees and program directors. *Acad Med*. 2014 Apr;89(4):652-7. Doi: 10.1097/ACM.0000000000000174. PMID: 24556769.

135. Shahbazi J, Scarlett CJ, Norris MD, Liu B, Haber M, Tee AE, Carrier A, Biankin AV, **London WB**, Marshall GM, Lock RB, Liu T. Histone deacetylase 2 and N-Myc reduce p53 protein phosphorylation at serine 46 by repressing gene transcription of tumor protein 53-induced nuclear protein 1. Oncotarget. 2014 Jun 30;5(12):4257-68. PMID: 24952595

136. Meany HJ**, **London WB**, Ambros PF, Matthay KK, Monclair T, Simon T, Garaventa A, Berthold F, Nakagawara A, Cohn SL, Pearson AD, Park JR. Significance of clinical and biologic features in Stage 3 neuroblastoma: a report from the International Neuroblastoma Risk Group project. *Pediatric blood & cancer,* 2014 Nov;61(11):1932-9. Doi: 10.1002/pbc.25134. Epub 2014 Jul 7.

PMID: 25044743.

137. Vo KT**, Matthay KK, Neuhaus J, **London WB**, Hero B, Ambros PF, Nakagawara A, Miniati D, Wheeler K, Pearson AD, Cohn SL, DuBois SG. Clinical, biologic, and prognostic differences on the basis of primary tumor site in neuroblastoma: a report from the International Neuroblastoma Risk Group project. J Clin Oncol. 2014 Oct 1;32(28):3169-76. Doi: 10.1200/JCO.2014.56.1621. Epub 2014 Aug 25. PMID: 25154816

138. Teshiba R, Kawano S, Wang LL, He L, Naranjo A**, **London WB**, Seeger RC, Gastier-Foster JM, Look AT, Hogarty MD, Cohn SL, Maris JM, Park JR, Shimada H. Age-Dependent Prognostic Effect by Mitosis-Karyorrhexis Index (MKI) in Neuroblastoma: A Report from the Children's Oncology Group. *Pediatric and Developmental Pathology* 2014 Nov-Dec;17(6):441-9. Doi: 10.2350/14-06-1505-OA.*1. E*pub 2014 Sep 10 PMID: 25207821 PMCID: PMC4340697

139. Hacein-Bey-Abina S, Pai SY, Gaspar HB, Armant M, Berry CC, Blanche S, Bleesing J, Blondeau J, de Boer H, Buckland KF, Caccavelli L, Cros G, De Oliveira S, Fernández KS, Guo D**, Harris CE, Hopkins G, Lehmann LE, Lim A, **London WB**, van der Loo JCM, Malani N, Male F, Malik P, Marinovic MA, McNicol AM, Moshous D, Neven B, Oleastro M, Picard C, Ritz J, Rivat C, Schambach A, Shaw KL, Sherman EA, Silberstein LE, Six E, Touzot F, Tsytsykova A, Xu-Bayford J, Baum C, Bushman FD, Fischer A, Kohn DB, Filipovich AH, Notarangelo LD, Cavazzana M, Williams DA, and Thrasher AJ. A Modified γ-Retrovirus Vector for X-Linked Severe Combined Immunodeficiency. *New England Journal of Medicine*. 2014 Oct 9:371(15): 1407-17. PMID: 25295500 PMCID: PMC4274995

- Distinguished Clinical Research Achievement Award from the Clinical Research Forum

140. Trippett TM, Schwartz CL, Guillerman RP, Gamis AS, Gardner S, Hogan S, **London WB**, Chen L, de Alarcon P. Ifosfamide and Vinorelbine is an Effective Reinduction regimen in Children with Refractory/Relapsed Hodgkin Lymphoma, AHOD00P1: A Children's Oncology Group Report. *Pediatric Blood and Cancer* 2015 Jan;62(1):60-4. Doi: 10.1002/pbc.25205. Epub 2014 Oct 12. PMID: 25308760.

141. Bona K**, **London WB**, Guo D**, Abel G, Lehmann L, Wolfe J. Prevalence and Impact of Financial Hardship Among New England Pediatric Stem Cell Transplant Families. *Biology of Blood and Marrow Transplantation*. 2015 Feb; 21(2):312-8. Doi: 10.1016/j.bbmt.2014.10.016. Epub 2014 Oct 23. PMID 25445021

142. Bresler SC, Weiser DA, Huwe PJ, Park JH, Krystka K, Ryles H, Laudenslager M, Rappaport EF, Wood AC, McGrady PW**, Hogarty MD, **London WB**, Radhakrishnan R, Lemmon MA, Mossé YP. ALK mutations confer differential oncogenic activation and sensitivity to ALK inhibition therapy in neuroblastoma. *Cancer Cell*. 2014 Nov 10; 26(5):682-94. Doi 10.1016/j.ccell.2014.09.019. Epub 2014 Nov 10. PMID: 25517749 PMCID: PMC4269829

143. Matthay KK, **London WB**, Maris J, Adamson PC, Park JR. Reply to N.K.V. Cheung et al. *J Clin Oncol.* 2014 Dec 20:32(36):4174-5. Doi: 10.1200/JCO.2014.58.7006. Epub 2014 Nov 17. PMID: 25403223.

144. Sheu J**, Hawryluk EB, Guo D**, **London WB**, Huang JT**. Voriconazole Phototoxicity in

Children: A Retrospective Review. *Journal of the American Academy of Dermatology*. 2015 Feb; 72(2):314-20. Doi: 10.1016/j.jaad.2014.10.10.023 Epub 2014 Dec 3. PMID: 25481710

145. Shulman DS**, **London WB**, Guo D**, Duncan CN, Lehmann LE. Incidence and Causes of Hospital Readmission in Pediatric Patients after Hematopoietic Cell Transplantation. *Biology of Blood and Marrow Transplantation*. 2015 Feb 7. Pii: S1083-8791(15)00108-1. Doi: 10.1016/j.bbmt.2015.01.027. [Epub ahead of print] PMID: 25667988

146. Forester CM**, Sartain SE**, Guo D**, Harris MH, Weinberg OK, Fleming MD, **London WB**, Williams DA, Hofmann I**. Pediatric aplastic anemia and refractory cytopenia: A retrospective analysis assessing outcomes and histomorphologic predictors. *American Journal of Hematology.* 2015 Apr;90(4):320-6. Doi: 10.1002/ajh.23937. Epub 2015 Mar 2. PMID: 25580823 PMCID PMC4384448

147. Parikh NS, Howard SC, Chantada G, Israels T, Khattab M, Alcasabas P, Lam CG, Faulkner L, Park JR, **London WB**, Matthay KK. SIOP_PODC adapted risk stratification and treatment guidelines: Recommendations for Neuroblastoma in low-and middle-income settings. *Pediatric Blood and Cancer.* 2015 Mar 21. Doi: 10.002/pbc.25501. [Epub ahead of print] PMID: 25810263.

148. Wang LL, Teshiba R, Ikegaki N, Tang XX, Naranjo A**, **London WB**, Hogarty MD, Gastier-Foster JM, Look AT, Park JR, Maris JM, Cohn SL, Seeger RC, Asgharzadeh S, Shimada H. Augmented Expression of MYC and/or MYCN Protein Defines Highly Aggressive MYC-Driven Neuroblastoma: A Children's Oncology Group Study. *British Journal of Cancer*. 2015 Jun 2. Doi:10.1038/bjc.2015.188. PMID: 26035700.

149. Mandriota SJ, Valentijn LJ, Lesne L, Betts, DR, Marino D, Boudal-Khoshbeen M, **London WB**, Rougemon, AL, Attiye EF, Maris JM, Hogarty MD, Koster J, Molenaar JJ, Versteeg R, Ansari M, Gumy-Pause F. Ataxia-telangiectasia mutated (ATM) silencing promotes neuroblastoma progression through a MYCN independent mechanism. *Oncotarget*. 2015 May 26. PMID 26053094.

150. Pinto NR, Applebaum MA, Volchenboum SL, Matthay KK, **London WB**, Ambros PF, Nakagawara A, Berthold F, Schleiermacher G, Park JR,Valteau-Couanet D, Pearson AD, Cohn SL. Advances in Risk Classification and Treatment Strategies for Neuroblastoma. *Journal of Clinical Oncology.* 2015 Aug 24. Pii: JCO.2014.59.4648. [Epub ahead of print] PMID: 26304901.

151. Bona K**, **London WB**, Guo D**, Frank DA, Wolfe J. Trajectory of Material Hardship and Income Poverty in Families of Children Undergoing Chemotherapy: A Prospective Cohort Study. *Pediatric Blood & Cancer*. 2015 Sept 23. Doi: 10.1002/pbc.25762. [Epub ahead of print]. PMID 26398865

152. Poorvu PD**, Barton SE, Duncan CN, **London WB**, Laufer MR, Lehmann LE, Marcus KJC. Use and effectiveness of GnRH agonists for prophylactic menstrual suppression in post-menarchal females undergoing hematopoietic cell transplantation. *J Pediatr Adolesc Gynecol*. 2015 Oct 23. PMID: 26506031.

153. Thompson D, Vo KT, **London WB**, Fischer M, Ambros PF, Nakagawara A, Brodeur GM, Matthay KK, DuBois SG. Identification of Patient Subgroups with Markedly Disparate Rates of MYCN Amplification in Neuroblastoma: A Report from the International Neuroblastoma Risk Group (INRG)

Project. *Cancer.* 2016 Mar 15;122(6):935-45. Doi: 10.1002/cncr.29848. Epub 2015 Dec 28. PMID: 26709890

154. Tubman VN**, Marshall R, Jallah W, Guo D**, Ma C**, Ohene-Frempong K, **London WB**, Heeney MM. Newborn Screening for Sickle Cell Disease in Liberia: A Pilot Study. *Pediatric Blood & Cancer.* 2016 Apr 1;63(4):671-6. Doi: 10.1002/pbc.25875. Epub 2016 Jan 6. PMID: 26739520 PubMed Central PMCID: PMC4755789

155. Ullrich CK**, Lehmann L, **London WB**, Guo D**, Sridharan M**, Koch R, Wolfe J. End-of-Life Care Patterns Associated with Pediatric Palliative Care among Children Who Underwent Hematopoietic Stem Cell Transplant. *Biol Blood Marrow Transplant*. 2016 Feb 20. Pii: S1083-8791(16)00117-8. Doi: 10.1016/j.bbmt.2016.02.012. [Epub ahead of print]. PMID: 26903381

156. Treister NS, **London WB**, Guo D**, Malsch M, Verrill K, Brewer J, Margossian S, Duncan C. A Feasibility Study Evaluating Extraoral Photobiomodulation Therapy for Prevention of Mucositis in Pediatric Hematopoietic Cell Transplantation. *Photomed Laser Surg*. 2016 Apr;34(4):178-84. Doi: 10.1089/pho.2015.4021. Epub 2016 Mar 16. PMID: 26982624

157. O'Brien R, Tran SL, Maritz MF, Liu B, Kong CF, Pugato S, Yang C, Murray J, Russell AJ, Flemming CL,von Jonquieres G, Pickett HA, **London WB,** Haber M, Gunaratne PH, Norris MD, Perini G, Fletcher JI, MacKenzie KL. MYC-Driven Neuroblastomas are Addicted to a Telomerase-Independent Function of Dyskerin. *Cancer Res.* 2016 Jun 15; 76(12):3604-17. Doi: 10.1158/0008-5472. CAN-15-0879. Epub 2016 Apr 13. PMID 27197171

158. Harris MH, DuBois SG, Glade Bender J, Kim A, Crompton BD, Parker E, Hong AL, Guo D**, Church, A, Stegmaier, K, Roberts CW, Shusterman S, **London WB**, MacConail LE, Lindeman NI, Diller L, Rodriguez-Galindo C, Janeway KA. Multicenter Feasibility Study of Tumor Molecular Profiling to Inform Therapeutic Decisions in Advanced Pediatric Solid Tumors: The Individualized Cancer Therapy (iCat) Study. *JAMA Oncology.* 2016 Jan 28. Doi: 10.001/jamaoncol.2015.5689 [Epub ahead of print] PMID: 26822149

159. Rowe RG**, Guo D**, Lee M, Margossian S, **London WB**, Lehmann L. CMV Infection in Pediatric Hematopoietic Stem Cell Transplantation: Risk Factors for Primary Infection, and Cases of Recurrent and Late Infection at a Single Center. *Biol Blood Marrow Transplant*. 2016 Apr 15. Pii: S1083-8791(16)30022-2. Doi: 10.1016/j.bbmt.2016.04.004. [Epub ahead of print] PMID: 27090959

160. Morgenstern DA**, **London WB**, Stephens D, Volchenboum S, Simon T, Nakagawara A, Shimada H, Ambros PF, Matthay KK, Cohn SL, Pearson ADJ, Irwin MS. Prognostic significance of pattern and burden of metastatic disease in patients with stage 4 neuroblastoma: a study from the International Neuroblastoma (NB) Risk Group (INRG) database. *Eur J Cancer*. 2016 Sep;65:1-10. Doi: 10.1016/j.ejca.2016.06.005. Epub 2016 Jul 17 PMID: 27434878

161. Yagyu S, Iehara T, Tanaka S, Gotoh T, Misawa-Furihata A, Sugimoto T, **London W**, Hogarty MD, Teramukai S, Nakagawara A, Hiyama E, Maris JM, Hosoi H. Serum-Based Quantification of MYCN Gene Amplification in Young Patients with Neuroblastoma: Potential Utility as a Surrogate Biomarker for Neuroblastoma. *PloS one*. 2016; 11(8): e0161039. PubMed PMID: 27513929

162. Xue C, Yu D M, Gherardi S, Koach J, Milazzo G, Gamble L, Liu B, Valli E, Russell AJ, **London W**, Liu T, Cheung BB, Marshall GM, Perini G, Haber M, Norris MD. MYCN promotes neuroblastoma malignancy by establishing a regulatory circuit with transcription factor AP4. *Oncotarget*. 2016 Jul 19. PubMed PMID: 27448979

163. Li R**, Polishcuck A, Dubois SG, Hawkins R, Lee SW, Bagatell R, Shusterman S, Hill-Kayser C, Al-Sayegh H, Diller L, Haas-Kogan DA, Matthay K, **London WB***, Marcus KJ*. Patterns of relapse in high-risk neuroblastoma patients treated with and without total body irradiation. *International Journal of Radiation Oncology Biology Physics* 2017 Feb 1;97(2):270-277. Doi: 10.1016/j.ijrobp.2016.10.047. Epub 2016 Nov 8. PMID:28068235 (*co-senior authors)

164. von Allmen D, Davidoff AM, **London W**, Van Ryn C**, Haas-Kogan DA, Kreissman SG, Khanna G, Rosen N, Park JR, La Quaglia MP. Impact of Extent of Resection on Local Control and Survival in Patients from the COG A3973 Study with High-Risk Neuroblastoma. *Journal of Clinical Oncology* 2017 35:2, 208-216 PubMed PMID: 27870572

165. Jung M, Russell AJ, Liu B, George J, Liu PY, Liu T, DeFazio A, Bowtell DD, Oberthuer A, **London WB**, Fletcher JI, Haber M, Norris MD, Henderson MJ. A Myc Activity Signature Predicts Poor Clinical Outcomes in Myc-Associated Cancers. Cancer Res. 2017 02 15; 77(4):971-981. PMID: 27923830.

166. Applebaum MA**, Vaksman Z, Lee SM, Hungate EA, Henderson TO, **London WB**, Pinto N, Volchenboum SL, Park JR, Naranjo A**, Hero B, Pearson AD, Stranger BE, Cohn SL, Diskin SJ. Neuroblastoma survivors are at increased risk for second malignancies: A report from the International Neuroblastoma Risk Group Project. *Eur J Cancer*. 2016 Dec 26;72:177-185. PubMed PMID: 28033528

- Audrey Evans Prize for the Outstanding Paper in Clinical Research, Advances in Neuroblastoma Research (ANR) 2016 meeting

167. Park JR, Kreissman SG, **London WB**, Naranjo A**, Cohn SL, Hogarty MD, Tenney SC, Haas-Kogan D, Shaw PJ, Geiger JD, Doski JJ, Gorges SW, Khanna G, Voss SD, Maris JM, Grupp SA, Diller L. A phase III randomized clinical trial (RCT) of tandem myeloablative autologous stem cell transplant (ASCT) using peripheral blood stem cell (PBSC) as consolidation therapy for high-risk neuroblastoma (HR-NB): A Children's Oncology Group (COG[1]) study. *Journal of Clinical Oncology* 2016 34:18_suppl, LBA3-LBA3

168. Rubens SL**, Loucas CA, Marybeth Morris M, Manley P, Ullrich NJ, Muriel AC, Guo D**, **London WB**, Northman L**. Parent-reported outcomes associated with utilization of a pediatric cancer school consultation program. *Clin Practice in Ped Psych* 2016, Vol 4. No. 4, 383-395. Doi: 10.1037/cpp0000150.

169. Song JS**, **London WB**, Hawryluk EB, Guo D**, Sridharan M**, Fisher DE, Lehmann LE, Duncan CN, Huang JT**. Risk of melanocytic nevi and nonmelanoma skin cancer in children after allogeneic hematopoietic stem cell transplantation. *Bone Marrow Transplantation* 2017 Apr 3. Doi: 10.1038/bmt.2017.57. [Epub ahead of print] PMID: 28368380

170. LaQuaglia MP, Haas-Kogan D, Park J, Kreissman SG, von Allmen D, Davidoff A, **London WB**, Khanna G. Reply to J. Stenman et al. *J Clin Oncol*. 2017 Apr 19:JCO2017722777. Doi: 10.1200/JCO.2017.72.2777. [Epub ahead of print] PMID: 28422554

171. Park JR, Bagatell R, Cohn SL, Pearson AD, Villablanca JG, Berthold F, Burchill S, Boubaker A, McHugh K, Nuchtern JG, **London WB**, Seibel NL, Lindwasser OW, Maris JM, Brock P, Schleiermacher G, Ladenstein R, Matthay KK, Valteau-Couanet D. Revisions to the International Neuroblastoma Response Criteria (INRC): A consensus statement from the National Cancer Institute Clinical Trials Planning Meeting. *Journal of Clinical Oncology.* 2017 May 4:JCO2016720177. Doi: 10.1200/JCO.2016.72.0177. [Epub ahead of print] PMID:28471719

172. Mody R, Naranjo A**, Van Ryn C**, Yu AL, **London WB**, Shulkin BL, Parisi MT, Servaes SE, Diccianni MB, Sondel PM, Bender JG, Maris JM, Park JR, Bagatell R. Irinotecan-temozolomide with Temsirolimus or Dinutuximab in Children with Refractory or Relapsed Neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial. *Lancet Oncology* 2017 Jul;18(7):946-957. Doi: 10.1016/S1470-2045(17)30355-8. Epub 2017 May 23 PubMed PMID: 28549783; PubMed Central PMCID: PMC5527694.

173. Erbe AK, Wang W, Reville PK, Carmichael L, Kim K, Mendonca EA, Song Y, Hank JA, **London WB**, Naranjo A, Hong F, Hogarty MD, Maris JM, Park JR, Ozkaynak MF, Miller JS, Gilman AL, Kahl B, Yu AL, Sondel PM. HLA-Bw4-I-80 Isoform Differentially Influences Clinical Outcome as compared to HLA-Bw4-T-80 and HLA-A-Bw4 Isoforms in Rituximab or Dinutuximab-based Cancer Immunotherapy. *Frontiers in Immunology* 2017 Jun 12;8:675. Doi: 10.3389/fimmu.2017.00675. eCollection PMID: 28659916 PMCID: PMC5466980

174. Campbell K**, Gastier-Foster JM, Mann M, Naranjo AH**, Van Ryn C**, Bagatell R, Matthay KK, **London WB**, Irwin MS, Shimada H, Granger MM, Hogarty MD, Park JR, DuBois SG. Association of MYCN Copy Number with Clinical Features, Tumor Biology, and Outcomes in Neuroblastoma: A Report from the Children's Oncology Group. *Cancer* 2017 Jul 11. Doi: 10.1002/cncr.30873. [Epub ahead of print] PubMed PMID: 28696504.

175. Marinoff AE**, Ma C**, Guo D**, Snuderl M, Wright KD, Manley PE, Al-Sayegh H, Sinai CE, Ullrich NJ, Marcus K, Haas-Kogan D, Goumnerova L, **London WB**, Kieran MW, Chi SN, Fangusaro J, Bandopadhayay P. Rethinking Childhood Ependymoma: a Retrospective, Multi-center Analysis Reveals Poor Longterm Overall Survival. *J Neurooncol.* 2017 Jul 21. Doi: 10.1007/s11060-017-2568-8. [Epub ahead of print] PubMed PMID: 28733870.

176. **London WB**, Bagatell R, Weigel BJ, Fox E, Guo D**, Van Ryn C**, Naranjo A**, Park JR. Historical time to disease progression and progression-free survival in patients with relapsed/refractory neuroblastoma treated in the modern-era on Children's Oncology Group early-phase trials. *Cancer* 2017 Sep 8. Doi: 10.1002/cncr.30934. [Epub ahead of print] PMID:28885700

177. Erbe AK, Wang W, Carmichael L, Kim K, Mendonca EA, Song Y, Hess D, Reville PK, **London WB**, Naranjo A**, Hank JA, Diccianni MB, Reisfeld RA, Gillies SD, Matthay KK, Cohn SL, Hogarty MD, Maris JM, Park JR, Ozkaynak MF, Gilman A, Yu AL, Sondel PM. Neuroblastoma Patients' KIR and KIR-ligand Genotypes Influence Clinical Outcome for Dinutuximab-based Immunotherapy: A Report from the Children's Oncology Group. *Clin Cancer Res*. 2017 Oct 2. Pii: clincanres.1767.2017. doi: 10.1158/1078-0432.CCR-17-1767. [Epub ahead of print] PMID:28972044

178. O'Neill AF**, Voss SD, Jagannathan JP, Kamihara J, Nibecker C, Itriago-Araujo E, Masciari S, Parker E, Barreto M, **London WB**, Garber JE, Diller L. Screening with whole-body magnetic resonance imaging in pediatric subjects with Li-Fraumeni syndrome: A single institution pilot study. *Pediatr Blood Cancer*. 2017 Oct 27. Doi: 10.1002/pbc.26822. [Epub ahead of print] PMID:29077256

179. de Alarcon PA, Matthay KK, **London WB**, Naranjo A**, Tenney SC, Panzer JA, Hogarty MD, Park JR, Maris JM, Cohn SL. Intravenous immunoglobulin with prednisone and risk-adapted chemotherapy for children with opsoclonus myoclonus ataxia syndrome associated with neuroblastoma (ANBL00P3): a γ andomized, open-label, phase 3 trial. *Lancet Child Adolesc Health*. 2018 Jan;2(1):25-34. Doi: 10.1016/S2352-4642(17)30130-X. Epub 2017 Nov 3. PMID:29376112.

180. Ananth P**, Ma C**, Al-Sayegh H**, Kroon L, Klein V, Wharton C, Hallez E, Braun I, Michelson K, Rosenberg AR, **London W**, Wolfe J. Provider Perspectives on Use of Medical Marijuana in Children With Cancer. *Pediatrics*. 2018 Jan;141(1). Pii: e20170559. Doi: 10.1542/peds.2017-0559. Epub 2017 Dec 12. PMID:29233937.

181. Niemas-Teshiba R, Matsuno R, Wang LL, Tang XX, Chiu B, Zeki J, Coburn J, Ornell K, Naranjo A**, Van Ryn C**, **London WB**, Hogarty MD, Gastier-Foster JM, Look AT, Park JR, Maris JM, Cohn SL, Seeger RC, Asgharzadeh S, Ikegaki N, Shimada H. MYC-family protein overexpression and prominent nucleolar formation represent prognostic indicators and potential therapeutic targets for aggressive high-MKI neuroblastomas: a report from the children's oncology group. *Oncotarget*. 2017 Dec 15;9(5):6416-6432. Doi: 10.18632/oncotarget.23740. eCollection 2018 Jan 19. PMID:29464082.

182. Guenther LM**, Rowe RG, Acharya PT, Swenson DW, Meyer SC, Clinton CM, Guo D**, Sridharan M**, **London WB**, Grier HE, Ecklund K, Janeway KA. Response Evaluation Criteria in Solid Tumors (RECIST) following neoadjuvant chemotherapy in osteosarcoma. *Pediatr Blood Cancer*. 2018 Apr;65(4). Doi: 10.1002/pbc.26896. Epub 2017 Dec 18. PMID:29251406.

183. Grace RF**, Bianchi P, van Beers EJ, Eber SW, Glader B, Yaish HM, Despotovic JM, Rothman JA, Sharma M, McNaull MM, Fermo E, Lezon-Geyda K, Morton DH, Neufeld EJ, Chonat S, Kollmar N, Knoll CM, Kuo K, Kwiatkowski JL, Pospíšilová D, Pastore YD, Thompson AA, Newburger PE, Ravindranath Y, Wang WC, Wlodarski MW, Wang H, Holzhauer S, Breakey VR, Kunz J, Sheth S, Rose MJ, Bradeen HA, Neu N, Guo D**, Al-Sayegh H**, **London WB**, Gallagher PG, Zanella A, Barcellini W. The clinical spectrum of pyruvate kinase deficiency: data from the Pyruvate Kinase Deficiency Natural History Study. *Blood*. 2018 Mar 16. Pii: blood-2017-10-810796. Doi: 10.1182/blood-2017-10-810796. [Epub ahead of print] PMID: 29549173

- Selected as one of the top 100 papers of 2018 by the journal *Blood*

184. Huang JT**, Song JS**, Hawryluk EB, **London WB**, Guo D**, Sridharan M**, Fisher DE, Lehmann LE, Duncan CN. Non-malignant late cutaneous changes after allogeneic hematopoietic stem cell transplant in children. *J Am Acad Dermatol*. 2018 Mar 24. Pii: S0190-9622(18)30481-X. doi: 10.1016/j.jaad.2018.03.029. [Epub ahead of print] PMID:29588248

185. Northman L**, Morris M, Loucas C, Ross S, Muriel AC, Guo D**, **London WB**, Manley P, Ullrich NJ. The Effectiveness of a Hospital-Based School Liaison Program: A Comparative Study of Parental Perception of School Supports for Children With Pediatric Cancer and Neurofibromatosis

Type 1. *J Pediatr Oncol Nurs*. 2018 Mar 1:1043454218765140. Doi: 10.1177/1043454218765140. [Epub ahead of print] PMID: 29600747

186. Heeney MM, Guo D**, De Falco L, Campagna DR, Olbina G, Kao PP**, Schmitz-Abe K, Rahimov F, Gutschow P, Westerman K, Ostland V, Jackson T, Klaassen RE, Markianos K, Finberg KE, Iolascon A, Westerman M, **London WB**, Fleming MD. Normalizing hepcidin predicts *TMPRSS6* mutation status in patients with chronic iron deficiency. *Blood*. 2018 Jun 12. Pii: blood-2017-03-773028. Doi: 10.1182/blood-2017-03-773028.

187. Ozkaynak MF, Gilman AL, **London WB**, Naranjo A**, Diccianni MB, Tenney SC, Smith M, Messer KS, Seeger R, Reynolds CP, Smith LM, Shulkin BL, Parisi M, Maris JM, Park JR, Sondel PM, Yu AL. A Comprehensive Safety Trial of Chimeric Antibody 14.18 with GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children's Oncology Group Study ANBL0931. *Front Immunol*. 2018 Jun 18;9:1355. Doi: 10.3389/fimmu.2018.01355. eCollection 2018. PMC6016521.

188. Ozkaynak MF, Gilman AL, **London WB**, Naranjo A**, Diccianni MB, Tenney SC, Smith M, Messer KS, Seeger R, Reynolds CP, Smith LM, Shulkin BL, Parisi M, Maris JM, Park JR, Sondel PM, Yu AL. Corrigendum: A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children's Oncology Group Study ANBL0931. Frontiers in immunology. 2018 Jul 16; 9: 1641. PubMed PMID: 30046297; PubMed Central PMCID: PMC6055015.

189. Shulman DS**, Klega K, Imamovic-Tuco A, Clapp A, Nag A, Thorner AR, Van Allen E, Ha G, Lessnick SL, Gorlick R, Janeway KA, Leavey PJ, Mascarenhas L, **London WB**, Vo KT, Stegmaier K, Hall D, Krailo MD, Barkauskas DA, DuBois SG, Crompton BD. Detection of circulating tumour DNA is associated with inferior outcomes in Ewing sarcoma and osteosarcoma: a report from the Children's Oncology Group. *Br J Cancer*. 2018 Aug;119(5):615-621. Doi: 10.1038/s41416-018-0212-9. Epub 2018 Aug 21. Erratum in: Br J Cancer. 2019 Apr;120(8):869. PubMed PMID: 30131550.

190. van Beers EJ, van Straaten S, Morton DH, Barcellini W, Eber SW, Glader B, Yaish HM, Chonat S, Kwiatkowski JL, Rothman JA, Sharma M, Neufeld EJ, Sheth S, Despotovic JM, Kollmar N, Pospíšilová D, Knoll CM, Kuo K, Pastore YD, Thompson AA, Newburger PE, Ravindranath Y, Wang WC, Wlodarski MW, Wang H, Holzhauer S, Breakey VR, Verhovsek M, Kunz J, McNaull MA, Rose MJ, Bradeen HA, Addonizio K, Li A**, Al-Sayegh H**, **London WB**, Grace RF**. Prevalence and management of iron overload in pyruvate kinase deficiency: report from the Pyruvate Kinase Deficiency Natural History Study. Haematologica. 2019 Feb;104(2):e51-e53. Doi:10.3324/haematol.2018.196295. Epub 2018 Sep 13. PubMed PMID: 30213831; PubMed Central PMCID: PMC6355506.

191. Depuydt P, Boeva V, Hocking TD, Cannoodt R, Ambros IM, Ambros PF, Asgharzadeh S, Attiyeh EF, Combaret V, Defferrari R, Fischer M, Hero B, Hogarty MD, Irwin MS, Koster J, Kreissman S, Ladenstein R, Lapouble E, Laureys G, **London WB**, Mazzocco K, Nakagawara A, Noguera R, Ohira M, Park JR, Pötschger U, Theissen J, Tonini GP, Valteau-Couanet D, Varesio L, Versteeg R, Speleman F, Maris JM, Schleiermacher G, De Preter K. Genomic Amplifications and Distal 6q Loss: Novel Markers for Poor Survival in High-risk Neuroblastoma Patients. *J Natl Cancer Inst*. 2018 Mar 5. Doi: 10.1093/jnci/djy022. [Epub ahead of print] PMID:29514301.

192. Esrick E**, Manis JP, Daley H, Baricordi C, Trébéden-Negre H, Pierciey FJ, Armant M, Nikiforow S, Heeney M, **London WB**, Biasco L, Asmal M, Williams D, Biffi A. Successful hematopoietic stem cell mobilization and apheresis collection using plerixafor alone in sickle cell patients. *Blood* advances. 2018 Oct 9; 2(19): 2505-2512. PubMed PMID: 30282642; PubMed Central PMCID: PMC6177648.

193. Twist CJ, Naranjo A**, Schmidt ML, Tenney SC, Cohn SL, Meany HJ, Mattei P, Adkins ES, Shimada H, **London WB**, Park JR, Matthay KK, Maris JM. Defining Risk Factors for Chemotherapeutic Intervention in Infants with Stage 4S Neuroblastoma: A Report from Children's Oncology Group Study ANBL0531. *Journal of Clinical Oncology*. 2019 Jan 10; 37(2): 115-124. PubMed PMID: 30444686; PubMed Central PMCID: PMC6325354.

194. Morgenstern DA**, Bagatell R, Cohn SL, Hogarty MD, Maris JM, Moreno L**, Park JR, Pearson AD, Schleiermacher G, Valteau-Couanet D, **London WB***, Irwin MS*. The challenge of defining "ultra-high-risk" neuroblastoma. Pediatr Blood Cancer. 2019 Apr;66(4):e27556. Doi: 10.1002/pbc.27556. Epub 2018 Nov 26. Review. PubMed PMID: 30479064. (*share senior authorship)

195. Naranjo A**, Irwin MS, Hogarty MD, Cohn SL, Park JR, **London WB**. Statistical Framework in Support of a Revised Children's Oncology Group Neuroblastoma Risk Classification System. JCO Clin Cancer Inform. 2018 Dec;2:1-15. doi: 10.1200/CCI.17.00140. PMID: 30652588; PMCID: PMC6421832.

196. Gamble LD, Purgato S, Murray J, Xiao L, Yu DMT, Hanssen KM, Giorgi FM, Carter DR, Gifford AJ, Valli E, Milazzo G, Kamili A, Mayoh C, Liu B, Eden G, Sarraf S, Allan S, Di Giacomo S, Flemming CL, Russell AJ, Cheung BB, Oberthuer A, **London WB**, Fischer M, Trahair TN, Fletcher JI, Marshall GM, Ziegler DS, Hogarty MD, Burns MR, Perini G, Norris MD, Haber M. Inhibition of polyamine synthesis and uptake reduces tumor progression and prolongs survival in mouse models of neuroblastoma. Sci Transl Med. 2019 Jan 30;11(477). Pii: eaau1099. Doi:10.1126/scitranslmed.aau1099. PubMed PMID: 30700572.

197. Pinto N, Naranjo A**, Hibbitts E, Kreissman SG, Granger MM, Irwin MS, Bagatell R, **London WB**, Greengard EG, Park JR, DuBois SG. Predictors of differential response to induction therapy in high-risk neuroblastoma: A report from the Children's Oncology Group (COG). Eur J Cancer. 2019 May;112:66-79. Doi: 10.1016/j.ejca.2019.02.003. Epub 2019 Apr 1. PubMed PMID: 30947024; PubMed Central PMCID: PMC6491235.

198. Braunstein SE, **London WB**, Kreissman SG, Villablanca JG, Davidoff AM, DeSantes K, Castleberry RP, Murray K, Diller L, Matthay K, Cohn SL, Shulkin B, von Allmen D, Parisi MT, Van Ryn C**, Park JR, La Quaglia MP, Haas-Kogan DA. Role of the extent of prophylactic regional lymph node radiotherapy on survival in high-risk neuroblastoma: A report from the COG A3973 study. Pediatr Blood Cancer. 2019 Apr 9:e27736. Doi: 10.1002/pbc.27736. [Epub ahead of print] PubMed PMID: 30968542.

199. Huang JT**, Coughlin CC, Hawryluk EB, Hook K, Humphrey SR, Kruse L, Lawley L, Al-Sayegh H**, **London WB**, Marghoob A, Phung TL, Pope E, Gerami P, Schmidt B, Robinson S, Bartenstein D, Bahrani E, Brahmbhatt M, Chen L, Haddock E, Mansour D, Nguyen J, Raisanen T, Tran G, Travis K, Wolner Z, Eichenfield LF. Risk Factors and Outcomes of Nonmelanoma Skin Cancer in Children

and Young Adults. J Pediatr. 2019 Aug;211:152-158. Doi: 10.1016/j.jpeds.2019.04.017. Epub 2019 May 15. PubMed PMID: 31103258.

200. Campbell K**, **Shyr D****, Bagatell R, Fischer M, Nakagawara A, Nieto AC, Brodeur GM, Matthay KK, **London WB***, DuBois SG*. Comprehensive evaluation of context dependence of the prognostic impact of MYCN amplification in neuroblastoma: A report from the International Neuroblastoma Risk Group (INRG) project. Pediatr Blood Cancer. 2019 Aug;66(8):e27819. Doi: 10.1002/pbc.27819. Epub 2019 May 21. PubMed PMID: 31115156. (*share senior authorship)

201. Shusterman S, Naranjo A**, Van Ryn C**, Hank JA, Parisi MT, Shulkin BL, **London WB**, Shimada H, Gan J, Gillies SD, Maris JM, Park JR, Sondel PM, Servaes S. Anti-tumor activity and tolerability of hu14.18-IL2 with GMCSF and isotretinoin in recurrent or refractory neuroblastoma: A Children's Oncology Group phase II study. Clin Cancer Res. 2019 Jul 29. Pii: clincanres.0798.2019. doi:10.1158/1078-0432.CCR-19-0798. [Epub ahead of print] PubMed PMID: 31358541.

202. Twist CJ, Schmidt ML, Naranjo A**, **London WB**, Tenney SC, Marachelian A, Shimada H, Collins MH, Esiashvili N, Adkins ES, Mattei P, Handler M, Katzenstein H, Attiyeh E, Hogarty MD, Gastier-Foster J, Wagner E, Matthay KK, Park JR, Maris JM, Cohn SL. Maintaining Outstanding Outcomes Using Response- and Biology-Based Therapy for Intermediate-Risk Neuroblastoma: A Report From the Children's Oncology Group Study ANBL0531. J Clin Oncol. 2019 Aug 6:JCO1900919. Doi:10.1200/JCO.19.00919. [Epub ahead of print] PubMed PMID: 31386611.

203. Li EB**, Song JS**, Huang JT**, Hawryluk EB**, **London WB**, Guo D**, Sridharan M**, Fisher DE, Rea CJ, Lehmann LE, Duncan CN. Sun exposure and protection practices in children after allogeneic hematopoietic stem cell transplantation: A Survey-Based Cross-Sectional Cohort Study. Pediatr Dermatol. 2019 Aug 13. Doi:10.1111/pde.13984. [Epub ahead of print] PubMed PMID: 31410910.

204. Park JR, Kreissman SG, **London WB**, Naranjo A**, Cohn SL, Hogarty MD, Tenney SD, Haas-Kogan D, Shaw PJ, Kraveka JM, Roberts SS, Geiger JD, Doski JJ, Voss SD, Maris JM, Grupp SA, Diller L. Effect of Tandem Autologous Stem Cell Transplantation vs Single Transplantation on Event-Free Survival in Patients With High-Risk Neuroblastoma: A Randomized Clinical Trial. *JAMA* 2019. Aug 27;322(8):746-755. Doi: 10.1001/jama.2019.11642. PMID:31454045.

205. Hofmann I**, Avagyan S, Stetson A, Guo D**, Al-Sayegh H**, **London WB**, Lehmann L. Comparison of Outcomes of Myeloablative Allogeneic Stem Cell Transplantation for Pediatric Patients with Bone Marrow Failure, Myelodysplastic Syndrome and Acute Myeloid Leukemia with and without Germline GATA2 Mutations. *Biol Blood Marrow Transplant*. 2020;26(6):1124-1130. Doi:10.1016/j.bbmt.2020.02.015

206. Bianchi, P, Fermo, E, Lezon-Geyda, K, van Beers, EJ, Morton, HD, Barcellini, W, Glader, B, Chonat, S, Ravindranath, Y, Newburger, PE, Kollmar, N, Despotovic, JM, Verhovsek, M, Sharma, M, Kwiatkowski, JL, Kuo, KHM, Wlodarski, MW, Yaish, HM, Holzhauer, S, Wang, H, Kunz, J, Addonizio, K, Al-Sayegh, H**, **London, WB**, Andres, O, van Wijk, R, Gallagher, PG, Grace, RFF**. Genotype-phenotype correlation and molecular heterogeneity in pyruvate kinase deficiency. *Am J Hematol*. 2020; 95: 472– 482. https://doi.org/10.1002/ajh.25753

207. Sokol E**, Desai AV**, Applebaum MA**, Valteau-Couanet D, Park JR, Pearson ADJ, Schleiermacher G, Irwin MS, Hogarty M, Naranjo A**, Volchenboum S, Cohn SL, **London WB**. Age, Diagnostic Category, Tumor Grade, and Mitosis-Karyorrhexis Index Are Independently Prognostic in Neuroblastoma: An INRG Project [published online ahead of print, 2020 Apr 21]. *J Clin Oncol*. 2020;JCO1903285. Doi:10.1200/JCO.19.03285

- Audrey Evans Prize for the Outstanding Paper in Clinical Research, Advances in Neuroblastoma Research (ANR) 2006 meeting

208. Mody R, Yu AL, Naranjo A**, Zhang FF, **London WB**, Shulkin BL, Parisi MT, Servaes SE, Diccianni MB, Hank JA, Felder M, Birstler J, Sondel PM, Asgharzadeh S, Glade-Bender J, Katzenstein H, Maris JM, Park JR, Bagatell R. Irinotecan, Temozolomide, and Dinutuximab With GM-CSF in Children With Refractory or Relapsed Neuroblastoma: A Report From the Children's Oncology Group. *J Clin Oncol*. 2020 Jul 01; 38(19):2160-2169. PMID: 32343642.

209. Al-Samkari H, Addonizio K, Glader B, Morton DH, Chonat S, Thompson AA, Kuo KHM, Ravindranath Y, Wang H, Rothman JA, Kwiatkowski JL, Kung C, Kosinski PA, Al-Sayegh H**, **London WB**, Grace RF**. The pyruvate kinase (PK) to hexokinase enzyme activity ratio and erythrocyte PK protein level in the diagnosis and phenotype of PK deficiency [published online ahead of print, 2020 May 28]. *Br J Haematol*. 2020;10.1111/bjh.16724. doi:10.1111/bjh.16724

210. Moroz V**, Machin D, Hero B, Ladenstein R, Berthold F, Kao P**, Obeng Y**, Pearson ADJ, Cohn SL, **London WB**. The prognostic strength of serum LDH and serum ferritin in children with neuroblastoma: A report from the International Neuroblastoma Risk Group (INRG). *Pediatric Blood and Cancer* 2020 May 30. https://doi.org/10.1002/pbc.28359

211. Liu KX, Naranjo A**, Zhang FF, DuBois SG, Braunstein SE, Voss SD, Khanna G, **London WB**, Doski JJ, Geiger JD, Kreissman SG, Grupp SA, Diller LR, Park JR, Haas-Kogan DA. Prospective Evaluation of Radiation Dose Escalation in Patients With High-Risk Neuroblastoma and Gross Residual Disease After Surgery: A Report From the Children's Oncology Group ANBL0532 Study. J Clin Oncol. 2020 Aug 20;38(24):2741-2752. Doi: 10.1200/JCO.19.03316. Epub 2020 Jun 12. PMID: 32530765; PMCID: PMC7430214.

212. Hawryluk EB**, Moustafa D, Bartenstein D, Brahmbhatt M, Cordoro K, Gardner L, Gauthier A, Grossman D, Gupta D, Hunt RD, Jen M, Kao PC**, Kruse LL, Lawley LP, **London WB**, Mansour D, O'Haver JA, Phung T, Pope E, Price HN, Rogers T, Shah SD, Wolner Z, Huang J**, Marghoob AA. A retrospective multicenter study of fatal pediatric melanoma. J Am Acad Dermatol. 2020 Nov;83(5):1274-1281. Doi: 10.1016/j.jaad.2020.06.1010. Epub 2020 Jul 2. PMID: 32622142.

213. Al-Samkari H, van Beers EJ, Morton DH, Barcellini W, Eber SW, Glader B, Yaish HM, Chonat S, Kuo KHM, Kollmar N, Despotovic JM, Pospíšilová D, Knoll CM, Kwiatkowski JL, Pastore YD, Thompson AA, Wlodarski MW, Ravindranath Y, Rothman JA, Wang H, Holzhauer S, Breakey VR, Verhovsek MM, Kunz J, Sheth S, Sharma M, Rose MJ, Bradeen HA, McNaull MN, Addonizio K, Al-Sayegh H**, **London WB**, Grace RF**. Characterization of the severe phenotype of pyruvate kinase deficiency. Am J Hematol. 2020 Jul 3. Doi: 10.1002/ajh.25926. Epub ahead of print. PMID: 32619047.

214. Zhong C**S, Coughlin CC, Hawryluk EB, Hook K, Humphrey SR, Kruse L, Lawley L, Kao PC**, **London WB**, Marghoob AA, Phung TL, Pope E; Skin Cancer in Children and Young Adults Consortium, Eichenfield LF, Huang JT**, Gerami P, Schmidt B, Bahrani E, Bartenstein D, Brahmbhatt M, Chen L, Haddock E, Mansour D, Nguyen J, Raisanen T, Robinson S, Rogers T, Tran G, Travis K, Wolner Z. Characteristics of non-melanoma skin cancer in children without identifiable risk factors. *J Am Acad Dermatol*. 2020 Jul 17:S0190-9622(20)32215-5. Doi: 10.1016/j.jaad.2020.07.046. Epub ahead of print. PMID: 32687967.

215. Bitterman DS**, Bona K, Laurie F, Kao PC**, Terezakis SA, **London WB**, Haas-Kogan DA. Race Disparities in Proton Radiotherapy Use for Cancer Treatment in Patients Enrolled in Children's Oncology Group Trials. JAMA Oncol. 2020 Sep 01; 6(9):1465-1468. PMID: 32910158.

216. Sokol E**, Desai AV**, Applebaum MA**, Valteau-Couanet D, Park JR, Pearson ADJ, Schleiermacher G, Irwin MS, Hogarty M, Naranjo A**, Volchenboum S, Cohn SL, **London WB**. Reply to Beiske et al. *Journal of Clinical Oncology*, 2020;38*(*31), 3720-3721. https://doi.org/10.1200/JCO.20.02147

217. Liang WH, Federico SM, **London WB**, Naranjo A**, Irwin MS, Volchenboum SL, Cohn SL. Tailoring Therapy for Children with Neuroblastoma on the Basis of Risk Group Classification: Past, Present, and Future. *JCO Clin Cancer Inform*. 2020 Oct;4:895-905. Doi: 10.1200/CCI.20.00074. PMID: 33058692; PMCID: PMC7608590.

218. Tao T**, Shi H, Wang M, Perez-Atayde AR, **London WB**, Gutierrez A, Lemos B, Durbin AD**, Look AT. Ganglioneuromas are driven by activated AKT and can be therapeutically targeted with mTOR inhibitors. J Exp Med. 2020 Oct 05; 217(10). PMID: 32728700

219. Wright KD, Yao X, **London WB**, Kao PC**, Gore L, Hunger S, Geyer R, Cohen KJ, Allen JC, Katzenstein HM, Smith A, Boklan J, Nazemi K, Trippett T, Karajannis M, Herzog C, Destefano J, Direnzo J, Pietrantonio J, Greenspan L, Cassidy D, Schissel D, Perentesis J, Basu M, Mizuno T, Vinks AA, Prabhu SP, Chi SN, Kieran MW. A POETIC Phase II study of continuous oral everolimus in recurrent, radiographically progressive pediatric low-grade glioma. *Pediatr Blood Cancer*. 2020 Nov 2:e28787. Doi: 10.1002/pbc.28787. Epub ahead of print. PMID: 33140540.

220. Moreno L**, Guo D**, Irwin MS, Berthold F, Hogarty M, Kamijo T, Morgenstern D, Pasqualini C, Ash S, Potschger U, Ladenstein R, Valteau-Couanet D, Cohn SL, Pearson ADJ, **London WB**. A nomogram of clinical and biologic factors to predict survival in children newly diagnosed with high-risk neuroblastoma: An International Neuroblastoma Risk Group project. *Pediatr Blood Cancer*. 2020 Nov 18:e28794. Doi: 10.1002/pbc.28794. Epub ahead of print. PMID: 33205902. https://neuroblastoma.shinyapps.io/High-Risk-Neuroblastoma-Nomogram/

221. Esrick EB**, Lehmann LE, Biffi A, Achebe M, Brendel C, Ciuculescu MF, Daley H, MacKinnon B, Morris E, Federico A, Abriss D, Boardman K, Khelladi R, Shaw K, Negre H, Negre O, Nikiforow S, Ritz J, Pai SY, **London WB**, Dansereau C, Heeney MM, Armant M, Manis JP, Williams DA. Post-Transcriptional Genetic Silencing of BCL11A to Treat Sickle Cell Disease. *N Engl J Med*. 2021; 384:205-215. Doi: 10.1056/NEJMoa2029392. [Epub ahead of print]

222. Yu AL, Gilman AL, Ozkaynak FM, Naranjo A**, Diccianni MB, Gan J, Hank JA, Batova A, **London WB**, Tenney SC, Smith MA, Shulkin BL, Parisi MT, Matthay KK, Cohn SL, Maris

JM, Bagatell R, Park JR, Sondel PM. Long-term follow-up of a Phase III Study of ch14.18 (Dinutuximab) + Cytokine Immunotherapy in Children with High-risk Neuroblastoma: COG Study ANBL0032. Clin Cancer Res January 27 2021 DOI**:** 10.1158/1078-0432.CCR-20-3909

223. Ma C**, Sridharan M**, Al-Sayegh H**, Li A**, Guo D**, Auclair M, Kuragayala V, Bandaru C, Milne D, Cruse H, Beaudoin R, Orechia J, Bickel J, **London WB**. Building a harmonized datamart by integrating cross-institutional systems of clinical, outcome, and genomic data: The Pediatric Patient Informatics Platform (*PPIP*). *J Clin Oncol Clinical Cancer Informatics*. 2021:5, 202-215

224. Kawano A, Hazard FK, Chiu B, Naranjo A**, LaBarre B, **London WB**, Hogarty MD, Cohn SL, Maris JM, Park JR, Gastier-Foster JM, Ikegaki N, Shimada H. Stage 4S Neuroblastoma: Molecular, Histologic, and Immunohistochemical Characteristics and Presence of 2 Distinct Patterns of MYCN Protein Overexpression-A Report From the Children's Oncology Group. Am J Surg Pathol. 2020 Dec 22:10.1097/PAS.0000000000001647. doi: 10.1097/PAS.0000000000001647. Epub ahead of print. PMID: 33739795; PMCID: PMC8217390.

225. Granger MM, Naranjo A**, Bagatell R, DuBois SG, McCune JS, Tenney SC, Weiss BD, Mosse YP, Asgharzadeh S, Grupp SA, Hogarty MD, Gastier-Foster JM, Mills D, Shulkin BL, Parisi MT, **London WB**, Han-Chang J, Panoff J, von Allmen D, Jarzembowski JA, Park JR, Yanik GA. Myeloablative Busulfan/Melphalan Consolidation following Induction Chemotherapy for Patients with Newly Diagnosed High-Risk Neuroblastoma: Children's Oncology Group Trial ANBL12P1. Transplant Cell Ther. 2021 Jun;27(6):490.e1-490.e8. doi: 10.1016/j.jtct.2021.03.006. Epub 2021 Mar 6. PMID: 33823167.

226. Gamble LD, Purgato S, Henderson MJ, Di Giacomo S, Russell AJ, Pigini P, Murray J, Valli E, Milazzo G, Giorgi FM, Cowley M, Ashton LJ, Bhalshankar J, Schleiermacher G, Rihani A, Van Maerken T, Vandesompele J, Speleman F, Versteeg R, Koster J, Eggert A, Noguera R, Stallings RL, Tonini GP, Fong K, Vaksman Z, Diskin SJ, Maris JM, **London WB**, Marshall GM, Ziegler DS, Hogarty MD, Perini G, Norris MD, Haber M. A G316A Polymorphism in the Ornithine Decarboxylase Gene Promoter Modulates MYCN-Driven Childhood Neuroblastoma. Cancers (Basel). 2021 Apr 9;13(8):1807. Doi: 10.3390/cancers13081807. PMID: 33918978; PMCID: PMC8069650.

227. Chonat S, Eber SW, Holzhauer S, Kollmar N, Morton DH, Glader B, Neufeld EJ, Yaish HM, Rothman JA, Sharma M, Ravindranath Y, Wang H, Breakey VR, Sheth S, Bradeen HA, Al-Sayegh H**, **London WB**, Grace RF**. Pyruvate kinase deficiency in children. Pediatr Blood Cancer. 2021 Jun 14:e29148. Doi: 10.1002/pbc.29148. Epub ahead of print. PMID: 34125488.

228. Balyasny S**, Lee SM, Desai AV**, Volchenboum SL, Naranjo A**, Park JR, **London WB**, Cohn SL, Applebaum MA**. Association Between Participation in Clinical Trials and Overall Survival Among Children With Intermediate- or High-risk Neuroblastoma. JAMA Netw Open. 2021 Jul 1;4(7):e2116248. Doi: 10.1001/jamanetworkopen.2021.16248. PMID: 34236408.

229. Irwin MS, Naranjo A**, Zhang FF, Cohn SL, **London WB**, Gastier-Foster JM, Ramirez NC, Pfau R, Reshmi S, Wagner E, Nuchtern J, Asgharzadeh S, Shimada H, Maris JM, Bagatell R, Park JR, Hogarty MD. Revised Neuroblastoma Risk Classification System: A Report from the Children's Oncology Group. J Clin Oncol. 2021 Jul 28:JCO2100278. Doi: 10.1200/JCO.21.00278. Epub ahead of print. PMID: 34319759.

230. Meany HJ, Widemann BC, Hinds PS, Bagatell R, Shusterman S, Stern E, Jayaprakash N, Peer CJ, Figg WD, Hall OM, Sissung TM, Kim A, Fox E, **London WB**, Rodriguez-Galindo C, Minturn JE, Dome JS. Phase 1 study of sorafenib and irinotecan in pediatric patients with relapsed or refractory solid tumors. Pediatr Blood Cancer. 2021 Aug 12:e29282. Doi: 10.1002/pbc.29282. Epub ahead of print. PMID: 34383370.

231. Shimano KA, Grace RF**, Despotovic JM, Neufeld EJ, Klaassen RJ, Bennett CM, Ma C**, **London WB**, Neunert C. Phase 3 randomised trial of eltrombopag versus standard first-line pharmacological management for newly diagnosed immune thrombocytopaenia (ITP) in children: study protocol. BMJ Open. 2021 Aug 27;11(8):e044885. Doi: 10.1136/bmjopen-2020-044885. PMID: 34452956; PMCID: PMC8404450.

232. Eiduson R**, Heeney MM, Kao PC**, **London WB**, Fleming MD, Shrier LA. Prevalence and Predictors of Iron Deficiency in Adolescent and Young Adult Outpatients: Implications for Screening. Clin Pediatr (Phila). 2021 Nov 19:99228211059647. Doi: 10.1177/00099228211059647. Epub ahead of print. PMID: 34796723.

233. Yaroslavsky AN, Juliano AF, Adnan A, Selting WJ, Iorizzo TW, Carroll JD, Sonis ST, Duncan CN, **London WB**, Treister NS. Validation of a Monte Carlo Modelling Based Dosimetry of Extraoral Photobiomodulation. Diagnostics (Basel). 2021 Nov 26;11(12):2207. doi: 10.3390/diagnostics11122207. PMID: 34943447; PMCID: PMC8700113.

234. Adnan A, Yaroslavsky AN, Carroll JD, Selting W, Juliano AF, **London WB**, Sonis ST, Duncan CN, Treister NS. The Path to an Evidence-Based Treatment Protocol for Extraoral Photobiomodulation Therapy for the Prevention of Oral Mucositis. Front Oral Health. 2021 Jul 16;2:689386. doi: 10.3389/froh.2021.689386. PMID: 35048034; PMCID: PMC8757848.

235. Bezler NS**, Ilowite M*, **London WB**, Kao P**, Joffe S*, Mack JW*. Health Literacy and Clinical Outcomes Following Hematopoietic Stem-Cell Transplantation. JCO Oncol Pract. 2022 Jan 21:OP2100049. doi: 10.1200/OP.21.00049. Epub ahead of print. PMID: 35061512.

236. Severyn CJ**, Siranosian BA, Kong STJ, Moreno A, Li MM, Chen N**, Duncan CN, Margossian SP, Lehmann LE, Sun S, Andermann TM, Birbrayer O, Silverstein S, Kim S, Banaei N, Ritz J, Fodor AA, **London WB**, Bhatt AS, Whangbo JS. Microbiota dynamics in a randomized trial of gut decontamination during allogeneic hematopoietic cell transplantation. JCI Insight. 2022 Apr 8;7(7):e154344. doi: 10.1172/jci.insight.154344. PMID: 35239511.

237. Desai AV**, Gilman AL, Ozkaynak MF, Naranjo A**, **London WB**, Tenney SC**, Diccianni M, Hank JA, Parisi MT, Shulkin BL, Smith M, Moscow JA, Shimada H, Matthay KK, Cohn SL, Maris JM, Bagatell R, Sondel PM, Park JR, Yu AL. Outcomes Following GD2-Directed Postconsolidation Therapy for Neuroblastoma After Cessation of Random Assignment on ANBL0032: A Report From the Children's Oncology Group. J Clin Oncol. 2022 Jul 15:JCO2102478. doi: 10.1200/JCO.21.02478. Epub ahead of print. PMID: 35839426.

238. Church AJ, Corson LB, Kao PC, Imamovic-Tuco A, Reidy D, Doan D, Kang W, Pinto N, Maese L, Laetsch TW, Kim A, Colace SI, Macy ME, Applebaum MA, Bagatell R, Sabnis AJ, Weiser DA, Glade-Bender JL, Homans AC, Hipps J, Harris H, Manning D, Al-Ibraheemi A, Li Y, Gupta H, Cherniack AD, Lo YC, Strand GR, Lee LA, Pinches RS, Lazo De La Vega L, Harden MV, Lennon

NJ, Choi S, Comeau H, Harris MH, Forrest SJ, Clinton CM, Crompton BD, Kamihara J, MacConaill LE, Volchenboum SL, Lindeman NI, Van Allen E, DuBois SG, **London WB**, Janeway KA. Molecular profiling identifies targeted therapy opportunities in pediatric solid cancer. Nat Med. 2022 Jun 23. doi: 10.1038/s41591-022-01856-6. Epub ahead of print. PMID: 35739269.

239. Connelly GG, Kirkland OO, Bohannon S, Lim DC, Wilson RM, Richards EJ, Tay DM, Jee H, Hellinger RD, Hoang NK, Hao L, Chhabra A, Martin-Alonso C, Tan EKW, Koehler AN, Yaffe MB, **London WB**, Lee PY, Krammer F, Bohannon RC, Bhatia SN, Sikes HD, Li H. Direct capture of neutralized RBD enables rapid point-of-care assessment of SARS-CoV-2 neutralizing antibody titer. Cell Rep Methods. 2022 Aug 22;2(8):100273. doi: 10.1016/j.crmeth.2022.100273. Epub 2022 Aug 4. PMID: 35942328; PMCID: PMC9350670.

240. Campbell K**, Kao PC**, Naranjo A**, Kamijo T, Ramanujachar R, **London WB***, DuBois SG*. Clinical and biological features prognostic of survival after relapse or progression of INRGSS stage MS pattern neuroblastoma: A report from the International Neuroblastoma Risk Group (INRG) project. Pediatr Blood Cancer. 2022 Oct 31:e30054. doi: 10.1002/pbc.30054. Epub ahead of print. PMID: 36316811.

241. **London WB.** WANTED: Better neuroblastoma biomarkers and better stratification. *eBioMedicine*.. 2022 Dec;86:104358. doi: 10.1016/j.ebiom.2022.104358. Epub 2022 Nov 23. PMID: 36434948; PMCID: PMC9699935.

- Invited commentary

242. Eapen M, Brazauskas R, Williams DA, Walters MC, St Martin A, Jacobs BL, Antin JH, Bona K, Chaudhury S, Coleman-Cowger VH, DiFronzo NL, Esrick EB**, Field JJ, Fitzhugh CD, Kanter J, Kapoor N, Kohn DB, Krishnamurti L, **London WB**, Pulsipher MA, Talib S, Thompson AA, Waller EK, Wun T, Horowitz MM. Secondary Neoplasms After Hematopoietic Cell Transplant for Sickle Cell Disease. J Clin Oncol. 2023 Jan 9:JCO2201203. doi: 10.1200/JCO.22.01203. Epub ahead of print. PMID: 36623245.

243. Erbe AK, Wang W, Carmichael L, Kim K, Mendonça EA, Song Y, Hess D, Reville PK, **London WB**, Naranjo A, Hank JA, Diccianni MB, Reisfeld RA, Gillies SD, Matthay KK, Cohn SL, Hogarty MD, Maris JM, Park JR, Ozkaynak MF, Gilman AL, Yu AL, Sondel PM. Neuroblastoma Patients' KIR and KIR-Ligand Genotypes Influence Clinical Outcome for Dinutuximab-based Immunotherapy: A Report from the Children's Oncology Group. Clin Cancer Res. 2018 Jan 1;24(1):189-196. doi: 10.1158/1078-0432.CCR-17-1767. Epub 2017 Oct 2. PMID: 28972044; PMCID: PMC5754221.

244. Bender HG**, Irwin MS, Hogarty MD, Castleberry R, Maris JM, Kao PC**, Zhang FF, Naranjo A**, Cohn SL, **London WB**. Survival of Patients With Neuroblastoma After Assignment to Reduced Therapy Because of the 12- to 18-Month Change in Age Cutoff in Children's Oncology Group Risk Stratification. J Clin Oncol. 2023 Jun 10;41(17):3149-3159. doi: 10.1200/JCO.22.01946. Epub 2023 Apr 25. PMID: 37098238; PMCID: PMC10256433.

245. Shaikh R, Weil BR, Weldon CB, Chen N, **London WB**, Krush M, Anderson M, Gebhardt M, Church AJ, DuBois SG, Pikman Y, Spidle J, Wall CB, Feraco A, Ullrich NJ, Mack JW, Mullen E, Kamihara J, Forrest S, Shusterman S, Janeway KA, Alomari A, Padua H, Rodriguez-Galindo C, O'Neill AF**. A single-institution pediatric and young adult interventional oncology collaborative:

Novel therapeutic options for relapsed/refractory solid tumors. Cancer Med. 2023 Jun;12(12):13300-13308. doi: 10.1002/cam4.6026. Epub 2023 Jun 1. PMID: 37264747; PMCID: PMC10315804.

246. Shulman DS**, Merriam P, Choy E, Guenther LM, Cavanaugh KL, Kao PC, Posner A, Bhushan K, Fairchild G, Barker E, Klega K, Stegmaier K, Crompton BD, **London WB**, DuBois SG. Phase 2 trial of palbociclib and ganitumab in patients with relapsed Ewing sarcoma. Cancer Med. 2023 Jul;12(14):15207-15216. doi: 10.1002/cam4.6208. Epub 2023 Jun 12. PMID: 37306107; PMCID: PMC10417097.

247. Rameh V, Vajapeyam S, Ziaei A, Kao P**, **London WB**, Baker SJ, Chiang J, Lucas J, Tinkle CL, Wright KD, Poussaint TY. Correlation between Multiparametric MR Imaging and Molecular Genetics in Pontine Pediatric High-Grade Glioma. AJNR Am J Neuroradiol. 2023 Jul;44(7):833-840. doi: 10.3174/ajnr.A7910. Epub 2023 Jun 15. PMID: 37321859; PMCID: PMC10337620.

248. Streby KA**, Parisi MT, Shulkin BL, LaBarre B, Bagatell R, Diller L, Grupp SA, Matthay KK, Voss SD, Yu AL, **London WB**, Park JR, Yanik GA, Naranjo A**. Impact of diagnostic and end-of-induction Curie scores with tandem high-dose chemotherapy and autologous transplants for metastatic high-risk neuroblastoma: A report from the Children's Oncology Group. Pediatr Blood Cancer. 2023 Aug;70(8):e30418. doi: 10.1002/pbc.30418. Epub 2023 May 18. PMID: 37199022; PMCID: PMC10511015.

249. Labrosse R, Chu J, Armant M, Everett JK, Pellin D, Kareddy N, Frelinger AL, Henderson LA, O'Connell AE, Biswas A, Coenen-van der Spek J, Miggelbrink AM, Fiorini C, Adhikari H, Berry CC, Cantu VA, Fong J, Jaroslavsky JR, Karadeniz DF, Li QZ, Reddy S, Roche AM, Zhu C, Whangbo JS, Dansereau C, Mackinnon BL, Morris E, Koo SM, **London WB**, Baris S, Ozen A, Karakoc-Aydiner E, Despotovic JM, Forbes Satter LR, Saitoh A, Aizawa Y, King A, Nguyen MAT, Vu VDU, Snapper SB, Galy A, Notarangelo LD, Bushman FD, Williams DA, Pai SY. Outcomes of Hematopoietic Stem Cell Gene Therapy for Wiskott-Aldrich Syndrome. Blood. 2023 Jul 21:blood.2022019117. doi: 10.1182/blood.2022019117. Epub ahead of print. PMID: 37478401.

250. Cohen KJ, Munjapara V, Aguilera D, Castellino RC, Stapleton SL, Landi D, Ashley DM, Rodriguez FJ, Hawkins C, Yang E, **London W**, Chi S, Bandopadhayay P. A pilot study omitting radiation in the treatment of children with newly diagnosed Wnt-activated medulloblastoma. Clin Cancer Res. 2023 Jul 27:CCR-23-0348. doi: 10.1158/1078-0432.CCR-23-0348. Epub ahead of print. PMID: 37498309.

251. Labrosse R, Chu JI, Armant MA, Everett JK, Pellin D, Kareddy N, Frelinger AL, Henderson LA, O'Connell AE, Biswas A, Coenen-van der Spek J, Miggelbrink A, Fiorini C, Adhikari H, Berry CC, Cantu VA, Fong J, Jaroslavsky J, Karadeniz DF, Li QZ, Reddy S, Roche AM, Zhu C, Whangbo JS, Dansereau C, Mackinnon B, Morris E, Koo SM, **London WB**, Baris S, Ozen A, Karakoc-Aydiner E, Despotovic JM, Forbes Satter LR, Saitoh A, Aizawa Y, King A, Nguyen MAT, Vu VDU, Snapper SB, Galy A, Notarangelo LD, Bushman FD, Williams DA, Pai SY. Outcomes of hematopoietic stem cell gene therapy for Wiskott-Aldrich syndrome. Blood. 2023 Oct 12;142(15):1281-1296. doi: 10.1182/blood.2022019117. PMID: 37478401; PMCID: PMC10731922.

252. Yaroslavsky AN, Iorizzo TW, Juliano AF, Adnan A, Carroll JD, Sonis ST, Duncan CN, **London WB**, Treister NS. Monte Carlo based dosimetry of extraoral photobiomodulation for prevention of

oral mucositis. Sci Rep. 2023 Nov 22;13(1):20425. doi: 10.1038/s41598-023-47529-3. PMID: 37993500; PMCID: PMC10665335.

253. Hawryluk EB**, Moustafa D, Barry KK, Bahrani E, Reusch DB, Brahmbhatt M, Chen L, Coughlin CC, Gerami P, Haddock E, Hook K, Humphrey SR, Kao PC, Kruse LL, Lawley LP, Mansour D, Marghoob AA, Nguyen J, Phung TL, Pope E, Raisanen T, Robinson S, Rogers T, Schmidt B, Tran G, Travis K, Wolner Z, **London WB**, Eichenfield LF, Huang J. Risk factors and outcomes of melanoma in children and adolescents: A retrospective multicenter study. J Am Acad Dermatol. 2023 Nov 29:S0190-9622(23)03238-3. doi: 10.1016/j.jaad.2023.10.067. Epub ahead of print. PMID: 38040338.

254. Campbell K**, Posner A, Chen N**, Cavanaugh K, Bhushan K, Janeway KA, Shulman DS, George S, Klega K, Crompton B, **London WB**, DuBois SG. Phase 1 study of cabozantinib in combination with topotecan-cyclophosphamide for patients with relapsed Ewing sarcoma or osteosarcoma. Pediatr Blood Cancer. 2023 Dec;70(12):e30681. doi: 10.1002/pbc.30681. Epub 2023 Sep 16. PMID: 37715723.

255. Schoettler ML**, Lehmann L, Kao PC, Chen N**, Jodele S, Chonat S, Williams KM, **London WB**, Duncan C*, Dandoy C*. Pediatric transplant-associated thrombotic microangiopathy health care utilization and implications of eculizumab therapy. Blood Adv. 2024 Mar 12;8(5):1220-1233. doi: 10.1182/bloodadvances.2023011078. PMID: 38154068.

Non-peer reviewed scholarship in print or other media

Book chapters

1. Kasiske BL, **London W**, Ellison MD. "Factors influencing early placement on the kidney transplant waiting list in the United States" in *Organ Allocation*. J.L Touraine (ed.) Kluwer Academic Publishers, Great Britain, 1998. 135-137.
2. Lau L, **London WB**. "Recurrent Neuroblastoma" in *Neuroblastoma – Present and Future.* H. Shimada (ed.) InTech, 2012. 29-52. Web.
3. Brumback BA, **London WB**. "Causal Inference in Cancer Clinical Trials" in *Modern Clinical Trial Analysis*. Tang W and Tu XM (eds) Springer Science, New York, NY, 2013. 203-225.

Technical reports:

1. **London WB**, Gennings C, Edward E. (1999). A survival analysis of clusters of dependent times to event with censoring using a generalized estimating equations (GEE) approach. Technical Report Number 610, Department of Statistics, University of Florida.

Thesis

1. **London, Wendy Beth**. Application of within-cluster correlations in a generalized estimating equations (GEE) approach: Implications for inference in survival analysis. Virginia Commonwealth University, Tompkins-McCaw Library Special Collections and Archives R111.M489 1997 .L66

Abstracts, Poster Presentations and Exhibits Presented at Professional Meetings

Year(s)	Abstracts published/Exhibits presented
2022	COVID-19 Is Associated with an Increased Risk of Venous Thromboembolism, but Not Arterial Ischemic Stroke in Hospitalized Children: A Multicenter Observational Study American Society of Hematology Annual Meeting
2022	Long-Term Outcome of Gene Therapy for X-Linked Severe Combined Immunodeficiency (SCID-X1) Using an Enhancer-Deleted Self-Inactivating Gammaretroviral Vector American Society of Hematology Annual Meeting
2022	Induction of Fetal Hemoglobin and Reduction of Clinical Manifestations in Patients with Severe Sickle Cell Disease Treated with Shmir-Based Lentiviral Gene Therapy for Post-Transcriptional Gene Editing of BCL11A: Updated Results from Pilot and Feasibility Trial American Society of Hematology Annual Meeting
2022	Lentiviral Gene Therapy with Low Dose Conditioning for X-Linked SCID Results in Complete Immune Reconstitution and No Evidence of Clonal Expansion American Society of Hematology Annual Meeting
2022	Survival of patients with neuroblastoma before versus after reduction of therapy due to the change in age cut-off from 12 to 18 months in Children's Oncology Group (COG) risk stratification (selected for oral poster discussion) American Society of Clinical Oncology Annual Meeting
2022	Patterns of Relapse after Immunotherapy in Patients with High-Risk Neuroblastoma (selected poster) American Society of Clinical Oncology Annual Meeting
2021	Integrating Longitudinal Clinical, Sociodemographic and Genomic Data into the National Childhood Cancer Registry (NCCR) (selected poster) Childhood Cancer Data Initiative National Childhood Cancer Registry Data Summit
2021	Phase II Study of Nivolumab and Ipilimumab in Children and Young Adults with INI1-Negative Cancers (selected poster) American Society of Clinical Oncology Annual Meeting
2019	TARGET-CRM: a novel adaptive dose-escalation design for targeted therapies with applications in pediatric oncology (selected oral presentation) Society of Clinical Trials Annual Meeting, New Orleans, LA
2019	Pyruvate Kinase (PK) Protein and Enzyme Levels in the Diagnosis and Clinical Phenotype of PK Deficiency (selected poster) American Society of Hematology Annual Meeting
2019	A Phase 3 Study of Eltrombopag vs. Standard First-Line Management for Newly Diagnosed Immune Thrombocytopenia in Children (selected poster) American Society of Hematology Annual Meeting
2019	Outcome of Hematopoietic Stem Cell Gene Therapy for Wiskott-Aldrich Syndrome (selected poster) American Society of Hematology Annual Meeting
2019	Targeted sequencing in 386 patients with high-risk or recurrent / refractory pediatric extra-cranial solid malignancies: An interim report from the GAIN Consortium / iCat2 Study (selected poster) Pediatric Cancer Working Group of the American Association for Cancer Research

2019	Prognostic Influence of Lactate Dehydrogenase & Serum Ferritin in Neuroblastoma Continuing Umbrella of Research Experiences Symposium, Dana-Farber/Harvard Cancer Center
2019	Evaluation of the Intrinsic Hepcidin Idx™ Test to Detect Iron Deficiency in Adolescents/Young Adults (selected poster) American Society of Pediatric Hematology and Oncology Annual Meeting
2019	Health Literacy and Patient Outcomes following Bone Marrow Transplantation (selected poster) American Society of Pediatric Hematology and Oncology Annual Meeting
2019	Evaluation of the Intrinsic Hepcidin Idx™ Test to Detect Iron Deficiency in Adolescents/Young Adults (selected poster) Pediatric Academic Society Annual Meeting
2016	Second malignancies in patients with neuroblastoma: a report from the International Neuroblastoma Risk Group project (Audrey Evans Prize for the Outstanding Paper in Clinical Research) Advances in Neuroblastoma Research (ANR) 2016 Meeting
2008	A Randomized Phase 3 Trial of Myeloablative Autologous Peripheral Blood Stem Cell (PBSC) Transplant (ASCT) for High-Risk Neuroblastoma (HR-NB) Employing Immunomagnetic Purged versus Unpurged PBSC: A Children's Oncology Group (COG) Study (Audrey Evans Prize for the Outstanding Paper in Clinical Research) Advances in Neuroblastoma Research (ANR) 2008 Meeting
2007	Surgery and restricted use of chemotherapy as treatment of low-risk neuroblastoma: Preliminary results of Children's Oncology Group protocol 9641 ("Best of SIOP" Award Lecture) American Society of Pediatric Hematology/Oncology (ASPHO)
2006	Surgery and restricted use of chemotherapy as treatment of low-risk neuroblastoma: Preliminary results of Children's Oncology Group protocol 9641 (Winner of "Best Clinical Trials" presentation) 38th Congress of the International Society of Paediatric Oncology
2006	Age, Tumor Grade, and Mitosis-Karyorrhexis Index are Independently Predictive of Outcome in Neuroblastoma (Best Clinical Science Poster) University of Florida College of Medicine Research Day
2006	Age, Tumor Grade, and MKI Are Independently Predictive of Outcome in Neuroblastoma (Audrey Evans Prize for the Outstanding Paper in Clinical Research) Advances in Neuroblastoma Research (ANR) 2006 Meeting
1990	Teaching the SAS programming language to programmers and non-programmers ("Best Contributed Paper" in the section Education, Consulting, and Technical Support) SAS Users Group International 15th Annual Conference
1989	Standard operating procedure in the creation, maintenance, and quality assurance of SAS programs ("Honorable Mention" in the section on in Education, Consulting, and Technical Support) SAS Users Group International 14th Annual Conference

Narrative Report

I am a biostatistician, a teacher, a mentor, a leader, an administrator, a scientist. Team science: I am a recognized expert for design and analysis of pivotal clinical trials, improving cure rates for neuroblastoma (NB) and other pediatric cancers and blood disorders. Above and beyond team science, I lead independent research as a NB scientist; I am the world's leading expert in the identification and application of NB prognostic factors to determine treatment intensity. My NB research program has been conducted in my dry lab; I have mentored dozens of clinical investigators in successful publication of research and career development. My unique combination of expertise in NB and in biostatistics is synergistic; few others, if any, could develop the innovations in NB risk/treatment stratification that I have. My area of excellence is Investigation, with interdisciplinary expertise in biostatistics, pediatric solid tumors and blood disorders, leadership in clinical trials, and advancements in NB.

Early career - I played an instrumental role (1987-92) in the success of CRO start-up PRA Health Sciences. I trained at Virginia Commonwealth University's Medical College of Virginia while working at the United Network for Organ Sharing (UNOS). My interests in survival analysis and cancer led to a faculty position as a biostatistician in the Children's Oncology Group [COG[1]], an NIH/NCI cancer cooperative group, at the University of Florida's COG Statistics and Data Center. Thereafter, my research career evolved to a focus in NB.

NB Risk stratification research and impact - I am the world's leading statistical expert in NB risk stratification. My dry lab research has accurately identified which children need more/different therapy to survive, and who can survive/thrive with less/no therapy [33,34,37,38,43,51,53,56,59,60,66,68,71,80,86,92,94,97,100,114,127,133,136, 137,138,153,160,174,194,200,207,210,216,220]. I identified and validated an optimal 547-day (18-month) age cut-off to differentiate younger (better outcome) from older (worse outcome) patients [34,244]. We reached international consensus to change the age cut-off from 12 months to 18 months. COG[1] instituted a new standard of care for two subgroups of toddlers 12-18 months old at diagnosis: (INSS stage 4, favorable *MYCN*, INPC, and ploidy) and (INSS stage 3, *MYCN* not amplified, unfavorable INPC). Due to the age cut-off change, these patients received a reduction of therapy from intensive multi-modality including stem cell transplant, to response-adaptive chemotherapy, resulting in less treatment-related toxicity. The 18-month age cut-off was used in the new International Neuroblastoma Risk Group Staging System (INRGSS) [56]. As the Chair of the International Neuroblastoma Risk Group (INRG) Statistics Committee, I have scientific oversight for the INRG Data Commons (>24,000 patients), and review/approve national and international proposals for data analyses.

I have a unique perspective and skill set, a hybridization of expertise in NB and statistical methodology. Dr. Lucas Moreno and I developed a nomogram to identify an "ultra-high-risk" cohort [220] https://neuroblastoma.shinyapps.io/High-Risk-Neuroblastoma-Nomogram/, utilized by the Global Neuroblastoma Network (coordinated by St. Jude Children's Research Hospital). Next, my dry lab research seeks improvement in high-risk NB stratification. My mentee, Dr. Moreno (PI), and I (Co-PI) were awarded a 3-year grant from Solving Kids' Cancer to identify children with the highest chance of dying from their NB, to offer experimental therapy instead of standard of care at diagnosis. (Without a government funding system, preeminent European foundations like Solving Kids' Cancer use a rigorous NIH-like peer-review process to award funding.)

Clinical trials: design, conduct, and impact - The COG[1] is an NIH/NCI funded infrastructure for the conduct of trials that set the standard of care for children with cancer; COG is not a professional society. Unlike committees for societies, COG[1] committees are scientific working groups that design and conduct clinical trials, with a separate 'committee' for each disease. Appointment to a COG[1] committee as the biostatistician carries a greater level of national prominence than election to a national society. I was 95-100% funded by the NIH/NCI to perform research on COG[1] trials from 1998-2009, decreasing to 30% (2009-2014) when I moved to DFCI/BCH. During my tenure as a COG[1] statistician, our NB clinical trials resulted in dramatic improvements in outcome: 3-year overall survival for high-risk NB increased from ~30% in 1998 to >60% in 2019. Over two decades, I designed and conducted phase 2 and 3 trials that set new standards of care: FDA approval of dinutuximab after transplant in high-risk NB [75,82] (ANR[2] plenary 2010); tandem transplant for high-risk NB [204] (American Society of Clinical Oncology [ASCO] plenary 2016); expectant observation for infants <6 months old [116]; reduction of

chemotherapy in intermediate-risk NB [81,202]; emergent therapy for symptomatic intermediate-risk NB [193]; topotecan plus cyclophosphamide for relapsed/refractory [79] and newly diagnosed NB [99]; and, intravenous immunoglobulin for opsoclonus myoclonus ataxia syndrome [179]. I have been the statistician for key NB biomarkers, including ALK for targeted therapy (crizotanib) [53,92,142], 1p and 11q LOH [39], ODC1 [57], *MYCN* expression [11], and the genetic landscape of high-risk NB [120]. In addition, I led the efforts to describe progression-free survival in a large historical cohort of relapsed/refractory NB [176], providing a historical basis to which experimental therapies can be compared in future national/international phase 2 trials. I served as statistician on landmark trials for gene therapy for X-Linked Severe Combined Immunodeficiency [139], secondary malignancies in pediatric Hodgkin disease [49], outcome/staging/treatment of malignant germ cell tumors [19,20,22], NUT midline carcinoma [110], the kidney transplant waiting list [5], and response-based treatment for intermediate/high-risk Hodgkin disease [70].

International reputation in NB clinical research - I received invitations to present the landmark results of our randomized trial of dinutuximab at the University of Cologne (2009), Royal Marsden (2009) and the International Society of Pediatric Oncology (Sao Paolo, Brazil, 2009). Drs. Frank Berthold (University of Cologne) and Lothar Krempel (Max Planck Institute for the Study of Societies) conducted an analysis entitled, "The development of the ANR[2] (Advances in Neuroblastoma Research) network: A study of the contributions 1975-2015". Of 7,787 authors /investigators worldwide, I ranked 11[th] in the number of ANR[2] abstracts. My H-indices are 92 (Google Scholar) and 73 (Web of Science), my i10-index is 228, and my publications have been cited 33,339 times (Google Scholar) or 20,372 (Web of Science), large numbers given the rarity of NB.

COG[1] NB Virtual Tumor Bank development - I conceived and designed the COG[1]'s NB Virtual Tumor Bank (NVTB) database, linking clinical, biological, outcomes, and specimen data for COG[1] and international contributors. My foresight to require submission of outcome data on COG[1] NB biology studies laid the groundwork for two decades of fruitful genetic biomarker research that would otherwise have not been possible. Scientists use the NVTB for national and international basic science projects, including Dr. John Maris' [38,46,64,69,88,118,120], and Dr. Michelle Haber's labs [11,28,42,57,95,103,135,157,162,165,196,226].

Impact of statistical methodology development - I developed new methods for stratified Phase 2 designs [35], utilized for design and conduct of at least eight national multi-center NIH/NCI oncology phase 2 clinical trials of small, heterogeneous cohorts. I developed the statistical framework for the national COG[1] and international INRG risk stratifications; one approach used a novel finite mixture survival model [63]. I collaborated with Dr. Arlene Naranjo to create the new COG[1] NB risk stratification [195]. Under my mentorship, Dr. Clement Ma and I have developed new methods for novel adaptive phase 1 trial designs to favor accrual within rare genomic subgroups (manuscript in development). I am the statistician for four adaptive-design phase 1 trials currently underway at DFCI/BCH; adaptive phase 1 designs are a groundbreaking approach in pediatric oncology. Dr. Ma and I have developed the DEDUCE application for design and conduct of adaptive trials by a statistician-clinician duo. This application is open-source, available to scientists worldwide. https://deduce.shinyapps.io/DEDUCE/

Mentoring and teaching - I have mentored >100 fellows and junior faculty in COG[1], BCH, DFCI, and elsewhere; many have advanced to leadership roles or published landmark papers (see "Other Mentored Trainees and Faculty"). I have mentored five biostatistics graduate students, including two at Harvard School of Public Health. I mentored junior faculty on K awards (including Dr. David Shulman), and my first Wellesley College intern graduated in 2023 from University of Michigan medical school. I am an invited faculty member at the annual American Association for Cancer Research (AACR)/ASCO Methods in Clinical Cancer Research workshop (Vail, CO & La Jolla, CA) (plenary lecture on correlative studies), and will Co-Chair the workshop in 2024-26. I lecture on clinical trials and statistics to hem/onc fellows, clinicians and COG[1] members, some for CME credit. I have taught >20 oncologists in our Global Health Initiative. In my dry lab, I have mentored dozens of clinicians on NB clinical research projects, with successful manuscript publications. An integral component of my teaching occurs daily, in one-on-one sessions with clinician-scientists for specific trials.

National service - I serve on the Therapeutic Immune Regulation (TIR) Study Section, the Cellular, Tissue, and Gene Therapies Advisory Committee of the Food and Drug Administration, and the editorial board of the *Journal of the National Cancer Institute* (impact factor: 12.6). I have served as a permanent member on the NIH's Clinical Oncology (CONC) Study Section, ad-hoc on Subcommittee H (peer review of NIH/NCI Cancer Cooperative Groups), NIH's Cancer Biomarker Study Section, the Department of Defense Congressionally Directed Medical Research Neuroblastoma Peer Reviewed Cancer Research Program, the International Neuroblastoma Research Initiative for pilot trials for Solving Kids' Cancer UK, and the AACR Clinical Trials Committee. I served on the editorial board of the *Journal of Clinical Oncology* (impact factor: 44.54), ASCO Program Committee, and as an assistant editor for Medical and Pediatric Oncology.

Local administrative and informatics accomplishments - My Significant Supporting Activity is Administrative and Institutional Service. I led the University of Florida's COG[1] Statistics and Data Center while transitioning to electronic data capture, managing five PhD statisticians and 20 staff (~$2M annual budget). At DFCI/BHC, I built two new programs: the Biostatistics Program, and the Clinical and Translational Investigation Program (CTIP) to provide infrastructure for clinical research. CTIP is a model for clinical research infrastructure at BCH, growing from 15 to >60 staff and supporting seven disease programs during my 10-year tenure. The Biostatistics Program has a self-sustaining funding model. My infrastructure and training grant from Alex's Lemonade Stand Foundation (Multi-PI: London and Dubois) supports clinical research staff and protected time for junior faculty. To address a critical need to integrate and harmonize data between BCH and DFCI for efficient and reproducible analyses, I created the Pediatric Patient Informatics Platform (*PPIP*) [223], a datamart harmonizing 14 source databases: 2,622 data items/33,674 patients/3.6 million visits. *PPIP* contributes data to DFCI's PRISSMM project, the National Childhood Cancer Registry, Massachusetts Cancer Registry, locally to the oncology "clinical database", and internationally via NIH/AACR's Project GENIE. I am the Director for the DF/HCC Survey and Qualitative Methods Core (2014-present) and I have served on multiple institutional committees.

I take great pleasure and pride in the complimentary/interdisciplinary aspects of my research and teaching. It is a privilege to contribute to world class team science for pediatric cancers and blood disorders. Using my biostatistical and neuroblastoma expertise, I will continue work in my dry lab to advance my research program to improve treatment and outcome for children with neuroblastoma.